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Abstract
Cancer and infectious diseases, such as influenza infection, represent major threats to the
human population, especially since demographic change makes more and more people
vulnerable. Mathematical modeling of disease covers several layers of detail ranging
from epidemiological models for infection spread to cancer-associated signaling within
individual cells. These models, when being calibrated to biological data, can provide
useful means for generating hypothesis of priorly unknown interactions, predicting
drug targets for novel therapeutic substances and for improving the understanding and
efficient functioning of existing treatment strategies. In this thesis, I present several
projects in which predictive computational models are utilized to gain deeper insights
into the biological processes and to improve therapy of cancer and associated health
problems.
The first part highlights the importance of community-driven software development for
systems biology applications. Efficient, yet expandable and open software continuously
improves, driven by an active community of users and developers.
In the second project, the intracellular processes during the early influenza A infection
are investigated. Using a combination of experimental measurements and mathematical
modeling, degradation of the viral genome during its diffusion through the cytoplasm
could be identified as a limiting factor for a successful infection. By experimentally
increasing the pH sensitivity of the viral hemagglutinin protein, the distance of diffusion
was increased and the computationally predicted decrease in infectivity could be validated
in experiment.
The third project deals with cancer-associated health issues and their treatment. Patients
suffering from anemia, caused by the cancer itself or as a side-effect of chemotherapy,
are treated either with blood transfusions or with an erythropoiesis stimulating agent
(ESA). By adapting a published model of ESA-EpoR interaction, not only the biochemical
properties of different ESAs could be characterized in silico but also the number of
binding sites (i.e. Epo receptors on the cell surface) in different cell lines was accurately
determined. The model was extended by a pharmaco-kinetic and -dynamic part. The
combined ESA-EpoR-PK/PD model could be utilized to retrospectively optimize the
dosing regimen of patients suffering from anemia.
In the last project, a computational method for analyzing and deciphering the cellular
composition of bulk tumor samples is presented. Only recently, a new class of anti-cancer
drugs was introduced recruiting the body’s own immune system to combat malignant
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tissue. However, the efficient functioning of these immunotherapeutical drugs heav-
ily depends on the presence of specific immune cells in the tumor micro-environment.
Based on single-cell RNA sequencing data, an existing method for computational de-
convolution could be adapted for data from solid tumor tissue and its performance was
benchmarked.
Taken together, in this thesis I present approaches how predictive computational models
can be utilized to render more efficient existing treatment strategies.
Zusammenfassung
Krebs und Infektionskrankheiten, wie z.B. Influenza, stellen zwei der großen Bedrohun-
gen für die Menschheit dar. Gerade durch den demographischen Wandel sind immer mehr
Menschen gefährdet. Mathematische Modelle von Krankheiten decken verschiedene De-
tailebenen ab – von epidemologischen Modellen der Virusinfektion bis zu intrazellulären
Modellen der Signaltransduktion in einzelnen Krebszellen. Diese Modelle, sofern sie
anhand von biologische Daten kalibriert wurden, können sich als sehr nützlich erweisen
um Hypothesen zu bisher unbekannten Wechselwirkungen zu generieren, Wirkstoffkan-
didaten vorherzusagen, und die Funktionsweise von existierenden Wirkstoffen besser zu
verstehen.
Im Rahmen dieser Arbeit möchte ich mehrere Projekte vorstellen, in denen prädiktive
mathematische Modelle dazu benutzt wurden, tiefere Einblicke in die biologischen
Prozesse zu gewinnen und die Therapieansätze bei Krebserkrankungen und den damit
verbundenen Gesundheitsproblemen zu verbessern.
Im ersten Teil geht es um die Bedeutung von gemeinschaftlich entwickelter Software für
die Systembiologie. Eine offene und erweiterbare Modellierungssoftware ermöglicht es
ständig verbessert zu werden und an die Bedürfnisse der Nutzer angepasst zu werden.
Im zweiten Projekt wurden die intrazellulären Prozesse während der frühen Influenza
A Infektion untersucht. Durch eine Kombination von biologischen Messungen und ma-
thematischer Modellierung konnte der Abbau von viraler RNA wähernd des Transportes
durch das Wirtszellzytoplasma als limitierender Faktor für die erfolgreiche Infektion
identifiziert werden. Mit Hilfe eines experimentell modifizierten viralen Hämagglutintin-
Proteins mit veränderter pH-Abhängigkeit konnte gezeigt werden, dass sich der Abstand
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zum Zellkern, in dem das virale Genom freigesetzt wird, vergrößert. Die Modellvorher-
sage, dass die Infektion dadurch weniger effektiv wird, konnte experimentell bestätigt
werden.
Im dritten Projekt beschäftigte ich mich mit gesundheitlichen Problemen, die im Zu-
sammenhang mit einer Krebserkrankung und deren Behandlung auftreten können. Che-
motherapie oder die Krebserkrankung selbst führt bei vielen Patienten zu einer Blutar-
mut (Anämie). Diese wird aktuell entweder durch regelmäßige Bluttransfusionen oder
durch Verabreichung von sogenannten Erythropoiesis-Stimulating Agents (kurz: ESA, zu
Deutsch: Erythropoese-stimulierende Substanzen) behandelt. Mithilfe eines publizierten
mathematischen Modells zur ESA-EpoR Interaktion konnten die Bindungseigenschaften
verschiedener ESAs charakterisiert und zudem die Anzahl der Bindungsstellen auf unter-
schiedlichen Zelllinien bestimmt werden. Durch eine Erweiterung des Modells mit einem
pharmakokinetischen und -dynamischen Teil konnte die Dosierung für Anämiepatienten
retrospektiv verbessert werden.
Das letzte Projekt stellt eine computerbasierte Methode zur Analyse und Entschlüsselung
der zellulären Zusammensetzung von Tumorproben dar. In den vergangenen Jahren
wurde vermehrt eine neue Klasse von Krebsmedikamenten entwickelt, die sich das kör-
pereigene Immunsystem zunutze macht, um den Krebs zu bekämpfen. Das Funktionieren
dieser Medikamente hängt jedoch davon ab, ob bestimmte Immunzellen in der Umgebung
des Tumors vorhanden sind. Auf Grundlage von Einzelzell RNA-Sequenzierungsdaten
konnte eine existierende Methode so erweitert werden, dass nunmehr auch Proben von
soliden Tumoren entschlüsselt werden können. Zudem wurden die Einflüsse von ver-
schiedenen Faktoren, wie etwa der Gewebeherkunft oder dem verwendeten Algorithmus,
systematisch ausgewertet.
Zusammengefasst habe ich in dieser Arbeit dargestellt, wie prädiktive Computermodelle
dazu verwendet werden können bestehende Behandlungsansätze zu verbessern und
neue Wirkstoffkandidaten zu identifizieren.
v

Acknowledgement
First of all, I want to thank my supervisor Edda Klipp. She did not only offer me funding
for more than four years, but also gave me the freedom to grow into an independently
working researcher and gave me all the opportunities to discover the field of systems
biology.
Next, a big “thank you” goes to my colleagues from the group of theoretical biophysics,
especially to Björn Goldenbogen,Max Flöttmann, Katja Tummler andMarcus Krantz,
who joined me on many adventures – from the first attempts of kitesurfing to regular
Freeletics workouts in the lunch break to the pleasures of sky diving – and enriched my
daily work life with fruitful discussions.
Furthermore, I thank Andreas Raue, who invited me to join Merrimack Pharmaceuticals
in Cambridge, MA, USA where I had an extremely inspiring time and discovered the joys
of sailing.
I also want to thank all my collaboration partners from Berlin, Cambridge, Heidelberg
and Freiburg. With endurance and diligence, they acquired thousands of data points
and enabled our models to grow to something bigger.
Last but not least, I thank my dear family for always being there, my girlfriend Lisa for
her continuous loving support over the last years and my baby daughter for giving me
some extra time to finish this thesis.
vii

Contents
1 Introduction 1
2 Methods 5
2.1 Experimental methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
2.1.1 Fluorescence microscopy . . . . . . . . . . . . . . . . . . . . . . . 5
2.1.2 Flow cytometry and cell sorting . . . . . . . . . . . . . . . . . . . 5
2.1.3 Quantitative immunoblotting . . . . . . . . . . . . . . . . . . . . 6
2.1.4 Enzyme-linked immunosorbent assay (ELISA) . . . . . . . . . . . 7
2.1.5 Quantitative real-time PCR (qPCR) . . . . . . . . . . . . . . . . . 7
2.1.6 High-throughput RNA sequencing (RNA-seq) . . . . . . . . . . . 8
2.2 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.1 RNA-seq data processing . . . . . . . . . . . . . . . . . . . . . . . 11
2.2.2 Dimensionality reduction . . . . . . . . . . . . . . . . . . . . . . 13
2.2.3 Clustering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2.2.4 Support Vector Regression (SVR) . . . . . . . . . . . . . . . . . . 15
2.2.5 Decision-tree Classification . . . . . . . . . . . . . . . . . . . . . 16
2.3 Dynamic modeling . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.3.1 Biochemical reaction networks . . . . . . . . . . . . . . . . . . . 17
2.3.2 Parameter estimation . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.3.3 Parameter identifiability . . . . . . . . . . . . . . . . . . . . . . . 22
2.4 Numerical methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.4.1 Integration of differential equations . . . . . . . . . . . . . . . . . 24
2.4.2 Optimization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3 Developing software tools tailored to systems biology applications 31
3.1 Data2Dynamics – A framework for data-based modeling . . . . . . . . . 31
3.1.1 Community based development . . . . . . . . . . . . . . . . . . . 33
3.1.2 Selected features . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
3.1.3 Benchmark of sampling strategies and implemented fitting algorithms 38
3.2 A data interface for the ViroSign project . . . . . . . . . . . . . . . . . . 43
3.3 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
ix
4 Mathematical modeling of the influenza A infection 47
4.1 Introduction to influenza biology . . . . . . . . . . . . . . . . . . . . . . 47
4.1.1 The influenza A virus . . . . . . . . . . . . . . . . . . . . . . . . . 47
4.1.2 Epidemiology of influenza A . . . . . . . . . . . . . . . . . . . . . 48
4.1.3 The replication cycle of influenza A . . . . . . . . . . . . . . . . . 49
4.2 Dynamic modeling of the influenza A infection . . . . . . . . . . . . . . . 52
4.2.1 Existing models . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.2.2 An ODE model describing influenza A virus entry into the host cell 54
4.2.3 A stochastic model of vRNP diffusion to the nucleus . . . . . . . . 59
4.2.4 Combining both modeling approaches reveals vRNP removal in
the cytosol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
5 Computational approaches for optimized treatment of cancer-associated
health conditions 67
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
5.2 Optimized treatment strategies for anemia patients based on a mechanistic
multi-scale model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
5.2.2 Building a mathematical model of ESA-EpoR interaction . . . . . 71
5.2.3 Extending the model for multiple cell types and ESAs . . . . . . . 75
5.2.4 Incorporating ligand depletion experiments for various cell lines
and ESAs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
5.2.5 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
5.2.6 Linking the receptor model to JAK-STAT signaling . . . . . . . . . 88
5.2.7 Pharmacokinetics and -dynamics (PKPD) . . . . . . . . . . . . . . 90
5.2.8 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
5.3 Deciphering the cellular composition of unknown patient samples for
immunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
5.3.2 Single-cell RNA-seq data from multiple tissues and patients . . . 101
5.3.3 Classifying individual cells based on marker gene expression and
similarity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
5.3.4 Analyzing indication and patient-specific gene expression . . . . 108
5.3.5 Defining a benchmark based on single-cell gene expression data . 110
5.3.6 Impact of signature gene sets on deconvolution accuracy . . . . . 114
5.3.7 Evaluating deconvolution algorithms . . . . . . . . . . . . . . . . 114
5.3.8 Impact of patient- and indication-specific reference profiles . . . . 115
5.3.9 Estimating T cell subtypes and prognostic ratios . . . . . . . . . . 117
x
5.3.10 Predicting tumor expression profiles . . . . . . . . . . . . . . . . 119
5.3.11 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
5.4 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
6 Conclusions & Outlook 125
6.1 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 125
6.2 Outlook . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 130
Bibliography 133
A Mathematical modeling of the influenza A infection 149
B Computational approaches for optimized treatment of cancer-associated
health conditions 153
B.1 Optimized treatment strategies for anemia patients based on a mechanistic
multi-scale model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 153
B.1.1 Auxiliary ESA-EpoR model . . . . . . . . . . . . . . . . . . . . . . 153
B.2 Deciphering the cellular composition of unknown patient samples for
immunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161
Declaration 167
xi

Introduction 1
„Quite soon, as we move from genes to the proteins
that they code for, and then on to the interactions
between these proteins, the problems become
seriously complicated. [142]
— Denis Noble
The Music of Life: Biology beyond the Genome
When the Human Genome Project announced in 2001 that more than 90% of the se-
quence of the human genome was decoded [110], more questions were raised than
answered. Despite the big success of having almost all genetic information of a human
being available, functional dependencies remained unclear and the role of epigenetic
modifications and regulation of gene expression became more evident than ever. Thus,
understanding the functional behavior requires more than knowing the genetic code
or the amino-acid sequence of a protein. But how can we improve the bigger picture
when we focus on all the small details? In systems biology, interdependencies in com-
plex systems are disentangled through a combination of experimental approaches and
mathematical modeling. Furthermore, recent advances in the field of bioinformatics
help to extract valuable information from high-dimensional data obtained by modern
high-throughput technologies.
In this thesis, several projects making use of methods from computational systems biology
are presented. While their biological background might seem unconnected, all of them
rely on predictive mathematical models in one or the other way, thereby forming the core
of this thesis. Before going more into detail, I want to shortly introduce the projects and
motivate their research questions.
Software development for systems biology
In computational systems biology, methods originating from statistics, mathematics and
physics are adapted to describe the behavior of biological systems. Complex experimental
setups with various readouts and indirect observations need to be mapped to trajectories
of differential equation models in order to calibrate priorly unknown parameters. As most
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models are non-linear in their parameters, optimization is not trivial and requires efficient
and robust implementations of established algorithms and methods. Since the early
beginnings of computational systems biology in the late 1990s [98], various software
tools have been developed to enable both experimentalist and theoreticians to perform
model simulations [83, 178, 124]. However, many of those software solutions are
relatively problem-specific or sacrifice computational efficiency for graphical interfaces
designed for users without a profound theoretical background. Starting from the great
need for curated solutions for data-based computational modeling, a group of researchers
developed the Data2Dynamics modeling software for MATLAB. One by one, the basic
concepts as well as advanced features got implemented by a growing community of
developers continuously extending the range of possible use cases. The questions that
arise here are:
Can community-driven software development accelerate and improve workflows in com-
putational biology research? What features do software solutions need to facilitate model
construction, calibration and analysis for systems biology modeling?
Another example of a software tool was motivated by a collaborative research project
among several institutions providing multiple large-scale data sets. In order to make
these data easily accessible and searchable for all parties involved, a web-based interface
for the data was developed. Upcoming questions during development were:
Which functionality enables the initial assessment and analysis of big data sets? How can
data are made available to users from multiple institutions independently from their local
infrastructure and technical background?
Identification of limiting factors during influenza virus infection
Since the Spanish flu in 1918–19 killed 20 to 40million people worldwide [151], influenza
A virus (IAV) infection is known to be a continuous threat to humanity. While the human
transportation networks in 1918 were small and the means of transportation extremely
slow, todays air transportation system connects every small province airport to the
rest of the world in less than six stops [4]. The impact on the spread of infections
is tremendous and can be modeled as circular waves on a specific distance measure
[20]. Therefore, despite the advances in vaccination, prevention and treatment of IAV
infection, the risk of a new pandemic remains high. In order to identify new drug
targets and develop universal vaccines, a fundamental understanding of how influenza
viruses replicate is critical. In the scope of this thesis, I focus on the first steps of virus
infection, which are the entry of IAV into the host cell and the transport of the viral
genome into the nucleus. While the mechanisms of virus-endosome fusion have been
2 Chapter 1 Introduction
investigated experimentally, the impact of altered pH-sensitivity to the success rate of
infection remained largely unclear. Using a systems biology approach, I want to tackle
the following set of questions:
How can intracellular processes regulate host specificity and strain pathogenicity? Which
nodes in the reaction network are limiting for the infection? How do changes in pH-sensitivity
of the viral hemagglutinin affect the infectivity of IAV?
Optimizing the treatment of cancer and associated health conditions
The lack of red blood cells is termed anemia and represents a major issue in cancer
patients, both as a side-effect of chemotherapy or induced by the malignancy itself
[174]. Also in patients suffering from chronic kidney disease (CKD), anemia is highly
prevalent. Almost every second pre-dialysis CKD patient shows hemoglobin levels below
12 g dl−1 [129]. The standard of care for anemic patients consist of a treatment either
by blood transfusion or by administering an erythropoiesis stimulating agent (ESA).
While blood transfusions can be very costly and are associated with an increased risk of
infections [174], the treatment using ESAs can be realized in self-administration using
a pen injection similar to an insulin pen for patients with diabetes [171]. However,
the treatment of cancer patients suffering from anemia using ESAs has been discussed
controversially as the ESA might stimulate survival and proliferation of cancer cells
[78]. Furthermore, even within the dosing guidelines provided by the drug authorities,
the dose might be inadequate for patients with an altered responsiveness to the drug
and might cause severe damage in risk groups. Here, a well-studied model of receptor
trafficking and signaling in response to ESA treatment is utilized to characterize the
in vivo properties of different ESAs and to infer the number of ESA binding sites for
different cell lines. By extending the model with a PK/PD part, the effect of the ESA
dose can be simulated and the dosing schedule for individual patients can be optimized
on-the-fly. This optimized treatment strategy can potentially contribute to a safe and
efficacious ESA treatment of anemic patients. The corresponding research questions are
formulated as:
Is there a better way to treat anemic patients? How can an optimal dosing schedule for
individual patients be achieved?
The treatment of cancer itself typically relies on surgery, chemotherapy and radiation
therapy. Only recently, a new class of anti-cancer drugs entered the field: immunotherapy
drugs. These drugs aim to recruit and activate immune cells to fight malignant tissue
and therefore might be used in combination with conventional treatments improving
the outcome of therapy significantly [109]. The key to success is the identification
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of appropriate patient populations for immunotherapy treatment. It was shown that
infiltration of the tumor micro-environment by certain immune cell types can serve as
a prognostic factor for overall survival [147]. However, the composition of the tumor
micro-environment is largely unknown and can only be broken down by histology of
tissue samples. In the past decade, high-throughput sequencing technologies evolved
rapidly and acquisition of RNA-seq data of tumor biopsies has become a common step in
clinical protocols [184]. Bulk gene expression data can be used for obtaining the cellular
composition via mathematical deconvolution. Previous deconvolution approaches were
based on micro array data and their accuracy was benchmarked on liquid samples
such as in vitro cell mixtures or whole blood samples [1, 157, 139]. In this project, I
investigated how RNA-seq data can be used for deconvolution of solid tumor samples. By
adapting existing methods to the new technology, absolute proportions of immune cells
and tumor-associated cells can be derived based on reference gene expression profiles
from single-cell RNA-seq data. The questions asked here are:
Does the micro-environment of immune cells affect gene expression? How reliably can the
immune cell content in tumor tissue be predicted from blood-derived reference profiles?
Thesis structure
In the following, I want to shortly outline the structure of this thesis. In Chapter 2,
both the experimental and the computational methods utilized in the scope of this
thesis are introduced. Here, the focus is on the basic concepts of the methods rather
than on an exhaustive description. In Chapter 3, two customized software solutions for
computational biology projects are presented. While the MATLAB based D2D software,
presented in Section 3.1, provides efficient implementations of established methods
mainly for ODE modeling, the data interface presented in Section 3.2 aims to make
big data sets easily accessible for users without a computational background. Next, in
Chapter 4, the infection of an organism with the influenza A virus is investigated. By
using a combination of ODE and spatial-stochastic modeling, limiting factors of virus
entry into the host cell could be determined. Chapter 5 spans two projects that deal with
cancer-related modeling approaches to optimize treatment strategies. The first project
deals with an optimized ESA treatment in cancer-associated anemia while the second uses
computational deconvolution of tumor tissue from RNA-seq data to characterize immune
cell infiltration. In the last chapter (Chapter 6), the individual results are brought into
a broader context and the projects are embedded into the current developments in the
field of systems biology.
4 Chapter 1 Introduction
Methods 2
2.1 Experimental methods
In this section I want to introduce the biological measurement techniques that have been
used to generate the data for the different projects. The aim is to give the reader a very
short introduction into the techniques and to provide references to literature where more
detailed descriptions can be found.
2.1.1 Fluorescence microscopy
Fluorescence microscopy is used to monitor specific features within a living or fixated
cell. Therefore, parts of the cell or individual molecules are labeled directly with a
fluorescent molecule (e.g. nucleus staining using DAPI) or labeled indirectly through
a conjugated antibody and a fluorescent secondary antibody. Another option is the
expression of fluorescent proteins (e.g. green fluorescent protein; GFP) coupled to a
protein of interest. The sample is then excited at a fluorophore-specific wavelength
and the resulting emission at higher wavelength is captured using a camera on the
microscope.
A review on the topic providing physical details and explaining recent developments is
given in Lichtman & Conchello [118].
2.1.2 Flow cytometry and cell sorting
Flow cytometry – in combination with cell sorting also known as Fluorescence Activated
Cell Sorting (FACS) – is a technique to characterize and sort cell populations according
to fluorescent cell markers, for instance antibodies. By applying multiple steps of cell
sorting, even cells with a low abundance in the overall population can be separated (e.g.
regulatory T cells in whole blood samples).
The method was developed by Fulwyler [62]. The principle is as follows: cells in suspen-
sion are entrained into a stream of liquid. The stream is broken into droplets containing
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only one cell each. Just before splitting the stream into droplets, fluorescently labeled
antibodies are excited by a corresponding laser and, depending on the fluorescence
intensity, the droplets are charged accordingly. Cell droplets are then sorted based on
their charge through deflection in an electrical field. The process not only sorts the cells
but also measures fluorescence and scattering of the light source in two directions to the
stream (i.e. forward scatter (FSC) and side scatter (SSC)). These parameters provide addi-
tional information on cell size (proportional to FSC) and surface properties (granularity;
proportional to SSC) of the analyzed cells.
While first generation FACS devices could measure three parameters (one fluorescence
color and two scattered-light signals), modern devices offer up to 19 parameters (17
fluorescence colors and two scattered-light signals) [153]. Therefore, modern flow
cytometry can, for instance, characterize many subpopulations of immune cells in only
one experiment. The historical development is reviewed in Herzenberg et al. [80]. The
more recent development of multi-color devices is described in Perfetto et al. [153].
2.1.3 Quantitative immunoblotting
Immunoblotting, also known as Western blotting, is a method to detect and quantify
specific protein content in a biological sample using antibodies that react with the target
protein. The technique was developed by Towbin et al. [193] and named in reference to
the Northern and Southern blotting technique to detect RNA and DNA, respectively.
For quantification of relative protein concentrations, cells are lysed and the proteins
are sorted by size via gel electrophoresis. Proteins move towards the anode at a speed
according to their molecular mass, usually measured in kDa. The resulting bands in
the gel can be transferred to a nitrocellulose membrane and the membrane is treated
with an antibody against the proteins of interest (primary antibody). The concentrations
can be detected through an enzymatic process of a reporter linked to the secondary
antibody. The chemiluminescent or fluorescent signal is then recorded by a CCD camera
and quantified from the band intensity of the image. A more extensive description of
the method including protocols for the experiment can be found in Yang & Mahmood
[215].
As investigated by Schilling et al. [177], gel effects can be minimized using a randomized
order of lanes. The errors of Western blotting data were shown to be mostly log-normally
distributed [104].
6 Chapter 2 Methods
Solid support
Substrate
Product
Protein
Capture
antibody
Enzyme-linked
detecting antibody
Fig. 2.1.: Schematic representation of a sandwich ELISA. A known quantity of capture anti-
body is bound to a surface. The sample is added and the protein of interest binds the
capture antibody. A secondary detecting antibody is added and binds to the protein.
This antibody is linked to an enzyme, which converts an added substrate to a product
with specific absorption at a defined wavelength. The absorbance can be measured
and quantifies the abundance of the protein.
2.1.4 Enzyme-linked immunosorbent assay (ELISA)
ELISA is an analytical biochemistry assay originally developed by Weemen & Schuurs
[209] and Engvall & Perlmann [56]. Using at least one enzyme-linked antibody, the
presence of a target protein is made visible through a color change caused by an enzymatic
reaction. To asses the concentration quantitatively, absorbance of the converted substrate
is measured. In Figure 2.1 the biochemical process of a sandwich ELISA is schematically
depicted.
2.1.5 Quantitative real-time PCR (qPCR)
PCR
Using the polymerase chain reaction (PCR) technique, single copies of pieces of DNA can
be amplified over several orders of magnitude. The process is depicted in Figure 2.2.
In a first step, original DNA is denaturated by a temperature increase to 94 ◦C to 96 ◦C.
At given annealing temperature, two primers bind to the 3’ and 5’ end of the target
sequence thereby flanking it. A heat resistant polymerase detects the double-stranded
regions and starts to elongate the primers according to the complementary strand at an
enzyme-specific higher elongation temperature. This temperature cycle is repeated 20 to
40 times until the reaction saturates due to exhaustion of reagents and enzyme.
2.1 Experimental methods 7
Fig. 2.2.: Scheme of the processes involved during PCR. (1) The original DNA to be replicated
(green) is denaturated by a temperature step to 94 ◦C to 96 ◦C. (2) Primers (red) bind
to DNA at ∼68 ◦C. (3) Elongation of new double-stranded DNA (blue) at ∼72 ◦C.
Repetition of steps (1)-(3) until saturation is reached. The figure is taken from
Enzoklop [57].
.
quantitative real-time PCR
In order to quantify the amplification, the original DNA is labeled using a fluorescent
dye. Therefore, in each cycle, fluorescence increases proportionally to the amount
of amplified DNA. The cycle number at which the fluorescence raises above a noise
threshold corresponds to initial number of copies in the sample.
2.1.6 High-throughput RNA sequencing (RNA-seq)
High-throughput RNA sequencing aims to quantify gene expression of the whole transcrip-
tome. It is based on next-generation sequencing of cDNA obtained by reverse transcribing
RNA.
Next-generation sequencing (NGS)
High-throughput or next-generation sequencing is a technique to sequence large amounts of
DNA in parallel. There are multiple technologies available based on different sequencing
approaches. Here, I will focus on the sequencing by synthesis approach that is used by
Illumina/Solexa platforms.
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Fig. 2.3.: Next-generation sequencing using the Illumina/Solexa technology. (a) Bridge
amplification of molecular clusters. (b) Sequencing by cycles of binding of labeled
nucleotides, washing and four-color-imaging and cleaving of dyes and terminating
groups. (c) Exemplary imaging pictures for six sequencing cycles. The figure was
adapted from Metzker [132].
Firstly, a template library needs to be prepared by breaking the DNA into short fragments
(typically 100 bp to 250 bp) and ligating an adapter set on both ends of the fragment.
These single-stranded DNA templates are then hybridized to the corresponding adapters
that are covalently bound to a glass slide in a flow cell as shown in Figure 2.3a. Sub-
sequently, the templates are clonally amplified through a bridge amplification so that
spatially separated template clusters are produced.
After amplification of the templates, the sequencing process is initiated by adding primers
that are complementary to the adapter regions initiating the binding of polymerases
to double-stranded regions as shown in Figure 2.3b. In each cycle, a set containing
of all four labeled nucleotides is added and incorporated into the new DNA strand.
These nucleotides are 3’-blocked so that each cluster can only incorporate one base.
After washing all unincorporated bases, four-color imaging of the slide is performed,
fluorophore and blocking group are cleaved and the next cycle is started by adding new
nucleotides. This cycling is repeated until the whole fragment is imaged or a predefined
read length is reached. An exemplary imaging sequence of DNA template clusters is
depicted in Figure 2.3c. Each cluster emits one color depending on the lastly incorporated
labeled nucleotide. More in-depth descriptions of the commonly used technologies are
available in reviews by Metzker [132], Goodwin et al. [71], and Mardis [125].
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RNA-seq
As stated above, for RNA-seq RNA is converted to cDNA by reverse transcription before
NGS can be applied. Therefore, only a few additional details need to be introduced
here. As a first step in data generation, mRNA or total RNA is fragmented and is reverse
transcribed to a cDNA library. To ensure that also less abundant transcripts are detected,
ribosomal RNA and very abundant transcripts are removed beforehand. Also, poly(A)
selection is effective to remove non-coding mRNA from eukaryotic cells. Unlike in the
case of genome sequencing, assembling the whole transcriptome from short reads is
not trivial because transcripts can share some exons making mapping from reads to
transcripts ambiguous. Therefore, longer reads are preferred but the most common NGS
technologies (e.g. Illumina) only provide reads of 75 bp to 150 bp. This problem can be
alleviated by using a paired-end protocol, where overlapping reads from both ends of
the cDNA are merged computationally [126].
single-cell RNA-seq
For single-cell transcriptomics, a variant of the RNA-seq method can be applied: Solid
tissue samples are dissected into small cubes and digested to obtain a single-cell sus-
pension. RNA from individual cells is extracted and reverse-transcribed to cDNA. To
be able to determine the cell of origin after sequencing, an 8 bp-barcode is added to
the 5’-end of the template. As the initial amount of RNA and therefore of cDNA is very
small, amplification of cDNA by PCR is needed. However, it was shown that amplification
can cause a severe bias as not all transcripts are amplified equally. To overcome this
bias, the use of a second tag, called unique molecule identifier (UMI), typically 5 bp long,
was proposed [99] and was successfully used to correct for the amplification bias [91].
With these two tags, the cell-specific barcode and the molecule specific UMI, an absolute
molecule count per cell can be established [91].
2.2 Data analysis
High-throughput technology can produce enormous amounts of data that is often not
directly interpretable. Data from RNA-seq experiments, for instance, provide short reads
of cDNA snippets that need to be mapped to a reference genome and require correction
for miscellaneous sources of errors. Here, I briefly want to introduce the concepts used
to process and analyze these data and provide some useful references to respective
literature.
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Fig. 2.4.: Flow chart of a typical RNA-seq processing pipeline. The left branch represents the
pipeline for bulk data, the right branch for single-cell data.
2.2.1 RNA-seq data processing
The output of an RNA-seq experiment is stored in a text-based FASTQ file. For each
read, it contains a read identifier (instrument ID, read length, flow cell lane etc.), the
nucleotide sequence and the corresponding quality scores. These raw data files need to
be processed into a quantity that is proportional to the number of RNA molecules present
in the sample. The individual steps of such a processing pipeline are introduced in the
following paragraphs.
The typical steps for processing single-cell and bulk RNA-seq data are depicted in a flow
chart in Figure 2.4. For each step, various software solutions have been implemented and
many institutions developed custom in-house scripts for data processing. I therefore will
only mention the basic concept of each step and refer to some prominent solutions.
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Quality control (QC)
In the first quality control step, the raw data is scanned for low quality reads, for instance
reads with biased base composition, that can be filtered out prior to mapping to avoid
potential mismatches when mapping reads to the reference genome. A second QC step is
performed after mapping and typically includes analysis of GC-content bias, PCR bias,
nucleotide composition bias, sequencing depth, strand specificity, coverage uniformity
and read distribution over the genome structure. Available tools for QC are provided e.g.
by Wang et al. [205] and DeLuca et al. [42].
Demultiplexing
In the demultiplexing step, barcodes identifying individual cells or samples are removed
and the data are split into separate files accordingly. If UMIs were used for single-cell
RNA-seq experiments, these identifiers are extracted as well and stored as meta data.
Mapping short-reads to the transcriptome
The mapping step serves to align the short reads obtained by sequencing to a reference
genome or transcriptome. For large transcriptomes, short reads can match multiple
locations in the genome and therefore an unambiguous alignment is not given [207].
Using a paired-end protocol, the read-length can be increased alleviating the problem of
multiple matches across the transcriptome.
Prominent alignment algorithms are e.g. STAR [47], Bowtie [112] and Bowtie 2 [111].
Other algorithms like TopHat [194] enable identification of splice junctions from short-
read RNA-seq data.
Quantification of read counts
After mapping of short-reads to the reference genome, for each gene or isoform, the
occurrence can be counted. These raw counts, however, are highly biased by gene length
and library size. Typically, these biases are corrected by using measures like reads per
kilobase per million reads (RPKM) that aim to provide a quantity that is relative to the
molar RNA content in the sample. However, it has been shown that the RPKM measure
is inconsistent among samples and a corrected measure, i.e. transcripts per million (TPM)
was suggested by Wagner et al. [202]. Modern quantification algorithms like RSEM
[115] provide results in this format making data easier to interpret.
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Upcoming approaches for integrated mapping and quantification
More recently, novel approaches for combined alignment and quantification of RNA-seq
data have been developed [150, 19]. These algorithms are extremely efficient as the
actual alignment, which is computationally very expensive, is replaced by a rough pseudo-
alignment or lightweight-alignment that suffices for the integrated quantification strategy.
Using these new methods, it is possible to quantify raw short-read data within minutes
on a regular laptop computer while former alignment and quantification strategies take
hours to days and require big capacities of memory [19]. Interestingly, when comparing
quantification results of the novel algorithms with established methods, the overall
quality seems to be comparable.
Normalization
While the quantification result measured in TPM is consistent for all samples from the
experiment, comparing samples across different experiments and technologies requires
additional normalization strategies. Common methods involve median or upper quartile
normalization, assuming that most genes are expressed independently of the experimental
condition or origin of tissue. Also revised lists of house-keeping genes can be used for
normalization [52]. A comparison of normalization approaches was performed by Li
et al. [117]. For single-cell sequencing data, normalization methods have been compared
by Ding et al. [46].
2.2.2 Dimensionality reduction
Data obtained by high-throughput technologies such as RNA-seq are often hard to
interpret due to their high dimensionality. Instead of looking at gene expression levels
for individual transcripts, clusters of genes with related functionality and differences of
these clusters among cell types or patients are of interest. To extract and visualize these
properties, dimensionality reduction can be a valuable tool, reducing the space of ∼20 k
genes to a low-dimensional map.
Principle Component Analysis (PCA)
Principle component analysis [152] is a method for dimensionality reduction. It uses
an orthogonal transformation to transform a set of correlated variables into linearly
uncorrelated variables that are called principal components. These components are
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Fig. 2.5.: Example for PCA, t-SNE and DBSCAN clustering applied to the MNIST (Modified
National Institute of Standards and Technology) database of handwritten digits
[114]. (a) The first two principle components do not fully separate the points by
the digits, as depicted by colors. (b) Two-dimensional t-SNE mapping shows distinct
clusters for each digit. (c) DBSCAN clustering on the unlabeled t-SNE map can correctly
identify most of the clusters. Grey dots indicate points without cluster assignment.
The parameters for DBSCAN were set to Eps=1.0 and MinPts=50.
sorted by the amount of variance they explain. Therefore, often, only the first few
components are analyzed in order to identify interesting features in high-dimensional
data sets. In Figure 2.5a, the first two principal components of a typical test data set are
shown. In Section 5.3, PCA was applied before decision tree classification and t-SNE
mappings.
t-Distributed Stochastic Neighbor Embedding (t-SNE)
A recently developed approach for mapping a high-dimensional data set onto a low-
dimensional map is t-distributed stochastic neighbor embedding [196]. It maps each
high-dimensional feature, such as the gene expression profile of an individual cell, to
a two- or three-dimensional point in such a way that similar features result in nearby
points and dissimilar features are represented by more distant points. The resulting map
can be represented as a scatter plot. In Figure 2.5b, the result of a t-SNE mapping of the
MNIST database is depicted. In Section 5.3, t-SNE was used to identify clusters of single
cells belonging to the same cell type.
2.2.3 Clustering
DBSCAN
Density-based spatial clustering of applications with noise (DBSCAN) is a clustering algo-
rithm originally developed by Ester et al. [58]. The algorithm groups neighboring points
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Fig. 2.6.: Example of a ν-SVR on two-dimensional data. Depending on the choice of ν, the
number of support-vectors and thereby the width of the ε-insensitive tube is varied, as
depicted by the shaded area.
depending on their density and labels outliers without direct neighbors. It depends only
on two parameters, Eps and MinPts, that determine both, the sensitivity to noise and the
number of points per cluster. Therefore, for each point, the number of points within an
Eps-radius are counted. If at least MinPts are within distance Eps, the point is defined as
a core point. All core points that are mutually density-connected, i.e. that are reachable
from one another, form a cluster.
The result of a DBSCAN clustering on the t-SNE transformed MINST data set is shown in
Figure 2.5c. Most clusters, representing individual digits, can be assigned correctly. In
Section 5.3, the DBSCAN clustering algorithm was applied on the t-SNE map of single-cell
sequencing data to identify clusters of single cells belonging to the same cell type.
2.2.4 Support Vector Regression (SVR)
Support vector regression is an algorithm based on the supervised machine learning
method support vector machine (SVM). Other than SVM, which is used for classification
by defining separating planes in the high-dimensional space, SVR is used for regression of
high-dimensional data. The kernel used for regression can be either linear or non-linear
and various strategies for the choice of the parameter ε can be applied. When using an
ε-insensitive loss function, ε defines a range around the regression hyper-plane that does
not influence the regression result. Depending on the size of ε, the SVR becomes more
sensitive or robust to noise.
In Section 5.3, the ν-SVR algorithm Chang & Lin [25] with a linear kernel was used
for deconvolution of sequencing data from bulk patient samples. In contrast to ε-SVR,
instead of controlling the ε-insensitive range directly, the number of support vectors
is regulated through the choice of ν. Therefore, a small value of ν corresponds to a
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Fig. 2.7.: Scheme of a decision tree classification. A dataset containing five features x1, . . . , x5
is classified into four classes a, b, c, d. At each node, a binary decision is made based
on the value of one feature. Instead of the features xi, also the principle components
can be used for classification.
wide ε-tube, while a larger ν decreases ε, as shown in Figure 2.6. A detailed tutorial on
SVR is given by Smola & Schölkopf [185]. An efficient implementation in C is provided
by Chang & Lin [24] in the package libSVM, which includes wrappers for Python and
MATLAB.
2.2.5 Decision-tree Classification
Classification of unknown data into predefined categories is needed, for instance to
assign the cell type of single-cell data based on the gene expression profile. Given a data
set with known classes, a decision-tree classifier can be trained. Therefore, in each level
of hierarchy, the score of one feature defines a binary decision as shown in Figure 2.7.
In the case of gene expression data, the features correspond to genes. Thus, it can be
useful to reduce the high-dimensional feature space by performing a PCA beforehand.
The accuracy of the trained classifier can be assessed, for example, by cross-validation,
where the training is performed multiple times each time on a subset of the data. Once the
classifier is trained, it can be used to classify data with unknown labels. For assignment
of cell types for single cells based on RNA-seq data in Section 5.3, a combination of
dimensionality reduction, clustering and decision-tree classification was used.
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2.3 Dynamic modeling
Many of the methods introduced in this section are described in more detail in
Raue, A., Schilling, M., Bachmann, J., Matteson, A., Schelker, M., Kaschek, D., Hug, S.,
Kreutz, C., Harms, B. D., Theis, F. J., Klingmüller, U. & Timmer, J. „Lessons Learned
from Quantitative Dynamical Modeling in Systems Biology“. PLOS ONE 2013, 8(9):
e74335.
The concepts have been implemented in the Data2Dynamics modeling software that is
described in Section 3.1 of this thesis.
2.3.1 Biochemical reaction networks
Biochemical reactions are stochastic events. When the described system is spatially
homogeneous (i.e. “well-stirred”) and the number of reacting molecules large, so that
many simultaneous reaction events occur, the reactions can be described using ordinary
differential equations (ODEs) [88].
ODE models
The change over time of the concentration of a substance A can be written as
d[A]
dt = v (2.1)
where [A] denotes the concentration of A and v represents the reaction flux. Most
general, the form of v can be defined by mass-action kinetics where the reaction rate is
proportional to the concentration. Hence, for an example reaction
A→ B, (2.2)
we obtain
v = k1[A] (2.3)
and the temporal change of A is defined by the ODE
d[A]
dt = k[A]. (2.4)
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k is called the rate constant and describes the proportionality of the substance concentra-
tion to the reaction flux.
When reactions are catalyzed by an enzyme, Michaelis-Menten kinetics [133] can be used,
resulting in the ODE
d[S]
dt = −Vmax ·
[S]
KM + [S]
(2.5)
where Vmax defines the maximum reaction velocity, which depends on the amount
of available enzyme and the catalytic activity of the enzyme. KM is the Michaelis
constant describing the substrate concentration at which the reaction rate is half-maximal.
One important prerequisite for using Michaelis-Menten kinetics is that the enzyme
concentration is much less than the substrate concentration [180].
Other types of kinetics can be derived from mass action kinetics and can be tailored to
the required level of detail. A detailed review on kinetic laws and their applications is
given by Tummler et al. [195].
In the scope of this thesis, besides mass action, Hill-kinetics were utilized:
v = [A]
n
(KD)n + [A]n
(2.6)
where n is the Hill-coefficient defining the steepness of the sigmoidal reaction curve and
KD represents the dissociation constant. Hill kinetics describe the cooperative binding of
multiple substrate molecules to the enzyme. For n > 1, the affinity of a sustrate to bind
the enzyme is increased once one molecule is bound [195].
For describing a whole set of ODEs for all compounds involved in the reaction network,
we use a more general notation. The model species are denoted as x⃗ = (x1, . . . , xm)T and
the ODEs are defined by
dx⃗
dt = f⃗x(x⃗, t) (2.7)
where f⃗x(x⃗, t) is a function of the reacting species x⃗ and of the time t.
Stochastic models
When the number of molecules in a reaction compartment is very small, the assumptions
for describing the model dynamics using ODEs do no longer hold true. Thus, a stochastic
simulation of the model is needed reflecting the stochastic nature of the underlying
chemical reactions. Systems that require a stochastic description are, for instance, the
dynamics of gene expression on a single-cell level as investigated both experimentally
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and theoretically by Elowitz et al. [55]. A comprehensive review on the topic is provided
by Wilkinson [211].
While for ODE models, the model simulations for a given set of parameters always result
in the same trajectories (as the system is deterministic), each realization will be different
for stochastic models. Because the reactions need to be calculated on a single-molecule
level, the simulation becomes computationally more expensive for stochastic systems.
The Gillespie algorithm [68] provides an efficient way to simulate individual realizations
of these systems exactly while reducing the computational effort.
Another type of stochastic simulation is required when describing the movement of
individual particles, such as virions, in a defined geometry, where spatial aspects need
to be considered. Here, the stochastic simulation determines the direction, step-size
and time point of the movement rather than the probability of a chemical reaction and
the “well-stirred” assumption is no longer needed. On specific geometries, important
characteristics like the mean first passage time (MFPT) can be calculated analytically
[108, 179, 65].
Reaction-diffusion models
Reaction-diffusion models are used when the system under investigation is spatially
inhomogeneous, meaning that the diffusion is not sufficiently fast to make the system
“well-stirred”, and the molecule numbers are too small for a deterministic description
of the chemical reactions. Simulation of such models is achieved by discretizing the
space into small compartments where the „well-stirred“ assumption is valid again. The
transition from compartment to compartment can be simulated using a variant of the
Gillespie algorithm [212]. Therefore, individual simulations result in different trajectories
through the geometry but reactions within a compartment, such as the dimerization of
two molecules, follow mass action kinetics.
Modeling frameworks like STEPS [212, 79] and MesoRD [59] provide the means to
run simulations on complex, user-defined geometries and offer various features for
analysis and visualization. In Section 4.2, STEPS was utilized to describe the diffusion of
individual viral genome complexes through the cytosol of the host cell.
2.3.2 Parameter estimation
ODE models of biological systems aim to describe dynamics of the model species over
time. As introduced in Section 2.3.1, the differential equations describing biochemical
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reactions comprise parameters such as rate constants and Michaelis constants. The values
of these parameters may depend on experimental conditions and values from literature
are therefore only of limited use.
Experimental data quantifying, for instance the cellular response to an external stimulus,
can be utilized to infer unknown model parameters. The parameters to be inferred might
also comprise scaling parameters that account for an indirect experimental observation
of the quantity of interest or parameters of an error model, as introduced in the following
paragraphs.
Observables
Experimental measurements of biological species, such as proteins, often provide only
relative abundances, as in case of Western blotting or ELISA (see Section 2.1.3 and Sec-
tion 2.1.4). In order to link data to the model, so-called observable functions are required
that define the projections of the model species which are observable experimentally.
Typical examples are sums of proteins in different phosphorylation states combined with
a scaling parameter accounting for the relative nature of the measurement technique.
More generally, the model species x⃗ are mapped to an experimental observation through
a function f⃗y:
y⃗(t, θ) = f⃗y(t, x⃗(t, θx), θy), (2.8)
where θx denotes the parameters occurring in the ODEs f⃗x and θy are parameters in the
observables f⃗y such as scaling parameters.
Error models
The choice of the correct error model is crucial for reliable parameter estimation results.
In biology, multiple replicate measurements are generated to obtain an estimate of the
margin of fluctuation. These replicates are then used to calculate the mean and the
standard deviation for each time point. This assumes that two criteria are met: (1) the
uncertainty of the data is normally distributed and (2) the sample size n is large enough
to gain a meaningful estimate of the mean and the standard deviation [164].
These prerequisites, however, are not always met, for instance when only a single time
course measurement is available as is the case for some observables in Section 4.2. Using
a parametric error model, that is fitted simultaneously with the model parameters, can
overcome this issue. Therefore, individual replicates are included and the error model is
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defined according to the measurement technique, for instance log-normally distributed
errors for Western blot measurements [104].
The general form of the parametric error model reads as
σ⃗(t, θ) = f⃗σ(t, y⃗(t, θ), θσ, ) (2.9)
where θσ denote the parameters of the error model f⃗σ. Based on a simulation study, it
was shown that this approach yields more accurate parameter estimation results as in
case of preprocessed data [164]. For simplicity, in the following only the one-dimensional
case is shown and vector notation can be waived. The multidimensional case works
analogously.
Maximum likelihood estimation
The quality of a model simulation with respect to measured data can be assessed by the
likelihood [204]. For normally distributed measurement noise, the likelihood reads as
L(y†|θ) =
n∏
i=1
1√
2πσ(ti, θ)
exp
⎡⎣−12
(
y†i − y(ti, θ)
σ(ti, θ)
)2⎤⎦ (2.10)
where y†i denotes the i-th of n data points, y(ti, θ) represents the corresponding model
observable at time ti and σ(ti, θ) denotes the error model. When including more than
one replicate, ti can have multiple indices for the same time point.
By taking the logarithm of (2.10), it follows
−2LL(θ) = n · ln 2π  
const.
+
n∑
i=1
⎡⎣2 ln σ(ti, θ) +
(
y†i − y(ti, θ)
σ(ti, θ)
)2⎤⎦ (2.11)
with LL(θ) := lnL(y†|θ) denoting the log-likelihood.
Maximum likelihood estimation aims to maximize the likelihood L by systematically
varying the parameters θ. As the logarithm is a monotonous function, this is equivalent to
minimizing (2.11). For this purpose, numerical optimization algorithms can be utilized.
The concept of numerical optimization is introduced in Section 2.4.2.
When estimating a parametric error model simultaneously with the model parameters,
an additional correction term in (2.11) is needed to account for the reduced degrees of
freedom
α = n
n− ℓ (2.12)
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with n denoting the number of data points and ℓ := #θFit−#θσ representing the number
of fitted parameters minus the number of parameters comprised in the error model.
This term can be derived in analogy to Bessel’s correction for the standard deviation of a
finite sample, i.e.,
SD = 1
n− 1
n∑
i=1
(xi − x¯)2 (2.13)
where x¯ represents the sample mean [14].
The full log-likelihood then reads as
−2LL(θ) = const.+
n∑
i=1
2 ln σ(ti, θ) +
n∑
i=1
n
n− ℓ
(
y†i − y(ti, θ)
σ(ti, θ)
)2
. (2.14)
The maximum likelihood estimator, which is the parameter set yielding the highest
likelihood value, is denoted by θˆ and is defined as
θˆ := argmax
θ
LL(θ) (2.15)
or analogously
θˆ := argmin
θ
[−2LL(θ)]. (2.16)
2.3.3 Parameter identifiability
The identifiability of a model parameter describes how well the parameter can be
determined based on model structure and available data. Multiple approaches for
identifiability analysis have been developed and were compared e.g. by Raue et al. [159].
Here, the focus lies on the profile likelihood approach [203, 162] that allows for the
identification of structurally and practically non-identifiable parameters and provides
confidence intervals for the estimated parameters.
The profile likelihood (PL) is defined as
PL(θi) = min
θj ̸=i
[−2LL(θ)] (2.17)
where θi is the model parameter of interest and LL(θ) denotes the log-likelihood as
defined in (2.11).
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Fig. 2.8.: Identifiability analysis based on the profile likelihood approach. The solid black
line indicates the likelihood profile, the gray asterisk shows the value of the best point
estimate and the red dashed line indicates the 95%-confidence threshold (point-wise).
(a) Structurally non-identifiable parameters exhibit a flat likelihood profile. Changes
in the value of p1 do not affect the value of the profile likelihood. (b) Practically non-
identifiable parameters often have half-open confidence intervals due to insufficient
quality or amount of data. (c) Fully identifiable parameters show parabola-shaped
likelihood profiles.
Three exemplary likelihood profiles are shown in Figure 2.8. The shape of the profile
indicates the identifiability of the parameter. As shown in panel a), for structural non-
identifiable parameters, PL is constant resulting in a flat line. In case of a practical
non-identifiability, as depicted in panel b), the data are not sufficient to define both
confidence bounds or defines them only on a low level of confidence. The panel c) shows
a fully identifiable parameter, where both confidence bounds defined with sufficient
confidence.
The confidence intervals can be computed using the likelihood-ratio test [201]. Therefore,
the reduced model, where the parameter of interest is fixed, is compared with the full
model leading to
CIα(θi) = {θi| −2LL(θˆ)− PL(θi)  
∆LL
≤ icdf(χ2dof , α)}, (2.18)
where α represents the confidence level, icdf denotes the inverse cumulative density
function and dof are the degrees of freedom. As the reduced model differs only by one
parameter beeing fixed to its point estimate, here dof = 1 and for α = 0.95
icdf(χ2dof=1, 0.95) = 3.84 (2.19)
and thus
CIα=0.95(θi) = {θi|∆LL ≤ 3.84} (2.20)
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or, put another way, as soon as PL is by 3.84 greater than the negative log-likelihood at
the optimum, the confidence threshold is crossed.
2.4 Numerical methods
Coupled systems of ODEs, as used to model the dynamics of biological systems, are only in
special cases analytically solvable. Fitting unknown rate constants and other parameters
to measured data poses a non-linear optimization problem that often exhibits multiple
local optima. In this section, the fundamental methods for solving ODEs numerically and
for maximizing the likelihood of a model given the data shall be introduced.
2.4.1 Integration of differential equations
Let us start with a simple ODE of the shape
dx(t)
dt = f(t, x(t)) (2.21)
where f(t, x(t)) can be any function of the time t and the variable x(t).
The derivative of x(t) with respect to the time is defined as
dx(t)
dt = limh→0
x(t+ h)− x(t)
h
. (2.22)
When solving (2.21) numerically, (2.22) is used and the limh→0 is replaced by a small
number
f(t, x(t)) ≈ x(t+ h)− x(t)
h
. (2.23)
Starting from an initial value x(t = t0) := x0, a recursive formula for (2.23) is obtained
x(tn+1) = h · f(tn, x(tn)) + x(tn). (2.24)
This numeric approximation of the solution of (2.21) is called the Euler method [22]. It
represents the simplest approach of an explicit method for solving ODEs numerically.
More sophisticated approaches like Runge-Kutta methods make use of higher order terms
and therefore provide a higher accuracy of the solution. For an extensive description of
numerical algorithms for solving ODEs, refer, for example, to Butcher [22].
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In this thesis, the numerical solvers from the SUNDIALS suite [81] have been used
that are based on the Adams-Moulton method and backwards differentiation formula
(BDF). These implicit methods can also handle stiff equations, (i.e. ODEs that involve
different time-scales) and offer the simultaneous integration of sensitivity equations (see
Section 2.4.2).
2.4.2 Optimization
Estimating rate constants and other parameters comprised in an ODE model based on
experimental data is a crucial part of the modeling process. As introduced in Section 2.3.2,
the likelihood of a model given the data can be used as an objective function to estimate
parameters. This optimization problem needs to be tackled numerically as it can be
highly nonlinear with respect to the parameters.
Optimization algorithms
Gradient descent The minimum of an objective function g(z) can be found numerically
by descending iteratively in the direction of the negative gradient of g(z):
zn+1 = zn − γ∇g(z). (2.25)
The step-size γ can be determined in every step of the optimization, for instance using a
line search [143]
γˆ = argmin
γ
g(z − γ∇z). (2.26)
Newton’s method for optimization Newton’s method can be derived from the Taylor
expansion of g(z) around zn
g(zn +∆z) ≈ g(zn) +∇g(zn)∆z + 12∆z
THg(zn)∆z (2.27)
with [Hg(z)]ij = ∂
2g(z)
∂zi ∂zj
being the Hessian of g.
In order to minimize g(z), a minimum of (2.27) with respect to ∆z needs to be found,
thus
0 = dd (∆z)
(
g(zn) +∇g(zn)∆z + 12∆z
THg(zn)∆z
)
(2.28)
= ∇g(zn) +Hg(zn)∆z. (2.29)
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Hence, a step in direction
∆z = −[Hg(zn)]−1∇g(zn) (2.30)
and thus
zn+1 = zn − [Hg(zn)]−1∇g(zn) (2.31)
will decrease the value of g [143].
For so-called Quasi-Newton methods, the Newton step in (2.30) is scaled by a factor
γ ∈ (0, 1) and the Hessian Hg(z) is replaced by an approximation Bg(z) [143]
∆z = −γ[Bg(zn)]−1∇g(zn). (2.32)
Trust-region optimizers A trust-region optimizer approximates g locally by a simple,
often quadratic model. The trust-region defines the region where the model can be
trusted to be an adequate representation of the objective function. In this region, a
step minimizing the model is chosen. Therefore, the direction and step-size is chosen
simultaneously. If the step is not accepted, the trust-region is shrunk and a new step to
minimize the model is chosen [143].
In this thesis, for local optimization mainly the MATLAB function lsqnonlin was applied
which uses the residuals rather than the value of the objective function. This function is
based on a trust-region algorithm [35, 34] and it requires user-supplied gradient infor-
mation (see also the subsequent paragraph on derivatives). The Hessian is approximated
directly by the algorithm.
Local vs. global optimization
In Figure 2.9, the gradient-descent method is shown for a two-dimensional optimization
problem. Depending on the initial parameter values, the closest local optimum is reached
by descending in the direction of the negative gradient. In higher-dimensional systems,
such as biochemical reaction networks with several unknown parameters, the problem
of local optima can be aggravated. To overcome this issue, either stochastic, global opti-
mization algorithms or a multi-start strategy can be applied. While global optimization
claims to generally circumvent the problem of “getting stuck” in a local optimum [169],
it was shown that multi-start strategies can be more efficient at least for certain classes
of models [163]. An overview of different local and global optimization approaches and
their application in systems biology is given by [5].
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Fig. 2.9.: Local optimization of two parameters p1 and p2 from multiple starting points.
Lines in orange show the steps of a gradient descent method with a fixed γ = 0.02.
Depending on the initial values of p1 and p2, the closest local optimum is reached.
Derivatives
As introduced in the previous section, local optimization algorithms rely on the gradient
and Hessian of the objective function to define the direction and step-size of the optimizer.
Differentiating the log-likelihood, as defined in (2.14), with respect to θj gives
∂LL(θ)
∂θj
= −
n∑
i=1
1
σ(ti, θ)
· ∂σ(ti, θ)
∂θj
+ n
n− ℓ
n∑
i=1
y†i − y(ti, θ)
σ2(ti, θ)
[
∂y(ti, θ)
∂θj
+ y
†
i − y(ti, θ)
σ(ti, θ)
· ∂σ(ti, θ)
∂θj
]
, (2.33)
where the chain rule and the product rule were applied. Further applying the chain rule
leads to
∂y(ti, θ)
∂θj
= ∂y(ti, θ)
∂x
∂x(ti, θ)
∂θj
. (2.34)
Most of the terms in (2.33) can be determined analytically from the model equations.
Only the derivative
∂x(ti, θ)
∂θj
(2.35)
can, in most cases, not be calculated analytically as it depends on the solution of the
ODE
dx(t, θ)
dt = fx(t, x, θ). (2.36)
Therefore, (2.35) is typically approximated by finite differences, i.e.
∂x(t, θ)
∂θj
≈ x(t, θ +∆θj)− x(t, θ)∆θj , (2.37)
with ∆θj being a small perturbation in direction e⃗j .
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Fig. 2.10.: Comparison of finite differences and sensitivity equation based derivatives.
Both approaches are compared for the variable Epo and its derivatives with respect to
the parameters (a) kdi and (b) kde from the ESA-EpoR receptor model (Section 5.2).
The blue line depicts the solution of the sensitivity equation, red, yellow and purple
represent different values of ∆θ for the finite differences approach.
When solving the ODE numerically for two parameter sets θ and θ +∆θj , the numerical
algorithm for solving the ODE takes different time steps for both runs. Subtracting the
two solutions can therefore induce numerical noise as shown in Figure 2.10.
Sensitivity equations [44] provide an alternative way of calculating derivatives numerically
while avoiding the induction of numerical noise. They are obtained by solving an
additional system of ODEs where the derivative in (2.35) represents the new integration
variable:
SEj(t, θ) :=
∂x(t, θ)
∂θj
. (2.38)
Differentiating both sides of (2.38) with respect to the time
dSEj(t, θ)
dt =
d
dt
dx(t, θ)
dθj
(2.39)
and switching the differentiation variables leads to
dSEj(t, θ)
dt =
d
dθj
dx(t, θ)
dt . (2.40)
With (2.21) and (2.38), it follows the sensitivity equation
dSEj(t, θ)
dt =
∂fx(t, x, θ)
∂x
SEj(t, θ) +
∂fx(t, x, θ)
∂θj
. (2.41)
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Again, the partial derivatives of fx with respect to x and θj can be calculated analytically.
The numeric solution of (2.41), as shown in Figure 2.10, provides a smooth and accurate
approximation of the true derivative. An implementation of this method is used in the
Data2Dynamics software introduced in Section 3.1.
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Developing software tools
tailored to systems biology
applications
3
In this chapter, I want to highlight the importance of the development of special-
ized software for systems biology and present two examples of such tools: First, the
Data2Dynamics (D2D) software is introduced. It provides efficient implementations of
well-established methods for data-based dynamic modeling. It enables researchers to
include data obtained under various experimental conditions, to estimate measurement
uncertainties based on parametric error models and to analyze parameter identifiability.
In contrast to other freely available software tools for computational modeling, D2D is
constantly evolving through community-driven development on GitHub1. The second
project consists of a web-based interface for browsing, analyzing and filtering multiple
high-throughput data sets acquired within the research project ViroSign. It provides fast
and platform independent means for gathering from multiple sources and exporting
filtered subsets for further analyses.
3.1 Data2Dynamics – A framework for data-based
modeling
The Data2Dynamics software is developed in a community effort. The corresponding
publication is:
Raue, A., Steiert, B., Schelker, M., Kreutz, C., Maiwald, T., Hass, H., Vanlier, J.,
Tönsing, C., Adlung, L., Engesser, R., Mader, W., Heinemann, T., Hasenauer, J.,
Schilling, M., Höfer, T., Klipp, E., Theis, F., Klingmüller, U., Schöberl, B. & Tim-
mer, J. „Data2Dynamics: a modeling environment tailored to parameter estimation in
dynamical systems.“ Bioinformatics Nov. 2015, 31(21): 3558–3560.
1http://www.github.com
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The original parameter estimation benchmark study was published in:
Raue, A., Schilling, M., Bachmann, J., Matteson, A., Schelker, M., Kaschek, D., Hug, S.,
Kreutz, C., Harms, B. D., Theis, F. J., Klingmüller, U. & Timmer, J. „Lessons Learned
from Quantitative Dynamical Modeling in Systems Biology“. PLOS ONE 2013, 8(9):
e74335
My contributions to the project comprise a systematic evaluation of supported SBML
features based on the SBML Test Suite [96], improving the SBML import and export
capabilities and performing general maintenance and bug fixing. Moreover, I performed
the updated benchmark study presented in this section.
Intracellular models of signaling are mostly based on ODEs and therefore require numeric
integration routines. The model parameters, describing e.g. initial concentrations or
rate constants, are often unknown and existing values from literature are incompatible
due to differing experimental conditions. Therefore, efficient and reliable inference of
parameters is key for gaining insights from mathematical models of biological systems.
As introduced in Section 2.4, a variety of numerical algorithms for solving differential
equations and for optimizing the likelihood of a model given experimental data have
been developed in the past and implementations in common programming languages are
publicly available. Over the last decade, several software tools for model construction,
calibration and identification have been developed [178, 83, 219, 124] and have been
successfully utilized to model biological systems [see e.g. 154, 187, 218, 12].
Model quantities are often not directly detectable and require mapping through model
observables (see Section 2.3.2). Furthermore, data can be acquired under multiple
experimental conditions, such as different doses of ligand stimuli, and model variants
may apply for data generated using mutants with deletions or over-expression of specific
genes of interest. These complex setups demand for flexible modeling frameworks that
can be adapted to the specific requirements of individual users. While existing software
is often available in a compiled form and providing graphical user interfaces (GUIs) to
its users, the software tool presented here, is based on a transparent source code written
in the scientific computing language MATLAB (The MathWorks Inc, Natick, MA) and the
main functionality does not rely on GUIs. As the name of the software, Data2Dynamics
(D2D), implies, it has a strong focus on data-based dynamic modeling. Unlike most
existing tools, D2D is intended for advanced users of whom many also contributed as
authors to the development of individual features.
In the following sections, I want to quickly motivate the use of community based
development exemplified by the genesis of D2D, give an overview of the key features
of D2D and eventually, provide a benchmark of different algorithms for parameter
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estimation on two published models with biological data. For the computational methods
D2D is based on please refer to Section 2.4.
3.1.1 Community based development
The development of non-commercial, scientific software is mostly performed by scientists
from individual work groups. As permanent positions in science are rare and frequent
changes in work locations and institutions are common, the long-term development and
maintenance of software cannot be guaranteed and many project can quickly become
orphans. Thus, an active community of developers and users from multiple institutions
enhances the development of scientific software tools and ensures that the correct
operation does not depend on a individual person or work group. This is also crucial for
reproducing published models and therefore for reproducibility of science in general. In
the following, the genesis of the D2D software is briefly introduced and the strong link
to its community-driven development is highlighted.
Version control & community work
The development of the D2D software was initiated by Andreas Raue. During the first
two years of development, the number of users and contributors increased continuously
and the organization of code became more and more complex. Therefore, in March
2013, the source code of D2D was transferred to the hosting service Bitbucket2 and the
development was tracked using the version control system (VCS) Mercurial. This step
simplified and accelerated the development dramatically, as all registered users could
now contribute to the source code and make their changes available to the community.
Also the process of bug fixing is strongly facilitated by the embedded issue tracking
system on the web platform.
With the publication of the manuscript [164], the repository was opened to the public
and a documentation was created on the wiki of the repository. In spring 2016, the
repository, including all revision history and documentation, was migrated to GitHub
and the VCS was converted to git. While there are only minor differences between both
VCS, the choice of the web-platform is crucial to reach potential users and to motivate
interested scientists from the field to contribute to the project.
2http://www.bitbucket.org
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Fig. 3.1.: Evaluation of individual contributions as measured by LOC and number of com-
mits. (a) LOC is shown for all parts of D2D written in MATLAB over time. Colored
circles indicate the author responsible for the commit. Color-coding as in panel b).
Please note that the measure is cumulative and does not represent the LOC added by
each commit. (b) Number of commits per author. The first five authors account for
∼90% of the commits.
Statistics and contributions
By using a VCS, the activity of all contributors can be tracked over time. Here, I present
a short analysis of the individual contributions over time to emphasize the advantages
of a community-based, open development process. The data shown in Figure 3.1 were
obtained through a custom shell script making use of the git functions git log, git
ls-tree and git show.
In Figure 3.1a, the cumulative measure lines of code (LOC) is plotted over time for the
whole D2D MATLAB source code. Third party code was excluded from the analysis. The
color-coding indicates the author responsible for each commit but does not reflect the
extent or importance of individual commits. From the figure it can be seen that from
March 2013 to the end of 2014, the development was mainly driven by three authors
and the LOC increased only gently from ∼25 k to ∼35 k. In 2015 new authors joined and
the LOC increased drastically. Therefore, also the functionality of D2D was diversified as
authors tend to implement new features required for their own research.
In Figure 3.1b, the overall number of commits is depicted for all contributing developers.
Over the last four years, 17 authors made a total of more than 1400 commits to the source
code repository. While some authors implemented a few small bug fixes or a specific
feature for their projects and therefore had only a few commits, the five most active
authors account for ∼90% and the seven most active developers even for ∼95% of the
commits. This distribution exemplifies that the development is driven by only a few
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authors but a larger community contributes sporadically to fix issues and add missing
functionality.
Despite the good availability of data from the VCS, it is difficult to find a measure that
quantifies the contribution to the functionality, scope and stability of a software, as
commits can contain minor or major changes and revision of existing code can even have
a negative net LOC despite its utility. Nevertheless, as the software evolves, an increase
in LOC, number of commits and contributing authors indicates a steady improvement of
existing code and a diversification of features.
3.1.2 Selected features
The core features of D2D, which are simulation of ODE models, parameter estimation and
identifiability analysis, have been extended and improved over time. In the following, a
small selection of the features of D2D is presented. The emphasis lies on those features
that distinguish D2D from existing tools.
SBML import and export
The systems biology markup language (SBML) [84] is a model format that enables a
detailed description of all species, compartments and reactions. Therefore, SBML import
and export functionality is key for the compatibility with other software in the field of
systems biology and was included early on.
D2D, as many other tools, makes use of the libSBML library [17] to translate the
xml format of SBML to a structured array in MATLAB. One difficulty are the different
approaches of the model description in SBML vs. D2D: While D2D has a strong focus on
signaling models that are comprised of model states, external inputs, time independent
parameters and conditions that allow to transform parameters and/or states, in SBML
models there are many more possibilities to define the model behavior based on rules,
events etc.. Hence, the challenge is to map and translate SBML features to D2D syntax
back and forth. However, it should be stated that a full support of all SBML features is
not intended as this would go beyond the scope of the software. Even extensive software
tools like COPASI [83], that cover a broad field of use cases, provide only partial coverage
of the SBML support.
To evaluate the SBML import functionality, the SBML Test Suite [96] can be utilized.
The current version consists of a total of 1219 models covering the majority of model
features that can be defined using SBML. For each SBML model file, a results file indicates
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the correct results in terms of the simulated model trajectories and serves as the gold
standard. Based on the comparison of the gold standard with the D2D simulations, the
percentage of supported SBML test models can be compared to other software solutions.
For D2D, a total of 273 out of the 1218 test models yielded trajectories with a deviation
from the gold standard of less than 1× 10−6. Thus, 22.4% of the test cases are supported.
For established software tools this ratio is substantially higher, as obtained from the
SBML Test Suite Database3: While COPASI [83] supports 1014 out of 1185, libRoadRunner
[186] even supports 1072 out of 1185 test cases, corresponding to 85.6% and 90.5%,
respectively.
Multi-experiment fitting
In computational modeling, models often need to be consistently calibrated to data
obtained under multiple experimental condition such as wild-type vs. knock-out exper-
iments. Thus, the model to be calibrated comprises two conditions that can contain
common as well as individual, that is, condition-specific parameters and inputs. When
performing parameter estimation, the individual model conditions can be simulated
separately but are linked by the common parameters and their contributions to the
likelihood.
While this fundamental setting can be difficult to implement in other modeling software,
in D2D a separate model variant is automatically generated for each condition defined in
the data sheet and no additional configuration is required. As an example for multiple
experimental conditions, the different ligands of the Epo receptor in Section 5.2 can be
mentioned.
Efficient numerical integration of ODEs
During the process of parameter estimation, the solution of the model simulation for the
current set of parameters is compared to the corresponding experimental data. Hence,
in each step of the optimization, the ODE system forming the model needs to be solved
numerically. Therefore, the numerical integration of the model equations represents
a major bottleneck of parameter estimation and needs to be performed as efficient as
possible. While scripting languages like MATLAB or Python offer many advantages
for fast and human-readable implementation of algorithms, they lack the performance
of low-level programming languages such as C or C++. By using an efficient solver
3http://sbml.org/Facilities/Database/Simulator
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implemented in C [81] and connecting it to D2D through MATLAB’s mex compiler, the
numerical integration can be accelerated by up to two orders of magnitude [197]. Also,
the CVODES solver of the SUNDIALS package [81] provides the option of solving the
sensitivity equations simultaneously with the model equations and therefore enables
the efficient calculation of derivatives of the likelihood as required by deterministic
optimizers (see also Section 2.4.2).
Multi-start deterministic parameter estimation
As introduced in Section 2.4.2 and described in more detail by Raue et al. [164], local
optima during optimization can be overcome either by applying stochastic, global, op-
timization or by performing many runs of deterministic, local, optimization strategies
with different initial parameter guesses. For these guesses random sampling can be
utilized to cover the parameter space. However, as the parameter space quickly becomes
higher-dimensional, more sophisticated strategies like Latin hypercube sampling (LHS)
[146] can be applied. In D2D, both strategies are implemented and can be utilized
for multi-start deterministic parameter estimation. Which method is favorable depends
on the model size (number of parameters) and the shape of the likelihood landscape
(i.e. how many local optima exist etc.). In Section 3.1.3, a benchmark study was per-
formed that evaluates the performance of both strategies on two published models with
experimental data.
Identifiability analysis
Depending on model structure and data availability model parameters might not be deter-
mined unambiguously by the best fit. This property is called parameter identifiability and
is introduced in more detail in Section 2.3.3. To study the identifiability of parameters,
methods for identifiability analysis have been proposed [77, 162] and implemented in
D2D. The concept of likelihood profiles can be extended to model predictions (Prediction
profile likelihood; PPL) [106, 105] which are also available in D2D.
Sensitivity analysis and metabolic control analysis
Knowing which parameter has the most influence on a certain model feature is an
important aspect for better understanding models in general and in the quest for identi-
fying drug targets [100]. Sensitivity analysis provides exactly this information for each
model variable and observable in a dynamic manner. Metabolic control analysis offers a
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framework of control coefficients and response coefficients [74]. While the control coeffi-
cients quantify the influence of reactions on the steady-state concentrations, response
coefficients describe the impact of parameters on the steady state. An extension of this
framework to non-steady state trajectories was developed by Ingalls & Sauro [89]. Both
concepts are included into D2D.
3.1.3 Benchmark of sampling strategies and implemented fitting
algorithms
As parameter estimation is one of the key applications D2D is designed for, its efficient
and robust functioning is essential. As mentioned before, local optima represent a big
challenge when estimating model parameters in non-linear ODE models. Therefore,
the choice of the optimization strategy – whether global or local – and the numerical
algorithm is critical for successful model fitting. In this section, several optimizers
implemented in D2D are evaluated based on a benchmark setup using two existing
models with measurement data. For the local optimizers, the two different sampling
strategies for the initial parameter guesses are tested and compared for both benchmark
models.
Benchmark models
For evaluating the performance of different optimization strategies, the two published
models from Becker et al. [12] and Bachmann et al. [8] have been employed including
the published data sets. The model by Becker et al. is described in more detail in
Section 5.2.2 of this thesis. It consists of 6 model species describing the interactions of
the hormone erythropoietin (Epo) with its receptor. The model is composed of 8 reactions
comprising 7 rate constants. Together with the initial conditions for the model species
and the observation parameters it sums up to a total of 16 parameters that have to be
calibrated based on experimental observations. Only for the initial Epo concentration,
prior information is available which is included by an additional term in the likelihood
function.
The model by Bachmann et al. describes the downstream signaling of the STAT5/JAK2
pathway upon stimulation with Epo. It describes the dynamics of 25 model species
through 36 reactions comprising 21 rate constants. The stimulation of the pathway is
triggered by the extracellular Epo level which is modeled as a constant external input.
The total number of parameters is 115 of which 2 are fixed to a constant due to non-
identifiability and for one initial condition the value is set to priorly known value with
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Tab. 3.1.: Key figures of the two models used for the benchmark study.
Quantity Becker et al. Bachmann et al.
# of model species 6 25
# of reactions 8 36
# of parameters 16 115
# of external inputs 0 1
# of experimental conditions 1 23
# of data points 85 542
average runtime for one simulation [sec] 0.0043 0.1014
a corresponding penalization term in the likelihood. Another level of complexity is
added by the number of experimental conditions: time course data, dose-response
experiments and over-expression experiments lead to a total of 542 data points over 23
model conditions.
The two models are very different in size (number of parameters and model species)
and complexity (number of experimental conditions, complexity of the kinetic rate laws
etc.). Therefore, optimizers are challenged in two very different scenarios that reflect
common applications in data-based systems biology modeling projects. The key figures
are summarized in Table 3.1. The model equations as well as a schematic representation
of the reaction network can be found in the original publications [12, 8].
Comparison of sampling strategies
While random sampling is the straight-forward option to generate a sample of initial
parameter guesses for multi-start optimization, the coverage of the high-dimensional
parameter space cannot be ensured. As introduced in Section 2.3.2 and in Section 3.1.2,
sampling using LHS prevents randomly selected initial parameters from being close
to each other. Thus, each optimization run starts in a different region of the high-
dimensional parameter space. The effect of the sampling strategy on the performance
of multi-start optimization has not been investigated on systems biology models. Here,
I want to compare the performance of the two sampling strategies based on the two
previously introduced benchmark models.
The result is depicted in Figure 3.2 where the left panel shows 1000 fits for the model
by Becker et al. and the right panel the results based on the model by Bachmann et al.
On the y-axis, a measure for the goodness of fit is given by the negative log-likelihood
(−2LL, see also Equation 2.14), the x-axis indicates the fit index sorted by the likelihood
value. A plateau represents a local optimum [164]. The two sampling strategies are
marked by blue (LHS) and red (random sampling) circles.
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Fig. 3.2.: Comparison of LHS and random sampling based on two published models includ-
ing experimental data. The upper panels indicate the goodness of fit as measured by
the negative log-likelihood on a logarithmic scale vs. the sorted run index. Plateaus in
the plot correspond to local minima. Fit based on LHS are depicted as blue circles, fits
starting from random sampling are shown in red. The lower panels show a histogram
of the fitting times for both sampling strategies and models.
For the model by Becker et al. (left panels), only 16 parameters were fitted. Therefore,
the parameter space is relatively low-dimensional and the differences in performance, as
measured by the number of runs where the best optimum has been found, are small (40%
vs. 38% for LHS and random sampling, respectively). For the significantly larger model
by Bachmann et al. (right panels), a total of 115 parameters were fitted. However, despite
the high-dimensional parameter space, also here only a small difference in performance
can be observed: While the global optimum was found in 16% of the runs when using
LHS, for random sampling, 14% of the runs found the global optimum.
In terms of the average fitting time, both sampling strategies perform equally well (1 s
for LHS and random sampling for Becker et al. and 65 s vs. 63 s for Bachmann et al.;
simulations have been performed on an Intel Xeon X5690 3.47GHz CPU with 12 cores
and 94GiB RAM).
To summarize, both sampling strategies are able to overcome the problem of local optima
when the initial sample size is “adequately” large (D2D uses jackknife resampling [50]
to evaluate whether the sample size was large enough). Even though random sampling
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Tab. 3.2.: Optimization algorithms used in the benchmark study.
# Name Implementation
1 lsqnonlin MATLAB
2 fmincon MATLAB
3 STRSCNE [13]
4 arNLS [161]
5 fmincon_as_lsq MATLAB
6 arNLS_SR1 [161]
7 NL2SOL [43]
8 TRESNEI [136]
9 Ceres [2]
10 lsqnonlin_repeated MATLAB
11 fminsearch MATLAB
12 patternsearch MATLAB
13 patternsearch_hybrid MATLAB
14 particleswarm MATLAB
15 simulannealbnd MATLAB
16 geneticalgorithm MATLAB
performs slightly worse, there is one important advantage as compared to LHS when it
comes to resampling, i.e., increasing the sample size retroactively: While for LHS the
size of the sample cannot be enlarged without starting over, for random sampling the
sample can be extended without losing the existing optimization runs.
Benchmark of optimization algorithms
Next, I want to evaluate how different optimizers perform on both benchmark models.
The performance of several optimization algorithms implemented in D2D has been
evaluated previously [164]. However, since the publication of this comparison, further
algorithms have been made available in the D2D framework. Here, a total of 16 optimizers
are compared based on the models from Becker et al. [12] and Bachmann et al. [8].
All optimizers have been used on default settings of their implementation in D2D. The
optimizers and the corresponding references for their implementations are summarized
in Table 3.2.
For each of the 16 optimization algorithms, 100 fits have been performed with initial
parameter guesses obtained by random sampling. The performance of an algorithm was
defined as the percentage of fits that converged to the global optimum. Furthermore, the
time needed to perform one fit was captured. The results for both models are depicted in
Figure 3.3.
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Fig. 3.3.: Comparison of 16 optimization algorithms based on two published models in-
cluding experimental data. The upper panels show the fitting results for all algo-
rithms as quantified by negative log likelihood. Plateaus correspond to local optima.
The best optimum was centered to 1. The lower panels indicate the overall perfor-
mance of each algorithm vs. the average fitting time. High performance and low time
values are desired.
As introduced in the comparison of sampling strategies, in the upper panels, the likelihood
is plotted against the sorted fit index so that plateaus, referring to local optima, can be
identified. In the lower panels, the performance is plotted against the average fitting
time. This diagram allows to evaluate and compare the different algorithms with respect
to their reliability in finding the global optimum and to their computation time.
In case of the Becker et al. model, two groups could be identified: The deterministic,
mostly derivative-based optimizers performed well while the derivative-free and/or
stochastic optimizers all showed a poor performance. The top six strategies reached
a performance of 15% to 50% with an average time of ∼1min to 10min per fit (on
an Intel Xeon X5690 3.47GHz CPU with 12 cores and 94GiB RAM), the remaining
algorithms took up to several hundred minutes per fit and succeed only in one out
of 100 runs (particleswarm) or not at all. For the Bachmann et al. model, a similar
behavior could be observed. The maximal performance of 10% was only reached by two
deterministic algorithms, namely, NL2SOL and fmincon_as_lsq. The default optimizer
in D2D, lsqnonlin, succeeded in 6% of the fits. All derivative-free deterministic and
stochastic optimizers failed to reach the global optimum. Due to the increased complexity
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of the model, here, the fitting time ranged from ∼50min to 200min for algorithms with
successful fits, and from ∼100min to 5000min for the methods with 0% performance.
Taken together, the results of this benchmark study confirm the overall trend observed
in the previous analysis [164]: Deterministic, multi-start strategies seem to be more
reliable than derivative-free or stochastic optimization strategies. The differences in
performance for both benchmark models highlight that there is not one best optimizer
but rather a group of well-performing methods and their exact performance depends on
the complexity of the given model.
3.2 A data interface for the ViroSign project
This work was done in collaboration with Max Flöttmann in the scope of the ViroSign
project. The data were provided by the project partners and were taken from existing
publications.
The main goal of this project was to make all data sets from the ViroSign project partners,
as well as related published data sets, accessible for participating researchers. Based on
our discussions with the project partners, we defined the following list of requirements
for building a web interface for the data:
1. The data interface needs to be closed for the public yet accessible for all authorized
users,
2. existing data sets from publications can be added,
3. the user can combine (merge) individual data sets based on the gene_id,
4. the column gene_symbols can be searched by exact match and by regular expres-
sion patterns,
5. the two columns can be plotted as a scatter plot and the searched genes are
highlighted in the plot,
6. the table can be sorted by the values of each column (i.e. fold_change or log10_abundance),
and
7. the filtered table can be exported to a .csv or .xls file.
As a standard tool for data analysis, the statistics software R [158] is equipped with
most of the requested features. However, the user would need to learn the programming
language and have a copy of data and software installed on his local computer in order
to access the functionality. Therefore, we made of use the R-package shiny [26] which
provides an easy-to-use web interface for the user but offers the full functionality of R in
the background.
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We included a total of eight data sets comprising of two screens of small-interfering
RNA (siRNA) [95, 172], time-resolved SILAC-based proteomics data of IAV infected cells
[172], cap-snatching data [183], absolute protein abundance data of multiple cell lines
[66] and unpublished protein-protein-interaction screens for the viral proteins NP, NS1
and PB2.
Figure 3.4 shows a screen shot of the web interface. In the collapsible panels on the
left, data sets can be selected and filters based on gene names can be applied. Also, a
quick overview is provided by plotting two columns against each other as a scatter plot.
Further features are different data merging options and selection of columns to be shown
in the data table on the right. A download button below the table provides the capability
to save the filtered data to a .xls or .csv file.
3.3 Conclusions
Based on two projects, I showed that software development plays a crucial role for
scientific progress in computational systems biology. While the data interface for the
collaborative influenza research project ViroSign has a limited functionality and is closed
for the public, it provides unpublished data to all project partners and allows them
to obtain a first insight into the highly complex data sets. By contrast, the modeling
software Data2Dynamics is open to the public and shows a growing community of users
that also act as developers for novel features.
Specialized software for computational systems biology is mainly developed by re-
searchers at academic institutions. Thus, the long-term persistence and maintenance of
the software often relies on individual scientists employed on non-permanent positions.
By transferring the source code to open platforms like GitHub, the functionality of the
software can be extended by the users themselves and possible issues are often quickly
resolved by the community. Nevertheless, the administration of the project is critical to
ensure a well-organized progression. Therefore, software development within systems
biology research groups should be further professionalized by hiring programmers and
computer scientists for the core development and maintenance.
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Mathematical modeling of the
influenza A infection
4
„After all it really is all of humanity that is under
threat during a pandemic. [23]
— Margaret Chan
(Director-General of WHO)
In this chapter, the intracellular mechanisms during influenza A infection are investi-
gated using systems biology methods. Therefore, the reader is first introduced to the
fundamentals of influenza biology. Subsequently, a mechanistic ODE model for the virus
entry into the host cell is developed and refined through experimental measurements
in living cells. To further investigate the transport of the viral genome to the host cell’s
nucleus, a spatial modeling strategy is applied. Combining the predictive power of both
models, we obtain further insights into the early steps of influenza infection.
4.1 Introduction to influenza biology
The influenza A virus (IAV) belongs to the family of Orthomyxoviridae which are char-
acterized by a segmented, negative sense, single-stranded RNA (ssRNA) genome. The
nomenclature of IAV strains is based on the subtype of the two viral surface proteins
hemagglutinin (HA) and neuraminidase (NA). The strain H3N2, for instance, refers to
HA subtype 3, NA subtype 2. Furthermore, the strains are named by an isolate number,
year and place of their first characterization, for instance, A/Panama/2007/1999 (H3N2)
is a influenza A virus with the isolate number 2007 first characterized in 1999 in Panama
with the subtype H3N2 [18].
4.1.1 The influenza A virus
The virion, as shown in Figure 4.1a, consists of a viral envelope containing glycoproteins
HA and NA as well as the ion channel matrix protein 2 (M2). On the inside of the envelope
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the viral matrix protein 1 (M1) stabilizes the capsid and is attached to the eight viral
ribonucleoprotein (vRNPs) complexes coding for up to 11 viral proteins. These complexes
are organized in rod-like structures comprising the ssRNA, the nucleoprotein (NP), small
amounts of the nuclear export protein (NEP, also referred to as non-structural protein 2,
NS2) and the polymerase complex (subunits PA, PB1, PB2) needed for transcription in
the host cell (Figure 4.1b and c).
vRNPs
HAM2
NAM1
a
PB1
3‘
5‘
ssRNA
NP
PB2
PA
b
PB2
PB1/PB1-F2
PA
HA
NP
NA
M1/M2
NS1/NS2
c
Fig. 4.1.: Structure and components of the influenza A virus. (a) Detailed schematic of the
influenza A virus. The most abundant proteins are indicated. (b) Structure of an
exemplary vRNP. Single-stranded RNA is wrapped around NP protein. The polymerase
complex consisting of PA, PB1, PB2 is bundled with the RNP. (c) The eight genome
segments and the proteins they code for. PB1-F2 is a splicing variant with unknown
function.
4.1.2 Epidemiology of influenza A
The most recent H1N1 pandemic outbreak in 2009 killed more than 200 000 people
within 12 month [39]. In addition, not only pandemic influenza constitutes a threat
for human health. According to WHO, seasonal influenza strains are estimated to infect
5% to 10% of the world population every year [102]. Especially for the high-risk group,
such as pregnant women, children and elderly people, seasonal infection can become life
threatening causing up to 250 000 to 500 000 yearly deaths [102].
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Antigenic variability
Influenza has two sources of genetic variability called antigenic drift and antigenic shift.
While the antigenic drift is caused by simple point mutations during vRNA replication,
antigenic shift occurs through a recombination of HA and NA subtypes from different
virus strains mostly due to co-infection of a host organism with multiple strains. Genetic
changes of seasonal influenza strains originate from antigenic drift while pandemic strains
evolve due to antigenic shift Clements & Casani [33].
Vaccination
The first vaccines against seasonal influenza strains were invented in the 1940s. Due
to the antigenic drift, these vaccines need to be adapted repeatedly. While the original
vaccines were based on one specific inactivated strain, modern vaccines comprise three
different strains that are predicted to be dominant in the upcoming influenza season.
The selected vaccine strains are mainly grown in chicken eggs before they get inactivated.
Only since 2016, the first cell-based vaccine was approved by the FDA which could
reduce the offset of vaccine manufacturing dramatically [102]. Furthermore, so-called
universal vaccines do not train the immune system for recognizing HA or NA antigens but
the conserved stalk domain of the HA, NA or M2 protein [102].
Treatment
Two classes of antiviral treatment against influenza A have been approved by the drug
authorities: (1) M2-blockers prevent the acidification of the virus and thus the release of
the viral genome to the cytosol; (2) by inhibiting the viral NA protein, after budding, the
progeny fails to dissociate from the infected host cell preventing a spread of infection
Palese [148]. However, for both classes resistant strains have been reported necessitating
the development of alternative antiviral approaches such as small interfering RNA (siRNA)
Palese [148].
4.1.3 The replication cycle of influenza A
Virus entry
The replication cycle of IAV is depicted in Figure 4.2. After binding of HA to sialic acid
receptors on the host cell’s surface the virion gets internalized through endocytosis or
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macropinocytosis [200]. During endosomal maturation, the lumen is acidified and the
endosome travels along microtubules towards the microtubule organizing center (MTOC)
in the peri-nuclear region [85]. In the late endosome, the pH in the lumen drops below
a strain-specific threshold causing HA to undergo a conformational change. This triggers
the fusion of the viral envelope with the endosomal membrane and leads to the escape
of the vRNPs into the cytosol.
After the release, the vRNPs are transported to the nuclear membrane where they get
imported based on their nuclear localization signals [37]. It is commonly assumed that
the vRNPs is not actively transported, but diffuses to the nucleus [7]. Also, it is still under
debate whether all eight vRNPs remain attached as one complex or if they dissociate
shortly after endosomal fusion [127, 31].
Genome replication and synthesis of viral proteins
Being imported into the host cell’s nucleus, the viral RNA polymerase, that was bundled
in the vRNPs, starts to synthesize two positive-sense RNA templates: the vRNA that is
used for the viral progeny and the complementary cRNA which (after stealing caps from
host pre-mRNAs through cap-snatching [167]) can be used to produce viral proteins by
the host’s translation machinery. The surface proteins HA, NA and M2 are synthesized
directly into the endoplasmatic reticulum (ER) and transported to the cell membrane by
the Golgi apparatus while other viral proteins are produced in the cytoplasm of the host
cell.
Transport and assembly of new virions
Rab11 positive vesicles transport the newly synthesized vRNPs to the cell membrane [6,
135, 3] where they assemble with the surface proteins, form a bud and are released to
the extracellular space. As HA has a strong affinity for sialic acid receptors on the cell
membrane, these bonds needs to be cleaved by means of the NA protein [18]. Therefore,
NA-inhibitors like Oseltamivir (the active agent in Tamiflu) can been used to prevent the
successful reproduction of IAV in the host organism [38].
The packaging strategy of the vRNPs was, for a long time, thought to be completely
random [9, 86]. However, only recently Chou et al. [31] could show by colocalization
analysis of data obtained by single-molecule fluorescence in-situ hybridization (smFISH)
that selective packaging is more likely leading to virions with 8 unique vRNPs in place
[32].
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Fig. 4.2.: Replication cycle of the influenza A virus. A free virion binds to sialic acid receptors
on the membrane of the host cell and is taken up via endocytosis. Endosomes travel
along microtubules towards the MTOC. During maturation from early to late endosome
the lumen of the endosome is acidified. When the pH threshold of the viral protein
HA is reached, a conformational change causes the escape of the viral genome into
the host cell’s cytoplasm. Diffusive transport and active uptake through nuclear pores
make the vRNPs enter into the nucleus host cell where the vRNA is cap-snatched with
host pre-mRNA caps, transcribed and replicated. The viral proteins are synthesized
and transported back to the nucleus (NP, M1, PA, PB1, PB2, NS1, NS2) or shuttled to
the cell membrane via the Golgi (NA, HA, M2). vRNPs are formed and transported to
the cell membrane where the viral progeny assembles and new virions bud and are
released to the extracellular space.
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For more exhaustive descriptions of the replication cycle I refer to Cheung & Poon [30],
Bouvier & Palese [18], and Samji [173].
Virus-host interactions
In order to successfully infect an organism and replicate within a host cell, IAV relies on
multiple interactions with the host cell. These interactions comprise the entry into the
host cell through endocytosis, the escape from the endosome via membrane fusion but
also interactions that suppress or evade the immune response. Furthermore, replication
of viral RNA and synthesis of viral proteins strongly depends on the host machinery
that is hijacked via cap-snatching. The immune response to IAV is comprehensively
summarized by Kreijtz et al. [103]. Other interactions were reviewed in more detail e.g.
by Madrahimov et al. [122].
4.2 Dynamic modeling of the influenza A infection
This part of the thesis is based on the publication
Schelker, M., Mair, C. M., Jolmes, F.,Welke, R.-W., Klipp, E., Herrmann, A., Flöttmann,
M. & Sieben, C. „Viral RNA Degradation and Diffusion Act as a Bottleneck for the
Influenza A Virus Infection Efficiency“. PLOS Computational Biology 2016, 12(10):
e1005075
All biological experiments have been conducted by CMM, FJ, RWW and CS. Model
construction, simulation and analysis were performed by MF and MS.
As introduced in the previous section, the IAV infection is a multi-step process that
critically depends on the viral protein HA and its sensitivity to altering pH values. Since
endosomal transport towards the MTOC and acidification are concurrent, the distance
that released vRNPs need to overcome depends on the location of membrane fusion and
thereby on the pH-dependent conformational change of HA.
While endosomal transport is directed and actively driven by dynein and kinesin on mi-
crotubules [85], the movement of the viral genome after fusion is most likely passive and
undirected [7]. Larger particles like the complexes of eight vRNP segments diffuse slower
than their individual components due to their larger hydrodynamic radius. Nevertheless,
packages comprising eight unique vRNP segments could be advantageous especially at a
low multiplicity of infection (MOI) where a missing segment would cause a total failure
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of the infection. Although the vRNA and NP are tightly packed within the vRNP, the
genome remains sensitive to RNase digestion [214]. Therefore, it is unclear whether the
diffusing vRNPs might be damaged due to cytosolic degradation as recently reported for
the hepatitis C virus [15].
Here, we aimed to answer the question whether the entry of the virus and the transport
of its genome to the host cell’s nucleus might be limiting for the virus infection efficiency.
More specifically, we wanted to identify crucial factors that may act as bottleneck during
the infection. We therefore analyzed the virus entry using mathematical modeling
combined with experimental data of the involved processes.
4.2.1 Existing models
The earliest models describing the population dynamics of mice infected with influenza
were developed 40 years ago [113]. Since then, multiple models of IAV infection
have been developed, representing the infection at different levels of detail. There
are three main categories of influenza infection models: (1) epidemiological models
analyzing and predicting the infection on a population scale; (2) multi-cellular models
describing the spread of infection within the organism; and (3) intracellular models
of IAV infection characterizing virus uptake and replication on a molecular level. An
overview on modeling approaches of IAV infection is given in Beauchemin & Handel
[11]. For a review on epidemiological models of IAV infection, I refer to Nsoesie et al.
[144].
While the population scale is most evidently used for epidemiological risk prediction and
vaccination strategies, more fine-grained models can help to identify drug targets or can
be utilized to maximize the virus synthesis for cell culture-based vaccine production.
Here, we want to focus on the third category, which are models of intracellular processes
involved during IAV infection. Sidorenko & Reichl [182] and later Heldt et al. [76]
developed the first extensive intracellular models of IAV infection. However, due to
the great level of detail, these models contain a great number of unknown parameters
leading to a limited scope of reliable model predictions. In further work, intracellular
and population scale models were combined to a multi-scale model [75] providing a
more comprehensive model of virus infection.
Models of the intracellular dynamics of the Semliki Forest virus [41] and other acid-
dependent enveloped viruses [40] have been suggested and include the pH sensitivity of
the virus endosome fusion. However, as the pH dependency is not explicitly implemented,
these models are not able to cope with multiple virus strains with altered pH thresholds.
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4.2.2 An ODE model describing influenza A virus entry into the host cell
To investigate how pH sensitivity of HA influences the early IAV infection, existing models
were not sufficient in their description of viral genome release from the endosome.
Therefore, we built a relatively coarse-grained model of virus entry into the host cell
with more detailed pH-dependent kinetics for the virus-endosome fusion.
Model structure
Through an iterative cycle of data generation and model refinement, we evolved to a
first version of the model shown in Figure 4.3a. The model describes the following steps:
(1) Virus-receptor complexes are internalized into endosomes; the viral genome escapes
through (2) endosomal acidification and (3) a basal, meaning not pH-dependent, rate;
vRNPs either diffuse towards the nucleus (4) or are degraded (5); vRNPs in the vicinity
of the nucleus are imported (6). These six steps are described by the ODEs defined in
(4.1–4.9):
d[VirRecex]
dt = −kend · [VirRecex], (4.1)
d[VirRecend]
dt = kend · [VirRecex]− kbasal · [VirRecend]
− kfus · [H
+
end]
h · [VirRecend]
[H+end]
h + kH+h
, (4.2)
d[vRNPcyt]
dt = kbasal · [VirRecend] + kfus ·
[H+end]
h · [VirRecend]
[H+end]
h + kH+h
− kτ · [vRNPcyt]− kdeg · [vRNPcyt], (4.3)
d[vRNPcyt1]
dt = kτ · [vRNPcyt]− kτ · [vRNPcyt1]− kdeg · [vRNPcyt1], (4.4)
d[vRNPcyt2]
dt = kτ · [vRNPcyt1]− kτ · [vRNPcyt2]− kdeg · [vRNPcyt2], (4.5)
d[vRNPcyt3]
dt = kτ · [vRNPcyt2]− kτ · [vRNPcyt3]− kdeg · [vRNPcyt3], (4.6)
d[vRNPcyt4]
dt = kτ · [vRNPcyt3]− kτ · [vRNPcyt4]− kdeg · [vRNPcyt4], (4.7)
d[vRNPcyt5]
dt = kτ · [vRNPcyt4]− kdeg · [vRNPcyt5]− kimp ·
[vRNPcyt5]
kinhib + 1
, (4.8)
d[vRNPnuc]
dt = kimp ·
[vRNPcyt5]
kinhib + 1
, (4.9)
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Fig. 4.3.: Model and data of the influenza A virus entry into the host cell. (a) Model
structure of the ODE model. (1) Virus-receptor complexes are internalized into
endosomes; (2) Endosomal maturation acidifies the lumen causing the release of the
viral genome to the cytosol; (3) also pH-independent vRNP release is considered; (4)
vRNPs diffuse towards the nucleus or (5) are degraded; (6) import into the host cell‘s
nucleus completes the entry. (b) Measured data (dots) and fitted model dynamics
(lines) of four observables. The shading represents the measurement error estimated
based on a parametric error model. (c) Measured data and fitted model simulations
for vRNP content in the cytosol (blue) and the whole cell (yellow). Cells were treated
with different doses of importazole.
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where [X] denotes the concentration of a model species X and the dynamics of endosome
acidification are expressed as H+ concentration:
[H+end] := 10
−pHend . (4.10)
This concentration is increasing proportionally to the ATPase activity (kATPase):
H+end = 10
−(pHlb+(pHub−pHlb)·exp(−kATPase·t)), (4.11)
where pHub and pHlb and are the upper (directly after endocytosis) and lower bounds
(matured endosome) of the pH range in the endosome.
The delay τ caused by diffusion is implemented in the ODE model using a linear chain of
N = 5 reactions (model species [vRNPcyt1−5]) with simple mass action kinetics with the
parameter
kτ =
N
τ
(4.12)
specifying the delay times [119].
Calibrating the model to experimental data
The model parameters were calibrated based on multiple sets of experimental data.
Using flow cytometry, we could quantify the dynamics of the pH-level in the endosome.
The percentage of fused endosomes was measured using fluorescence microscopy with
two different fluorophores. The concentration of nuclear NP could be obtained as well
by fluorescence microscopy leading to the following model observables:
pHobs := −scalepH · log10([H+end]), (4.13)
Fusionobs := log10(offsetFus + scaleFus · ([vRNPcyt,diff ] + [vRNPnuc])), (4.14)
NPobs := log10(offsetNP + scaleNP · [vRNPnuc]). (4.15)
Model fits and data are depicted in Figure 4.3b. At time point t = 0, viruses are bound
to sialic acid receptors and internalization into endosomes is initiated by a temperature
shift from 4 ◦C to 37 ◦C. As the pH-level in the endosome decreases, after about 10min,
the threshold for the conformational change of HA is reached, the endosomal and viral
membranes fuse as indicated by a steep increase in the both fusion measurements. After
fusion, the released vRNPs travel towards the nucleus where they are imported leading
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to an increase of the nuclear NP curve at around 15min. The time delay between fusion
and nuclear import is modeled through a linear chain of reactions (4.4-4.8).
The pH-threshold at which fusion occurs can be determined by a dose-response experi-
ment making use of a fluorescence dequenching (FDQ) assay. Viruses labeled with R18 at a
selfquenching concentration are bound to sialic acid receptors on a ghost membrane from
erythrocytes. Unbound viruses are removed by washing and the pH is decreased by addi-
tion of citric acid. The reduction in pH induces membrane fusion between viruses and
the ghost membrane, which in turn leads to a reduction of the local R18 concentration
and thereby to increase in fluorescence via dequenching. The fraction of fluorescence is
calculated as
FDQ = F (t)− F (0)
Fmax − F (0) , (4.16)
where F (0) and F (t) represent the fluorescence intensity at t = 0 and at a given time t,
respectively.
This experimental observation can be linked to the model by simulating the fraction of
released vRNPs for different pH values
FDQobs :=
vRNPcyt,diff + vRNPnuc
[VirRecend]|t=0 . (4.17)
Performing the FDQ experiment with different strains of IAV with an altered pH-sensitivity
allows to investigate the model under various conditions.
Here, we make use of three IAV strains: (1) the A/X31 (H3N2) strain; (2) the recombinant
WSN H3 wt strain which is generated from the A/WSN/1933 (H1N1) strain with the HA
segment of the X31 strain; and (3) the recombinant WSN H3 mut strain, carrying the
destabilizing double-mutation T212E-N216R in the HA protein of X31.
While the FDQ curves in Figure 4.4a for X31 and WSN H3 wt strains are very similar, the
pH sensitivities for WSN H3 wild-type vs. the mutant strain are clearly distinct, as shown
in Figure 4.4b. The FDQ of the X31 and WSN H3 wt strains is half-maximal at pH 5.6
while the WSN H3 mut strain has a steeper FDQ curve being half-maximal at pH 5.8.
As the genome release occurs during endosomal transport towards the MTOC, a shift
in the pH-sensitivity to higher pH values, most likely, corresponds to a larger distance
to the nucleus that needs to be overcome via diffusion. We therefore hypothesize that
the mutant strain should show an altered infectivity, meaning less vRNPs arrive within a
certain time, as compared to the wild-type. When simulating our ODE model for both
conditions, however, we could not see any difference in the steady-state of NP in the
nucleus. By contrast, measuring the infection efficiency in MDCK cells showed a 40%
4.2 Dynamic modeling of the influenza A infection 57
b ca
In
fe
ct
io
n 
e
ci
en
cy
WSN H3 wt WSN H3 mut
Fig. 4.4.: Fluorescence dequenching and infection efficiency for different strains of IAV.
(a) Comparison of the pH sensitivity of the WSN H3 wt (green) and the X31 strain
(blue). (b) Comparison of the WSN H3 wt (green) and the mutant (blue). Dots
represent measured data, lines are the model simulations and the shading represents
the measurement error estimated based on a parametric error model. (c) Comparison
of the infection efficiency of WSN H3 wt and mut in MDCK cells measured by NP
accumulation upon infection. Data show mean and SEM from four independent
experiments.
to 50% lower infectivity for the mutant strain, as depicted in Figure 4.4c. Thus, we
concluded that there must be a missing reaction in our entry model, that reduces the
amount of vRNPs over time during their diffusion through the cytosol.
Using R18-labeled X31 viruses, we could show that the virus-endosome fusion is taking
place some micro-meters away from the nucleus (see Figure A.1 in the appendix). To
investigate this crucial transport step, we introduced a spatial component that accounts
for the diffusion of released vRNPs through the cytosol.
Parameter estimation and identifiability analysis
Parameter estimation was performed based on maximum likelihood estimation as de-
scribed in Section 2.3.2. The model was implemented in the D2D software (Section 3.1)
for MATLAB and a multi-start deterministic optimization strategy was applied. The
model simulations of the observables are shown together with the experimental data
in Figure 4.3b. The model trajectories for the best fit are depicted in Figure A.2 in the
appendix.
Parameter identifiability was analyzed based on likelihood profiles (Section 2.3.3).
As depicted in Figure 4.5, most parameters of interest are identifiable. Parameters
characterizing the two WSN H3 strains show distinct parameter values for kH+ and
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the Hill coefficient h. The maximum likelihood estimates and their likelihood-based
confidence intervals are indicated in Table 4.1.
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Fig. 4.5.: Profile likelihood analysis of selected model parameters. Lines represent the like-
lihood profile, point estimates are indicated by a gray asterisk. Red dashed lines
indicates the 95% point-wise confidence threshold. Parabola-shaped profiles indicate
identifiable parameters. Parameter values are plotted on the log-scale.
4.2.3 A stochastic model of vRNP diffusion to the nucleus
After having identified diffusion of the viral genome from the point of cytosolic release
to the nucleus as a critical step of the entry phase, we wanted to further investigate this
process. Using a spatial-stochastic model, we simulated the transport from the point
of virus-endosome fusion to the nucleus on a single molecule level. This allowed us to
relate the fusion distance and delay to the efficiency of the IAV entry taking degradation
of diffusing vRNPs, dissociation of vRNP packages and nuclear import into account.
We set up a reaction-diffusion model (see also Section 2.3.1) using the STEPS software
[79]. Based on a given geometry and tetrahedral meshing, the model was simulated
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Tab. 4.1.: Parameter names, optimal values, upper and lower bounds of 95%-confidence
intervals and units are given for all kinetic model parameters. Confidence inter-
vals were determined using the profile likelihood approach [162]. The plots of the
likelihood profiles are depicted in Figure 4.5.
Parameter θˆ conflb confub Unit
kATPase 7.94× 10−2 5.05× 10−2 1.17× 10−1
[
min−1
]
h 1.90 1.39 2.62 [1]
hWSN_H3_mut 4.25 3.02 6.67 [1]
hWSN_H3_wt 2.29 1.72 3.15 [1]
kH+ 4.86× 10−6 3.38× 10−6 1.01× 10−5
[
mol · l−1]
kH+_WSN_H3_mut 2.10× 10−6 1.79× 10−6 2.91× 10−6
[
mol · l−1]
kH+_WSN_H3_wt 4.34× 10−6 3.34× 10−6 8.11× 10−6
[
mol · l−1]
kbasal 9.24× 10−3 5.66× 10−3 1.31× 10−2
[
min−1
]
kdeg 1.89× 10−1 5.68× 10−2 ∞
[
min−1
]
kend 9.32× 10−2 4.28× 10−2 ∞
[
min−1
]
kfus 3.59× 10−1 2.79× 10−1 7.11× 10−1
[
min−1
]
kimp 1.00× 104 0.00 ∞
[
min−1
]
kinhib_100µM 1.84× 10−4 0.00 ∞ [1]
kinhib_40µM 9.89× 103 0.00 ∞ [1]
kτ 1.21 5.04× 10−1 ∞
[
min−1
]
pHlb 4.46 4.01 4.80
[
log10(mol · l−1)
]
pHub 6.20 5.65 6.91
[
log10(mol · l−1)
]
with locally well-mixed reactions within the volume of each tetrahedron and stochastic
transitions between tetrahedrons.
Performing spatio-temporal simulations of vRNP diffusion
The geometry of a generic MDCK cell was approximated by a cuboid as shown in
Figure 4.6a. The volume is split into a tetrahedral mesh using tetgen [29] consisting
of 25 664 tetrahedrons (thereof 22 805 in the cytosol and 2859 in the nucleus) with a
maximal volume of 0.9 fL per tetrahedron.
The principle of stochastic transitions is shown on the example of a two-dimensional mesh
in Figure 4.6b. The transition from tetrahedron k to the neighboring tetrahedron l takes
place with the rate dk,l that is proportional to the coefficient of diffusion D. Furthermore,
the surface Sk,l, which is the interface of both tretrahedra (in 2D represented by a line),
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Fig. 4.6.: Cell-like geometry used for spatial simulations and schematic mesh grid in two
dimensions. (a) The typical dimensions of a MDCK cell were adapted for a three-
dimensional geometry based on a cuboid. The nucleus is represented by a sphere of
5 µm in radius situated in the lower third of the volume. (b) Schematic representation
of a tetrahedral mesh of a circular structure in two dimensions. Measures introduced
in the drawing are used to calculate the transition rates dk,l and dl,k. D represents the
diffusion coefficient.
the volume Vk (here the triangular surface) and the euclidean distance between both
barycenters dxk,l adjust the transition rate.
In each volume, three possible well-mixed reactions were defined: (1) a vRNP package,
containing eight vRNP segments, can dissociate into its segments with a rate constant
kdiss; (2) both, vRNP packages and individual segments can be degraded during diffusion
in the cytosol with a parameter kdeg; (3) vRNP packages and individual segments can
bind to the nuclear membrane (kbind) and are no longer subjected to degradation and
dissociation.
Furthermore, the two initial conditions of the simulation, which are the distance to the
nucleus dnuc from the point of vRNP release and the number of released vRNP packages
(corresponding to the MOI) need to be defined.
Exploring the parameter space
While the binding rate could be defined based on a measured value from literature [7] to
kbind = 0.056min−1, the remaining parameters were not restricted by prior knowledge.
Therefore, we analyzed the parameter space by performing two-dimensional scans for
different pairs of parameters over several orders of magnitude. For each bin in Figure 4.7,
a population of 1000 cells was simulated with parameter values indicated on the x and
y-axis. The color-coding corresponds to the fraction of successful infections after 40min.
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Fig. 4.7.: Dependency of the infection efficiency on the values of different model parame-
ter. (a) Degradation vs. dissociation. High infection efficiencies were only observed for
low dissociation and degradation values. For the experimentally determined degrada-
tion constant (blue horizontal line), low dissociation was favorable. (b) Degradation
vs. multiplicity of infection. For the given degradation constant, only for high MOI
values all cells were infected. For simulations shown in a) one vRNP was initially
injected. In both panels, dnuc was set to 3 µm.
Here, successful is defined as arrival and binding of at least one complete set of vRNPs at
the nuclear membrane.
The heat-map depicted in Figure 4.7a shows the influence of dissociation and degradation
on the infection. For high dissociation and/or degradation constants, only a few out
of the 1000 simulated cells got infected. Only for very small degradation constants
(kdeg < 10−2) dissociated vRNP packages (kdiss > 10−1 were still able to reach infection
efficiencies of 50% and higher. The highest efficiencies were reached for both parameters
being small (kdiss < 10−2 and kdeg < 10−1). Thus, despite the higher mean displacement
of individual segments, our simulations clearly showed that the dissociation of complexes
lowered the probability of a complete genome in the nucleus. The larger the dissociation
constant in the model was set, the lower the percentage of complete genomes.
When looking at the impact of the initial amount of virus on the infection efficiency, as
shown in Figure 4.7b, we found that for MOI > 1 and kdeg < 10−1.5 an efficiency of
more than 50% was reached. When further increasing the MOI, also greater degradation
constants could be compensated.
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4.2.4 Combining both modeling approaches reveals vRNP removal in
the cytosol
With both models at hand, we tried to narrow down the details of the influence of fusion
distance to the infection efficiency. To quantify the rate constant of an assumed vRNP
degradation reaction, we performed a RT-PCR experiment measuring the amount of
vRNA of the HA segment (with specific primers for both, WSN H3 wt and mut) over
time. We compared the cytosolic RNA levels after treating the cells with importazole, an
inhibitor of nuclear import, with the total RNA levels as shown in Figure 4.3c. Fitting the
ODE model parameters kdeg and kinhib to the data revealed that there is a degradation or
removal of vRNPs from the cytosol. Interestingly the inhibition of nuclear import was
most prominent for the lower importazole dose (40 µM), most likely due to cell damage
or the activation of other import pathways for the higher dose (100 µM) of the drug as
reported by Kublun et al. [107].
Predicting the delay of the mutant strain
When simulating the amount of total and nuclear NP for both WSN H3 strains, we
obtained the curves shown in Figure 4.8. The delay caused by the diffusion is denoted
by τeff which corresponds to the half-maximal distance of the total and the nuclear NP
curve for the wild-type. For the mutant strain, we saw an additional delay ∆τeff that was
caused by the larger distance that the vRNPs need to diffuse in order to get imported to
the nucleus.
Updating the spatial simulations
We used the estimated parameter value, which is kdeg = 0.19min−1, for the spatial
model, as depicted by the blue horizontal line in Figure 4.7. Next, we could translate
the delay τ to the corresponding distance to the nucleus, as shown in Figure 4.9a for
both, vRNP packages and complete sets of individual segments. With the delay estimated
using the ODE model, we obtained a distance of 3 µm for the WSN H3 wt and 6 µm for
the mutant strain. Simulating the spatial model again for these two values of dnuc, we
obtained curves shown in Figure 4.9b. While for large dissociation constants the infection
efficiency was very low, for low dissociation constants, i.e. for stable vRNP packages, the
infection efficiency was increased, up to 40% for the wild-type and 20% for the mutant
strain.
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Fig. 4.8.: Model prediction of the amount of nuclear and total NP for the WSN H3 wt and
mut strain. Solid lines represent the total NP concentrations (cytosol and nucleus),
dashed lines show nuclear NP concentrations. The WSN H3 wt is depicted in blue,
the mut strain in green. The delay between both strains, denoted as ∆τeff , was
determined by simulating the ODE model with altered pH-sensitivity. τeff represents
the delay between fusion and nuclear import. The difference in infection efficiency
was determined by the concentration difference of nuclear NP after 60min, as denoted
by ∆vRNPnuc.
4.3 Discussion
Using a combination of a mechanistic intracellular model of the IAV entry into the host
cell and a stochastic spatial model of the diffusion of released vRNP, we could show that
stable packages are favorable to transport the genome into the nucleus.
We challenged the models with data from two IAV strains with altered pH sensitivity and
found that an assumed degradation of vRNPs during diffusion could explain differences
in the infectivity as observed experimentally. The existence of such a degradation reaction
could be shown experimentally with RT-qPCR of the HA vRNA segment for cells with
blocked nuclear import.
Taking both models together, we could translate the delay caused by diffusion to a
distance and the simulation for both strains are consistent with the experimental obser-
vations.
The infection of a host cell with the influenza A virus represents a complex multi-step
process with many viral and host factors being involved. The presented modeling
approach captures the main characteristics of two different strains during the virus
entry. Although the transport of the viral genome to the nucleus of the host cell is an
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Fig. 4.9.: Estimating fusion distance and analyzing dependence of infection efficiency on
dissociation. (a) Based on simulations of the spatial model, the delay is related to the
fusion distance. Dashed lines indicate values for both IAV strains obtained from the
ODE model. (b) Simulation of the infection efficiency for both strains. The different
fusion distances result in a decreased infectivity of the mutant strain to ∼50% of the
wt value.
indispensable step during infection, differences in infectivity on the multi-cellular scale
can have various sources. The investigated combination of passive transport and genome
degradation provides one possible explanation for the observed phenomena.
Modern techniques such as single-molecule FISH with individually labeled genome
segments could provide further insights into the critical steps of virus entry. Also,
the spatial resolution and geometry of the model could be further refined to perform
simulations in a more realistic setting.
Another possible limitation of our approach represents the lack of interaction with the
immune system of the host in both models. The viral genome can be recognized through
RIG-I that induces a type 1 interferon response [156]. However, it is not known whether
the imported vRNPs are sufficient to trigger the innate immune response or only the
newly synthesized ssRNA is detected by RIG-I [92].
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„Cancer is not just a dividing cell. It’s a complex
disease: It invades, it metastasizes, it evades the
immune system. [137]
— Siddhartha Mukherjee
(Oncologist and author)
5.1 Introduction
Cancer is one of the world’s major causes of death. According to WHO [188], in 2014
14.1 millions new cases of cancer occurred world wide and an estimated number of 8.2
million people died from cancer. While lung cancer still has the highest incidence and
mortality rates among both, men and women (13%), for women, breast cancer shows the
highest incidence with more than 25% of the total cases of cancer. Unlike for lung cancer,
that is mainly caused by smoking, for other common types of cancer, the causes are often
unknown and only risk factors such as overweight, obesity and familial predisposition
can be identified. Besides prevention of cancer, for instance by dietary restrictions and
increased physical activity, the early diagnosis can increase the chances of a success in
therapy tremendously.
Treatment of cancer
The treatment of cancer depends on the specific indication of the patient. Typical
approaches are surgical removal of tumors followed by radiation and/or chemotherapy.
Other approaches involve specific antibodies or small-molecules that inhibit signaling
pathways that are constantly activated in cancer cells [87].
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Haematopoiesis and cancer
One prominent side effect of chemotherapy is anemia. Patients suffering from anemia are
unable to produce sufficient amounts of red blood cells (erythrocytes) and therefore need
to be treated either with blood transfusions or with injection of erythropoiesis stimulating
agents (ESAs) like erythropoietin (Epo). The mode of action of Epo is based on the
interaction of the hormone with the Epo receptor (EpoR) which induces differentiation
of erythrocyte progenitor cells through activation of the JAK2-STAT5 signaling cascade.
However, presence of the EpoR on the surface of various cancer cell types has been
shown and anemia therapy using ESAs is therefore discussed controversially [78].
Immunotherapy as a novel treatment
While the human body is able to cope with various pathogens through the innate and
adaptive immune response, for most types of cancer the immune system is incapable
to successfully intervene and prevent the disease. Only recently, a new field of cancer
treatments arose from this issue. Using immunotherapeutical drugs, the body’s immune
response is activated in order to fight cancer cells. The induced immune response is
merely sufficient to combat an existing tumor but can render other therapies more
efficient and reduce the side effects caused by the therapy [109].
Bridging the gap
Here, I want to present two projects that tackle cancer-associated issues with means of
computational biology. The first aims to improve the current standard of care treatment
for chemotherapy-associated anemia while the latter attempts to facilitate the quest for
biomarkers for immunotherapy. In both cases, methods from computational biology
bridge the gap between basic research and clinics and enable the selection of the best
medication and dosing scheme on a patient-specific level.
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5.2 Optimized treatment strategies for anemia patients
based on a mechanistic multi-scale model
The following work emerged from joint project of experimentalists from the German
Cancer Research Center in Heidelberg and theoreticians from University of Freiburg.
Experiments and model simulations have been performed over the last 5 years in an
iterative manner.
My contribution to this project consists of adapting the original model and data,
incorporating new depletion data sets into the model, identifying model parameters and
quantifying the uncertainties. Preliminary results of this project have been presented in
the scope of my diploma thesis in 2012. However, as the project has made substantial
progress since then, I want to present the final stage of it in this thesis.
To integrate this part into the bigger picture, in Section 5.2.6–5.2.7, I briefly present the
continuation of the work which was mainly carried out by other people. A publication
of the whole project with the title
Rodriguez-Gonzalez, A., Schelker, M., Raue, A., Steiert, B., Böhm, M., Salopiata,
F., Adlung, L., Stepath, M., Depner, S., Wagner, M.-C., Merkle, R., Kramer, B. A.,
Lattermann, S., Wäsch, M., Franke, A., Klipp, E., Wuchter, P., Ho, A. D., Lehmann,
W. D., Jarsch, M., Schilling, M., Timmer, J. & Klingmüller, U. „Mechanistic multiscale
modelling enables personalized treatment“. Manuscript in preparation 2017
is currently in preparation. Furthermore, a patent titled
Rodriguez, A., Schilling, M., Klingmüller, U., Raue, A., Schelker, M., Timmer, J., Jarsch,
M. & Steiert, B. „Methods for the prediction of a personalized ESA-dose in the treatment
of anemia“. WO Patent App. PCT/EP2015/063,775 2016
was filed.
5.2.1 Introduction
Erythropoiesis
Renewal of red blood cells (erythrocytes) is achieved by differentiating hematopoietic
stem cells (HSC) into erythrocytes. This process is tightly regulated by the cytokine
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Fig. 5.1.: Schematic representation of the stages of erythropoiesis. Hematopoietic stem cells
(HSC) differentiate to burst-forming unit erythroids (BFU-E) that express EpoR on
their surface. Colony-forming unit erythroids (CFU-E) cells crucially depend on the
presence of Epo for survival and differentiation to pro-erythroblasts. Erythroblasts
eject their nucleus and differentiate to reticulocytes and eventually to red blood cells
(erythrocytes). Figure adapted from Sankaran & Weiss [174].
erythropoietion (Epo). Based on the oxygen level in blood, the kidney regulates the
release of Epo and thereby the production of red blood cells.
As depicted in Figure 5.1, there are several stages of maturation in erythropoiesis:
pluripotent hematopoietic stem cells (HSC) in the bone marrow differentiate into burst-
forming unit erythroid cells (BFU-E). While it has been shown that these early stages
in erythropoiesis can exhibit EpoR on the cell surface [60], differentiation and cell
survival does not critically depend on the presence of Epo at this stage [213]. BFU-E
cells differentiate further into colony forming unit erythroid cells (CFU-E) that express
substantial amounts of EpoR on the membrane. These cells can, upon stimulation with
Epo, proliferate and differentiate into erythroblasts that expel their nucleus (reticulocyte)
and are released into circulation where they mature into erythrocytes [174].
JAK2-STAT5 signaling
When Epo or a similar erythropoiesis stimulating agent (ESA) binds to a dimer of the
corresponding Epo receptor (EpoR) on the cell surface, the receptor undergoes a con-
formational change resulting in the auto-phosphorylation of the janus kinase 2 (JAK2)
associated to the receptor. JAK2 in turn, phosphorylates the protein signal transducer
and activator of transcription 5 (STAT5) which dimerizes and translocates to the nucleus
where it acts as a transcription activator for genes controlling cell fate decisions.
Anemia
In patients suffering from chronic kidney disease (CKD) or chemotherapy-associated
anemia, the production of Epo and therefore of erythrocytes is reduced leading to an
acute lack of red blood cells. In addition, the pro-inflammatory state of CKD causes
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the release of other cytokines that inhibit maturation of blood progenitor cells [174].
This shortage of red blood cells is called anemia and may decrease the quality of life
dramatically and contributes to morbidity [16]. Also, the decreased health-status may
delay therapy of the primary diseases (such as cancer or CKD).
Treatment
Anemia is commonly treated by red blood cell transfusion or by administration of Epo
to the patient. Variants of the recombinant human erythropoietin have been developed,
such as C.E.R.A. and NESP, and offer a longer half-life in vivo while increasing the potency
[120].
Adverse effects
Despite the general success in curing anemia using ESAs, the risk for hypertension and
thrombotic events increases [192]. Furthermore, it was shown that cancer cells can also
express low levels of the Epo receptor [78]. These receptors are potentially capable
of activating the JAK2-STAT5 signaling pathway and therefore could increase survival
and proliferation of cancer cells. These adverse effects are still discussed controversially
[53].
A computational model of Epo-EpoR interactions
In the past, a model of Epo-EpoR dynamics has been developed and was successfully
validated in vitro [12]. Here, this established model is utilized for characterizing different
ESAs in both, mouse and human cell culture. The calibrated model enables us to
determine not only the binding properties of new Epo variants but also can be utilized to
estimate the number of binding sites of the cell type under investigation.
5.2.2 Building a mathematical model of ESA-EpoR interaction
Core model
The core model of Epo-EpoR interaction was originally developed by Becker et al. [12]
and is depicted in Figure 5.2. It consists of a system of six ordinary differential equations
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Fig. 5.2.: Model of EpoR receptor trafficking. A compatible ligand binds to the EpoR on the
cell surface. Ligand-receptor complexes are internalized and degraded. A constant
turnover of EpoR ensures responsiveness of the cell to ESA stimuli on a broad dynamic
range. Figure adapted from Rodriguez-Gonzalez et al. [170].
comprising seven kinetic parameters and additional six initial concentrations of the
model species.
d[ESA]
dt = −[ESA] · [EpoR] · kon + [ESA-EpoR] · koff + [ESA-EpoRi] · kex (5.1)
d[EpoR]
dt = −[ESA] · [EpoR] · kon + [ESA-EpoR] · koff + ESAbind · kt
− [EpoR] · kt + [ESA-EpoRi] · kex (5.2)
d[ESA-EpoR]
dt = [ESA] · [EpoR] · kon − [ESA-EpoR] · koff − [ESA-EpoR] · ke (5.3)
d[ESA-EpoRi]
dt = [ESA-EpoR] · ke − [ESA-EpoRi] · kex − [ESA-EpoRi] · kdi
− [ESA-EpoRi] · kde (5.4)
d[dESAi]
dt = [ESA-EpoRi] · kdi (5.5)
d[dESAe]
dt = [ESA-EpoRi] · kde (5.6)
The reactions in (5.1)–(5.6) describe the biological processes of association and dis-
sociation of the ligand Epo (more generally any ESA) to the receptor (EpoR), the
ligand-receptor complex’ internalization, dissociation as well as the degradation and
export of ligand inside the cell. Moreover, the receptors on the cell surface show a
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constant turn-over, as modeled by a production (proportional to the initial number of
binding sites ESAbind) and degradation term.
Auxiliary model for streptavidin kinetics
To characterize the turnover rate kt, a variant of the core model was implemented by
Becker et al. [12] that describes the interaction dynamics of streptavidin (SAv) and its
binding to a SAv-binding peptide (SBP)-tagged EpoR. While the binding properties of
SAv to the tagged EpoR and the internalization rates might be very different, the constant
turnover of unoccupied EpoR remains unchanged. Therefore, the parameters of both,
the core and the auxiliary model could be simultaneously estimated.
A sub-model for binding kinetics
A small static model was created for characterizing the ligand-receptor interactions
as measured by the dose-response experiments. In the original work [12], a one-site
saturation regression (Michaelis-Menten kinetics) was utilized to fit the data
[ESAspec_bound] =
ESAbind · [ESAfree]
[ESAfree] +KD
(5.7)
where ESAbind denotes the number of ESA binding sites and KD is the dissociation
constant which is linked to the association and dissociation rate constants kon and koff by
the relation
KD =
koff
kon
. (5.8)
Experimental data
The original data from Becker et al. [12] consist of time course data of Epo alfa and SAv
as well as dose-response data of Epo alfa and SAv. The data was acquired by measuring
the radioactivity of ligands labeled with the instable isotope 125I. The experiments were
performed in BaF3-HA-mEpoR and BaF3-SBP-EpoR cells respectively.
With this technique, they could monitor the dynamic changes in radioactivity of three
quantities, (1) extracellular Epo (ESAext), (2) membrane bound Epo (ESAmem), and (3)
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internalized Epo (ESAint). These could be mapped to the model states by the following
relations:
[ESAext] := [ESA] + [dESAe] (5.9)
[ESAmem] := [ESA-EpoR] (5.10)
[ESAint] := [ESA-EpoRi] + [dESAi] (5.11)
To quantify the binding properties of Epo alfa and SAv, a binding assay was performed.
For this purpose, BaF3-HA-mEpoR and BaF3-SBP-mEpoR cells were incubated for 4 h at
21 ◦C with different doses of the 125I-labeled ligand.
Parameter estimation and identifiability
The two parameters from the sub-model describing the binding kinetics, i.e. ESAbind and
KD, were plugged into the core model of Epo-EpoR interaction and its variant for SAv
respectively. The remaining model parameters describing association, internalization
and degradation of Epo-EpoR complexes were estimated simultaneously for both, the
core and the auxiliary model.
Identifiability analysis based on non-parametric bootstrapping [77] and on the profile
likelihood method (see Section 2.3.3) was performed and all parameters could be
estimated within tight confidence bounds.
Model predictions and validation
Using the calibrated model, they generated two hypotheses: (1) Epo is quickly depleted
from the medium due to internalization of Epo-EpoR complexes followed by degradation
of the ligand, and (2) Epo receptors on the cell surface recover rapidly after stimulation
with Epo.
These predictions were then validated experimentally. Therefore, BaF3-HA-EpoR were
treated with 5U/ml of Epo alfa and the cultured medium was used to stimulate a second
cell pool. As a read-out for the presence of Epo in the medium, phosphorylated EpoR
(pEpoR) was monitored over 300min in both cell pools. Quantitative immunoblotting
confirmed the prediction and showed lower pEpoR values for the pool stimulated using
the cultured medium as compared to the control.
Also the second prediction could be confirmed by quantitative immunoblotting. After
stimulating BaF3-HA-EpoR cells with 5U/ml of Epo alfa, pEpoR level returned to the
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basal level within 60min to 120min after stimulation. When stimulating these cells again
with an excess of ligand (50U/ml), the phosphorylated EpoR could still reach the same
levels as in the initial activation validating the hypothesis of rapid replenishment of EpoR
on the cell surface.
5.2.3 Extending the model for multiple cell types and ESAs
Although the model was successfully used to describe the Epo alfa and SAv interactions at
the receptor level in BaF3-HA-EpoR cells, several modifications needed to be implemented
in order to include novel data for other ESAs and cell types.
Correcting the time course data for experimental delay
The existing time course data were adjusted by shifting the recorded time points by a
time shift τ . This was necessary due to limitations in the experimental setup that had
not been taken into account in the original work.
The exact value of τ is determined by a series of model fits with increasing values of τ
where in each step, the corresponding time points were shifted to t→ t+ τ . Using this
approach, a profile for each time course experiment is generated. The best value for τ
was found to be τ = 0.82min for Epo alfa replicate 1, τ = 0.76min for Epo alfa replicate
2 and τ = 2.19min for the SAv time course data.
Fitting all sub-models simultaneously
While in the original setup the sub-model for ESA binding was fitted separately and
the resulting parameters KD and ESAbind were then plugged into the dynamic model,
one could also fit both models simultaneously thereby making sure that uncertainties
in the estimation are correctly propagated. However, in the process it turned out that
the affinity constants obtained using the binding assay are not fully compatible with
those controlling the dynamics in the ESA-EpoR model. This is most likely due to the
difference in temperature the two experiments were performed at (21 ◦C vs. 37 ◦C) and
was handled by allowing for a individual KD parameter for both settings.
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Using Hill-kinetics for the binding model
Another modification was necessary to link the dynamic core model and the static binding
model. In the original work the binding process was described as Michaelis-Menten
type saturation kinetics. However, the shape of the dose-response data for SAv could
not be captured accurately with this assumption. We therefore substituted the one-site
saturation by the more general Hill kinetics
[ESAspec_bound] =
ESAbind · ([ESAfree])n
([ESAfree])n + (KD)n
(5.12)
and estimated the Hill coefficient n together with the other parameters. Also, as both the
dependent and the independent variable in (5.12) represent protein concentrations, the
model is fitted on a log-log scale to account for the log-normally distributed uncertainties
of the data [104].
Incorporating individual data points instead of mean and standard error
As described more extensively in the methods chapter (see Section 2.3.2), preprocessing
of experimental data by taking mean and standard error of the mean over several
replicates can be inaccurate when the number of replicates is low. An alternative
approach to quantify measurement uncertainties is to setup a parametric error model
that is calibrated simultaneously with the model parameters.
Parameter estimation on the log-scale
As the uncertainties of protein measurements are most likely described by a log-normal
distribution[104, 164], all model quantities and data points describing protein concen-
trations are transformed to the log-scale. For the time course data of Becker et al. [12],
a scaling and offset parameter is introduced to account for the relative nature of the
experiment and possible background radiation. After these adjustments, the observables
defined in (5.9)–(5.11) are replaced by
[ESAext] = log10 (offsetj + scalej · ([ESA] + [dESAe])) , (5.13)
[ESAmem] = log10 (offsetj + scalej · [ESA-EpoR]) , (5.14)
[ESAint] = log10 (offsetj + scalej · ([ESA-EpoRi] + [dESAi])) , (5.15)
where the index j indicates that the parameters can be experiment-specific.
76 Chapter 5 Computational approaches for optimized treatment of cancer-
associated health conditions
Tab. 5.1.: Experimental combinations of different ESAs and cell lines. For each combination
the respective number of data points is indicated.
Epo alfa Epo beta NESP C.E.R.A.
BaF3 parental 40 40 12 26
BaF3-HA-mEpoR 54 65 0 0
BaF3-HA-hEpoR 60 74 46 70
hCD34+ 0 17 0 0
hCFU-E 0 28 0 0
H838 83 184 0 0
H838-HA-hEpoR 42 42 144 24
H1944 0 42 0 0
H1299 0 63 0 0
A549 0 168 0 0
5.2.4 Incorporating ligand depletion experiments for various cell lines
and ESAs
In this follow-up project, the original model was utilized and new data for different cell
lines and ESAs were added. Therefore, we assume that most kinetic parameters remain
unchanged. Only the constants describing the binding kinetics (i.e. kon and koff) and the
number of binding sites on each cell (i.e. ESAbind) are thought to be ESA and cell-specific
properties.
The radio-labeling experiments, as performed by Becker et al. [12], were very complex
and could not be adapted for other cell lines and ESAs. Therefore, a new experimental
platform was established that measures the depletion of ESA in the supernatant of cells
based on enzyme-linked immunosorbent assay (ELISA). This depletion data consists of
a panel of four ESAs and 13 cell types leading to 77 time course measurements with a
total of 1405 data points. In Table 5.1 the number of data points is indicated for each
combination of ESAs and cell type.
Making depletion experiments comparable
As we included data from various cell types treated with different doses of several ESAs,
the experimental setup for each depletion experiment could be very different in terms
of the used volume of medium V and the number of cells N contained in each well.
Therefore, a standardized volume Vˆ and cell number Nˆ were defined
Vˆ = 0.1ml, Nˆ = 1× 106 (5.16)
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and the parameter ESAbind representing the number of ESA binding sites on a per cell
basis was converted accordingly.
Moreover, for cell lines that express EpoR through retro-viral transfection, the transfection
efficiency φ ≤ 1 needs to be taken into account and the number of cells is corrected by
N = φ · N˜ . (5.17)
Mapping the depletion data to the model species
The ELISA experiment quantifies the concentration of ESAs in the supernatant. Due
to the specificity of the used antibodies, the observation can be directly linked to the
corresponding model species:
[ESAdepl] = log10 (offsetj + scalej · [ESA]) . (5.18)
Again, we use only relative measurements and thus need to introduce parameters
accounting for the scaling and possible background. Also the log-transformation is
applied respect the underlying error distribution. For the error model, an absolute error
on the log-scale was assumed
fσj = sdj (5.19)
which corresponds to a relative error in the non-log space.
Linking relative data to the absolute concentration scale
For both types of time course data, the radio-labeling and the ELISA, we deal with
relative data that is mapped to absolute concentrations in the model. To remove the
structural non-identifiability of the scalej parameters, an additional data point reflecting
the amount of the pipetted ESA dose is taken into account.
[ESAdepl]|t=0 = log10 ([ESA]|t=0) . (5.20)
As there is no actual control for the uncertainty of this value, we fixed the error model
for this observable to a relative standard deviation of 10%
sdj = log10(1.1). (5.21)
78 Chapter 5 Computational approaches for optimized treatment of cancer-
associated health conditions
Model calibration and identifiability analysis
In order to utilize the model as a tool for characterizing different ESAs and cell lines,
the model calibration was split into two separate fitting setups. In the first setting,
the model was calibrated to all data obtained using the BaF3 cell line expressing the
murine or human EpoR or its negative control that were stimulated with one of the four
different ESAs. While the receptor-ligand affinities are ESA-specific and the number
of binding sites, as described by the parameter ESAbind, are cell line-specific, all other
model parameters were assumed to be invariant under these different experimental
conditions. In the second setting, all model parameters were fixed to the optimal value
for the BaF3 cells and only the cell line-specific parameters were fitted to the data.
For parameter estimation and identifiability analysis, the D2D software was used, which
is described in more detail in Section 3.1. The best fit was determined by minimizing
the negative log-likelihood using the deterministic optimization algorithm lsqnonlin
in MATLAB (R2016a, The MathWorks Inc., Natick, MA) with randomly sampled initial
values (multi-start strategy, see also Section 2.3.2 and Section 3.1.2). The identifiability
was determined by calculating the profile likelihood (see Section 2.3.3). This method
also provides the corresponding confidence intervals. The corresponding likelihood
profiles are shown in Figure B.6 and Figure B.7, respectively for both settings. The full
table of parameter estimates from both settings and their confidence intervals are given
in Table B.1 in the appendix.
5.2.5 Results
The data of Becker et al. [12] revisited
In Figure 5.3, the experimental data by Becker et al. [12] and the corresponding model
simulations of the best fit are depicted. The model observables show the concentration
of Epo alfa and SAv in medium, on the cell surface and within the cells. Additionally,
the binding kinetics are shown by plotting the specifically bound ligand against the free
ligand.
As the experimental data was obtained in a radio-labeling experiment, the observable for
Epo in medium, as defined in (5.9), also includes the degraded, non-functional form of
the ligand. Therefore, instead of a pure depletion, an increase of [ESAext] after ∼120min
is observed. By contrast, for the dynamics of SAv, due to the shorter measurement time
and the lower affinity to the receptor, no changes are seen in the medium and the ligand
concentrations on the membrane and within the cells increase only slowly.
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Fig. 5.3.: Model simulations and data for the revised model and data by Becker et al. [12].
Lines and symbols in light blue represent BaF3-HA-mEpoR cells stimulated with Epo
alfa, lines and symbols in purple depict BaF3-SBP-mEpoR cells stimulated with SAv.
Shading represents standard deviation of the data as estimated by a parametric error
model. Additional replicates are shown in Figure B.1 in the appendix.
While the model curves for Epo alfa match the data well, for the SAv data, deviations
can be observed. These deviations most probably originate from the fact, that internal
model parameters differ between the differently tagged cell lines (BaF3-HA-mEpoR and
BaF3-SBP-mEpoR) that have not been taken into account in the auxiliary model for SAv
dynamics. Nevertheless, a good overall agreement of model and data is obtained.
Depletion of four different ESAs in the medium of BaF3 cells
Based on the data by Becker et al. [12], the number of ESA binding sites and the affinities
of Epo alfa to the murine EpoR as well as the kinetic parameters of the core model
could be determined. The kinetic parameters of the core model accounting for ESA-EpoR
internalization, ESA degradation and receptor turn-over are assumed to be independent
of the ligand used for stimulation. Therefore, the calibrated model can be utilized to
characterize the binding properties of novel ESAs.
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Fig. 5.4.: Depletion of ESA in the supernatant of BaF3 cells. Colors indicate ESA (Epo alfa,
light blue; Epo beta, dark blue). Measured data are depicted by symbols, model curves
of the core ESA-EpoR model are indicated by lines. Shading represents standard
deviation of the data as estimated by a parametric error model. Epo alfa and beta
show similar depletion dynamics in BaF3-HA-mEpoR cells. In parental BaF3 cells, not
expressing the EpoR, no depletion can be observed. Additional replicates are shown in
Figure B.2 in the appendix.
A set of four ESAs was chosen to be investigated more closely: Epo alfa, Epo beta,
NESP and C.E.R.A.. The two recombinant Epo variants alfa and beta have the same
amino acid sequence as the endogenous version and show a very similar binding affinity
[54, 73]. More recently, two genetically modified variants, called novel erythropoiesis
stimulating agent (NESP) and continuous erythropoiesis receptor activator (C.E.R.A.), have
been engineered that offer an easier dosing schedule due to a drastically increased half
life and potency in vivo [120].
First, the depletion of Epo alfa and beta in the BaF3 cell line carrying the murine EpoR
(BaF3-HA-mEpoR) and in parental BaF3 cells is analyzed, as shown in Figure 5.4. While
the stimulated parental BaF3 cells show almost no change in ESA concentration over time
(upper panels), the cells expressing EpoR rapidly deplete the ligand from the medium
(lower panels). This indicates that the main proportion of ESA depletion is due to
internalization of receptor-bound ligand.
The shape of the decay depends very much on the number of binding sites, represented
by the model parameter ESAbind, and on the receptor’s binding affinity for a certain
ligand, represented by the forward rate constant kon and the backward rate constant koff .
For the data shown in Figure 5.4, both ESAs have similar affinities whereas the number
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Tab. 5.2.: ESA affinities for mEpoR as determined by the ESA-EpoR model. Confidence
intervals are based on the profile likelihood method. The corresponding likelihood
profiles are shown in Figure B.6 in the appendix.
ESA Parameter Unit Affinity
kon pM−1min−1 (2.215± 0.173)× 10−4
Epo alfa koff min−1 (4.449± 0.760)× 10−2
KD pM (2.009± 0.172)× 102
kon pM−1min−1 (2.000± 0.310)× 10−4
Epo beta koff min−1 (4.604± 1.435)× 10−2
KD pM (2.302± 0.313)× 102
of binding sites differs substantially between the parental and the transfected BaF3 cell
line.
Using the ESA-EpoR model, these differences can be quantified computationally. For
BaF3-HA-mEpoR cells, we find an estimated number of ESA binding sites of 7827± 377
which is perfectly in line with the result of 7769± 361 determined by a conventional
saturation binding assay [12]. For the control, the parental BaF3 cell line, only 29± 9
binding sites per cell are estimated by the model, confirming that no or only few receptors
are present. The affinity values of Epo alfa and beta with respect to the murine Epo
receptor (mEpoR) are denoted in Table 5.2. Both rate constants, kon and koff , deviate only
by about 10% between Epo alfa and beta leading to very similar depletion dynamics.
Next, the affinities of all four ligands with respect to the human Epo receptor are analyzed.
The data and model fits are depicted in Figure 5.5. Again, the upper panels show the
control experiments with parental BaF3 cells and the lower panels indicate the depletion
curves of the respective ESA in BaF3-HA-hEpoR cells.
The estimated affinities are given in Table 5.3. Comparing the values for mEpoR, an
about 4-fold larger kon rate for the human receptor is found for both ligands. For the
koff -rate, the human affinity is by a factor of two smaller than in the case of the murine
receptor. Looking at the ratio of both rates, which corresponds to the KD-value, a 10-fold
smaller value for hEpoR than for mEpoR is observed.
With these differences in mind, the two novel molecules NESP [51] and C.E.R.A. [121]
are added to the analysis. Both molecules were introduced with the claim of a greatly
prolonged half-life and potency in in vivo. For a short overview of the biochemical
properties of different ESAs, I refer to the review by Macdougall [120].
As indicated in Table 5.3, the KD-values of NESP and C.E.R.A. are indeed around 30 and
50-fold higher than for Epo alpha and beta, making the depletion of the ligands from
medium much slower and therefore prolonging the half-life. This 50-fold difference for
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Fig. 5.5.: Depletion of ESA in the supernatant of BaF3 cells. Colors indicate ESA (Epo alfa,
light blue; Epo beta, dark blue; NESP, orange; C.E.R.A., red). Measured data are
depicted by symbols, model curves of the core ESA-EpoR model are indicated by lines.
Shading represents standard deviation of the data as estimated by a parametric error
model. Additional replicates are shown in Figure B.3 in the appendix.
Tab. 5.3.: ESA affinities for hEpoR as determined by the ESA-EpoR model. Confidence
intervals are based on the profile likelihood method. The corresponding likelihood
profiles are shown in Figure B.6 in the appendix.
ESA Parameter Unit Affinity
kon pM−1min−1 (8.421± 0.536)× 10−4
Epo alfa koff min−1 (1.797± 0.313)× 10−2
KD pM (2.134± 0.221)× 101
kon pM−1min−1 (9.186± 0.551)× 10−4
Epo beta koff min−1 (1.981± 0.299)× 10−2
KD pM (2.157± 0.185)× 101
kon pM−1min−1 (1.257± 0.443)× 10−4
NESP koff min−1 (8.362± 4.639)× 10−2
KD pM (6.650± 1.055)× 102
kon pM−1min−1 (8.132± 1.720)× 10−5
C.E.R.A. koff min−1 (8.810± 3.265)× 10−2
KD pM (1.083± 0.142)× 103
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Fig. 5.6.: Two-dimensional identifiability of different ESAs. The values of the affinity pa-
rameters kon and koff for different ESAs are shown by symbols. Shading indicates
the 68%-confidence intervals based on the profile likelihood method. The gradi-
ent in the background indicates the corresponding KD value. The corresponding
one-dimensional likelihood profiles are shown in Figure B.6 in the appendix.
C.E.R.A. is in line with previous results obtained in a binding assay based on a surface
plasmon resonance measurement using an immobilized EpoR [93].
In order to directly compare all ligand affinities, two-dimensional likelihood profiles for
the parameters kon and koff are calculated. In Figure 5.6, this affinity landscape is shown
for all four ESAs. While the confidence regions for Epo alfa and beta overlap, NESP and
C.E.R.A. show distinct affinity values with C.E.R.A. showing to lowest kon value and thus
the highest KD value.
Utilizing the calibrated model to characterize cell lines
After having calibrated the affinities of all four ESAs to the EpoR in BaF3 cells, further
depletion experiments with one of the previously characterized ESAs can be performed
in other cell lines. As the internal model parameters and the affinities are identified,
the only remaining unknown quantity is the cell line-specific number of binding sites,
represented by the parameter ESAbind. Utilizing the calibrated model, this number can
be determined, which is of great use because the number of receptors on the cell surface
is experimentally difficult to obtain.
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Fig. 5.7.: Depletion of ESA in the supernatant of the NSCLC cell line H838. Colors indicate
ESA (Epo alfa, light blue; Epo beta, dark blue; NESP, orange; C.E.R.A., red). Measured
data are depicted by symbols, model curves of the core ESA-EpoR model are indicated
by lines. Shading represents standard deviation of the data as estimated by a parametric
error model. Additional replicates are shown in Figure B.4 in the appendix.
For the non-small-cell lung carcinoma (NSCLC) cell line H838 and other NSCLC cell lines,
it was shown that JAK-STAT signaling can be induced upon stimulation with an ESA [49]
suggesting that functional Epo receptors are present on the cell surface. Quantitative
real-time PCR (qRT-PCR) showed that low levels of EPOR mRNA are detectable in H838
cells and quantitative immunoblotting revealed that the EpoR protein is phosphorylated
10min after stimulation with 10U/ml of Epo beta, as depicted in Figure B.8 in the
appendix.
In the upper panels of Figure 5.7, experimental data and the corresponding model fits are
depicted for H838 cells stimulated with Epo alfa and beta. Because of the low expression
levels of EpoR, the depletion in the medium was monitored for up to 146 h (8760min).
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Fig. 5.8.: Depletion of Epo beta in the supernatant of NSCLC cells. Measured data are
depicted by symbols, model curves of the core ESA-EpoR model are indicated by lines.
Shading represents standard deviation of the data as estimated by a parametric error
model. Additional replicates are shown in Figure B.4 and Figure B.5 in the appendix.
The estimated number of binding sites in these cells is 82± 6 per cell and thus almost
100-fold lower than in BaF3-HA-EpoR cells but sill three times higher than in parental
BaF3 cells. Epo alfa and beta have, as previously discussed, a higher affinity for the
hEpoR than the novel ligands NESP and C.E.R.A.. For this reason, the depletion of NESP
and C.E.R.A. in H838 cells is even slower than with Epo alfa and beta. By adding the
transfected cell line H838-HA-hEpoR, that over expresses the human EpoR, to the panel,
also the interaction with the two novel ligands can be investigated, as shown in the lower
panels of Figure 5.7. For these cells, 6330± 138 ESA binding sites per cell are found
which is only slightly lower than for BaF3-HA-EpoR cells and almost 80-fold higher than
in untransfected H838 cells.
The panel of NSCLC cell lines is extended to H1944, H1299 and A549 cells. Previous
analyses using qRT-PCR showed that while H1299 cells have a non-zero gene expression
of EPOR mRNA, H1944 and A549 are below detection limit as shown in Figure B.8 in the
appendix. In quantitative immunoblotting, EpoR and pEpoR protein levels are detectable
in H1299 cells and small amounts in A549 cells. In Figure 5.8 the depletion of Epo beta
and the corresponding model fits are shown for these three cell lines.
For the EpoR abundance in H1944 and H1299 cells, the model predicts 7± 3 and 98± 15
binding sites, respectively, confirming the qRT-PCR data and immunoblotting data. For
the A549 cell line, 46± 2 binding sites are found, reflecting the HA-EpoR protein levels
in the immunoblot.
As a last step, the erythroid progenitor cells in the colony-forming unit stage (CFU-E) are
analyzed (see also fig:erythropoiesis). As mentioned in the introduction of this section,
these cells can differentiate into erythroblasts upon Epo stimulation and therefore need
to express substantial amounts of EpoR on the cell surface. The model fit of the depletion
data, as shown in Figure 5.9, provides 433± 23 binding sites. This is consistent with
previous experiments that reported 300 to 1100 binding sites per CFU-E cell [21]. As a
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Fig. 5.9.: Depletion of Epo beta in the supernatant of blood progenitor cells. Measured data
are depicted by symbols, model curves of the core ESA-EpoR model are indicated by
lines. Shading represents standard deviation of the data as estimated by a parametric
error model. Additional replicates are shown in Figure B.5 in the appendix.
control, also the human progenitor cells hCD34+, that lack the EpoR, are analyzed. As
expected, the depletion in the supernatant is very slow and the corresponding number of
binding sites is only 21± 15.
In summary, the computational model of ESA-EpoR interaction can be utilized to reliably
detect and quantify the number of ESA binding sites over three orders of magnitude
on various cell lines and types. Therefore, the model provides a helpful tool for char-
acterizing cell lines and novel ESAs. A patent describing the method and its potential
applications was filed in 2016 [168].
5.2 Optimized treatment strategies for anemia patients based on a
mechanistic multi-scale model
87
5.2.6 Linking the receptor model to JAK-STAT signaling
In the following sections, a short overview of the continuation of the project is presented.
As stated in the introduction, the simulations and analyses shown here were not
carried out by the author but were included in order to show the bigger picture of the
approach.
The number of ESA binding sites on a specific cell type determines the capability of
Epo-induced signaling. One of the main pathways activated upon Epo stimulation is
the JAK2-STAT5 pathway that controls cell fate decisions. After having characterized
the binding properties of four different ESAs and the EpoR abundance on the surface
of various cell lines, we want to link ligand-induced receptor activation to downstream
signaling.
In the last two decades, several computational models of JAK-STAT signaling have been
published [189, 8, 131]. Only recently, Merkle et al. [131] provided a model of Epo-
induced JAK2-STAT5 signaling that is able to capture the downstream dynamics in
multiple cell types including the NSCLC cell line H838 and erythroid progenitor cells in
the CFU-E stage. While the model by Merkle et al. [131] offers a great level of detail, here
we limit ourselves to a very reduced JAK-STAT model that is still able to link a given Epo
stimulus to a transcriptional read-out. This extended ESA-EpoR-STAT5 model is depicted
in Figure 5.10a. It consists of the ESA-EpoR core model as described in (5.1)–(5.6) and
two additional equations for STAT5 and phosphorylated STAT5 (pSTAT5) as defined in
(5.22)–(5.23):
d[STAT5]
dt = −[ESA-EpoR]
2 · [STAT5] · kSTAT5,act + [pSTAT5] · kSTAT5,deact (5.22)
d[pSTAT5]
dt = +[ESA-EpoR]
2 · [STAT5] · kSTAT5,act − [pSTAT5] · kSTAT5,deact (5.23)
Based on time course data of Epo beta-induced STAT5 phosphorylation in CFUE-E and
H838 cells, as shown in Figure 5.10b, the two additional parameters kSTAT5,act and
kSTAT5,deact can be calibrated. By measuring the pSTAT5 level in CFU-E cells in response
to increasing doses of Epo beta and C.E.R.A., the equipotent dose, which is the dose
at which pSTAT5 is half-maximal, can be determined for both ESAs (Epo beta 1331 pM,
C.E.R.A. 8841 pM), as depicted in Figure 5.10c.
When simulating the model for these equipotent doses, the model predicts a similar area
under curve (AUC) for both ESAs in the case of CFU-E cells, as shown in Figure 5.10d,
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Fig. 5.10.: Impact of differences in the abundance of EpoR and of ESA binding properties
on the dynamics of EpoR activation. (a) Graphical representation of the extended
ESA-EpoR-STAT5 model. (b) Epo beta-induced dynamics of STAT5 phosphorylation
was determined by mass spectrometry for hCFU-E. (c) Mass spectrometric quantifica-
tion of Epo beta and C.E.R.A. dose-dependent induction of STAT5 phosphorylation in
hCFU-E at 10min. Equipotent concentrations are indicated with vertical lines. (d)
Model-predicted time courses and area-under-curve (AUC) of EpoR occupancy for Epo
beta and C.E.R.A. in hCFU-E and H838 cells. (e) Model-predicted depletion of Epo
beta and C.E.R.A. by hCFU-E cells and H838. (f) Dynamics of STAT5 phosphorylation
induced by equipotent concentrations of Epo beta and C.E.R.A.. Model-predicted
time courses and absolute quantification of phospho-STAT5 molecules per cell in
hCFU-E and H838 cells by mass spectrometry are shown. Solid lines represent model
trajectories and shading reflects the standard deviation of the data, shadings delim-
ited with dashed lines indicate validation profile likelihood-based confidence band of
model predictions. Figure adapted from Rodriguez-Gonzalez et al. [170].
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which corresponds to a similar pathway activation. For the H838 cells, however, the
same dose lead to a different AUC for C.E.R.A.. This is due to the lower number of ESA
binding sites on H838 cells and the decreased affinity of C.E.R.A. as compared to Epo
beta. This can also be seen when simulating the depletion of Epo beta and C.E.R.A. in
CFU-E and H838 cells, as shown in Figure 5.10e. While for Epo beta, a strong depletion
is observed in CFU-E cells, H838 cells do not visibly deplete the ligand from the medium.
By contrast, for C.E.R.A., only a minor depletions occurs in CFU-E cells and in H838 cells
the concentration remains constant.
Model predictions for the number of phosphorylated STAT5 molecules in hCFU-E and
H838 cells during 60min after stimulation with Epo beta and C.E.R.A. are indicated by
the dashed areas in Figure 5.10f. Here, similar pSTAT levels in CFU-E cells in response
to Epo beta and C.E.R.A. are observed. By contrast, in H838 cells, C.E.R.A. induces a
weaker activation than Epo beta. These predictions were successfully validated using
mass-spectrometry, as represented by the symbols in Figure 5.10f.
5.2.7 Pharmacokinetics and -dynamics (PKPD)
In the previous parts, we could show that NSCLC cells can have signaling competent ESA
binding sites and that C.E.R.A. is less active in H838 cells than the equipotent dose of Epo
beta. In order to transfer these results to the patient level, another extended version of the
ESA-EpoR core model was built. This multi-scale model comprises the dynamics of ESA
in the interstitium (pharmacokinetics; PK) and also models hemoglobin degradation as a
function of the concentration of the ESA-EpoR complex (pharmacodynamics; PD). The
combined ESA-EpoR-PKPD model can be used to determine patient specific parameters
based on longitudinal data from clinical trials.
The model structure is depicted in Figure 5.11a. The corresponding equation system
consists of the core ESA-EpoR model converted to the hours time scale (5.26)–(5.31) as
well as two additional equations for the hemoglobin ([Hb]) level in the blood (5.24) and
the ESA concentration in the interstitium ([ESASC]) (5.25).
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d[Hb]
dt = +[ESA-EpoR] · khb_pro − [Hb] · khb_deg · khb_deg_PatientID (5.24)
d[ESASC]
dt = +[Injection]− [ESASC] · ksc_out −
[ESASC] · ksc_clear
[ESASC] + ksc_clear_sat
(5.25)
d[ESA]
dt = +[ESASC] · ksc_out − [ESA] · kclear − 60 · [ESA] · [EpoR] · kon
+ 60 · [ESA-EpoR] · koff + 60 · [ESA-EpoRi] · kex (5.26)
d[EpoR]
dt = −60 · [ESA] · [EpoR] · kon + 60 · [ESA-EpoR] · koff
+ 60 · ESAbind · kt − 60 · [EpoR] · kt + 60 · [ESA-EpoRi] · kex (5.27)
d[ESA-EpoR]
dt = +60 · [ESA] · [EpoR] · kon − 60 · [ESA-EpoR] · koff
− 60 · [ESA-EpoR] · ke (5.28)
d[ESA-EpoRi]
dt = +60 · [ESA-EpoR] · ke − 60 · [ESA-EpoRi] · kex
− 60 · [ESA-EpoRi] · kdi − 60 · [ESA-EpoRi] · kde (5.29)
d[dESAi]
dt = +60 · [ESA-EpoRi] · kdi (5.30)
d[dESAe]
dt = +60 · [ESA-EpoRi] · kde (5.31)
The model is calibrated to longitudinal data of several clinical trials: two phase II
trials conducted with C.E.R.A. in NSCLC patients suffering from normocytic anemia
(NCT00072059 [82], NCT00327535 [27]) and two phase I trials in healthy subjects [97,
166]. In all trials, the C.E.R.A. concentration and the Hb level were monitored for up to 12
weeks. While the parameters of the core model were defined by the previous calibration
based on in vitro data, the additional parameters needed to be estimated either for the
whole patient population or in a patient-specific manner. A model comparison using
the likelihood ratio test revealed that only the number of ESA binding sites (ESAbind)
and the Hb degradation rate khb_deg_PatientID need to be patient-specific while all other
parameters were compatible over all subjects from the four clinical trials.
In Figure 5.11 the data and model fits are shown for two representative patients, one
from NSCLC (panel b) and one from the healthy group (panel c). In Figure 5.11d, the
histograms for the whole patient population is given. In general, an increase of the Hb
degradation rate was observed in the NSCLC patient population while the number of
ESA binding sites decreased compared to the healthy subjects.
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Fig. 5.11.: Representation of clinical data by a multi-scale ESA-EpoR-PK/PD model and
patient-specific determination of ESA binding sites and hemoglobin degrada-
tion rates. (a) Graphical representation of the multi-scale ESA-EpoR-PK/PD model.
Hb: hemoglobin, sc: subcutaneous. (b) Timing of C.E.R.A. doses (arrows), phar-
macokinetics of C.E.R.A. and pharmacodynamics of Hb levels for a NSCLC patient
(purple) (ID:2101, clinical trial NCT00072059). (c) same as b) but with healthy
subject (green) (ID:25, CSR WP16422 clinical trial). Experimental measurements
are indicated by dots. Solid lines represent the model trajectories and shading the
standard deviation of the data. The model-estimated ESA binding sites and the
Hb degradation rate ± confidence intervals for each subject are given. (d) Model
estimated distributions of ESA binding sites and of the Hb degradation rates in
NSCLC patients (NCT00072059 clinical trial) in purple (N=96) and in healthy sub-
jects (CSR WP16422 and CSR BP18035 clinical trials) in green (N=79). For both
parameters, Wilcoxon rank analysis revealed p < 1× 10−5. Figure adapted from
Rodriguez-Gonzalez et al. [170].
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Model-based risk prediction
Although patients frequently suffer from anemia associated with chemotherapy, treating
them with ESAs has been associated with an increase in the risk of mortality [192].
Here, the patient outcome of two clinical trails in NSCLC patients is correlated with
ESA treatments using the patient-specific model parameters for Hb degradation and the
number of ESA binding sites. Applying Youden’s J statistic, the prognostic value of both
parameters and the given dose of ESA can be defined. The model was able to classify the
patients into high or low risk of fatal outcome and showed a good correlation between
patients in the high risk group and the deceased patients, as shown in Figure 5.11a. The
prediction was validated using only PD values and the ESA doses in an independent
group of patients. The mathematical model was capable to correctly assign the relative
majority of the deceased patients to the high risk group of fatal outcome, as depicted in
Figure 5.11b.
Predicting an optimal treatment strategy for individual patients
The response of individual patients to an ESA can be predicted by the model after the
first doses have been administered. Therefore, the multi-scale ESA-EpoR-PKPD model
can also be utilized to define optimal dosing schedules only a few weeks after the initial
treatment. The process is depicted in Figure 5.11c–f. When treating patients according to
the guidelines, as shown in panel c) and d), some patients might be over or under dosed.
In contrast, the model-based optimized treatment can correct the dosing, as shown
in panel e). Only a minority of the patients do not respond strong enough, therefore
requiring a more densely dosing schedule, as indicated in panel f).
5.2.8 Discussion
In sum, based on the Epo-EpoR model by Becker et al. [12] a mechanistic multi-scale
model could be established that is able to transfer the knowledge about ligand and cell
characteristics obtained from in vitro data to the dosing schedule for patients in clinics.
The first outcome of the project is, that the revised ESA-EpoR model is able to describe
the dynamics and thereby determine the ligand-receptor affinities of four different ESAs
in BaF3 cells stably expressing the murine or human EpoR. This calibrated model can be
utilized as a tool to characterize other cell lines and ligands. This can be of great value for
drug development as the standard approaches for characterizing ESAs like BIAcore suffer
from the artificial experimental conditions (e.g. the receptors are mounted on a metal
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Fig. 5.11.: Model-based response optimization and risk prediction. (a) Patient stratification
based on individual estimations of ESA binding sites and Hb degradation rate in
both NSCLC clinical trials (NCT00072059 and NCT00327535). Patients who died
during the trial are depicted as triangles, and survivors as squares. In the left panel,
the color code indicates the ESA dose given in the first three weeks. In the right
panel, red and blue colors indicate the classification of patients in high risk and
low risk of fatal outcome. (b) Representation of an independent dataset of the
NCT00072059 clinical trial for which only PD values were available. Left panel
corresponds to patient groups based on their predicted probability of fatal outcome.
Green and orange indicate the fraction of patients that survived or died. Dashed
line indicates the risk threshold. Overall survival is displayed as a Kaplan-Meier
plot (right panel), blue and red colors correspond to the predicted low and high risk
group. The cox-proportional hazard model was used to determine a 2.9-fold increase
in risk (p < 0.05). (c) C.E.R.A. treatment according to the guidelines for NESP for
three patients with distinct Hb degradation rates (NCT00072059, patient ID 2303,
2723 and 2652) was simulated by the multi-scale model. Model-predicted Hb levels
are displayed as solid lines and shading represents the standard deviation estimated
from the clinical data. Dashed lines indicate the optimal Hb response according to
the guidelines for ESAs. (d) Patient stratification based on the predicted outcome
of the C.E.R.A. treated patients in the NCT00072059 and NCT00327535 trials. For
each patient, the model-estimated ESA binding sites and the Hb degradation rates
are depicted. Overdosed patients (yellow) are defined as Hb ≥ 2σ above target
response by the guidelines (dashed line). Responding patients (blue) are defined as
Hb responses within the guidelines. Non-responding patients (red) are defined as
Hb ≥ 2σ below the target response given by the guidelines. The patients exemplified
in (c) are indicated. (e) Model-based optimized ESA treatment of patient 1, 2 and
3. Model-predicted optimal C.E.R.A. doses and predicted Hb responses (solid lines)
are indicated. Shaded areas indicate the standard deviation estimated from the
clinical data and dashed lines correspond to the optimal Hb response based on the
guidelines for ESAs. (f) Optimized ESA dosing and timing regimens are predicted
by the multi-scale model for all patients depending on Hb degradation rate and ESA
binding sites. ESA dosing and timing is indicated by shades of red. Figure adapted
from Rodriguez-Gonzalez et al. [170].
5.2 Optimized treatment strategies for anemia patients based on a
mechanistic multi-scale model
95
surface) and can therefore deviate drastically from in vivo values [141]. The second
feature of our method is to provide the number of ESA binding sites for the cell type
under investigation. Experimentally, this number can be measured by quantitative flow
cytometry (e.g. qFACS) which combines a specific antibody labeling with a calibration
of the fluorescence using beads and has been applied for quantifying the abundance of
subtypes of the IL1-receptor [198]. For our approach, we solely need to measure the
depletion of a well characterized ESA in the medium using ELISA and our model can
calculate the corresponding number.
In the second step, we linked the ESA-EpoR model to JAK-STAT signaling. Using this
ESA-EpoR-JAK-STAT model we could calculate equipotent doses of different ESAs based
on their in silico signaling activity. This allows us to perform simulations with ESAs like
C.E.R.A. that have not been tested or approved for chemotherapy-induced anemia but
provide more flexibility in the treatment due to their increased half-life.
The third step linked the cellular scale to the body level by extending the ESA-EpoR
model by a PK/PD part. Based on the data of four clinical trails with C.E.R.A. in NSCLC
patients and healthy subjects, we could calculate the patient-specific number of ESA
binding sites and thereby derive the number of CFU-E cells available for differentiation.
Also the patient-specific Hb degradation rate was estimated from the monitored Hb levels.
The comparison of the two populations, healthy subjects and NSCLC patients, showed a
general shift towards lower numbers of CFU-E cells and higher Hb degradation rates in
NSCLC patients. With this information at hand, we can predict the increase of Hb caused
by a dose of ESA administered to the patient and use the multi-scale model to optimize
the dosing schedule within the bounds of the regulatory restrictions.
Also, the patient outcome from another study could be correlated with the three features
number of ESA binding sites, Hb degradation rate and administered ESA dose. This
allows for a computational risk prediction that can help to avoid under or overdosing of
critical patients.
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5.3 Deciphering the cellular composition of unknown
patient samples for immunotherapy
This work was initiated during a six-month internship in 2015 at Merrimack Pharma-
ceuticals Inc. in Cambridge, MA, USA. The idea was inspired by a recent publication
by Newman et al. [139]. All steps have been developed in close collaboration with
Andreas Raue (Merrimack). Sample preparation and flow cytometry analysis of the
ovarian ascites samples were performed by Sonia Feau (Merrrimack) and Jinyan Du
(Merrimack). Processing of the single-cell RNA-seq data of the ascites samples was
performed by Nav Ranu (Merrimack). A publication of the project with the title
Schelker, M., Feau, S., Du, J., Ranu, N., Klipp, E., MacBeath, G., Schoeberl, B. &
Raue, A. „Estimation of immune cell content in tumour tissue using single-cell RNA-seq
data“. Manuscript in preparation 2017
is currently in preparation and a preprint is available on bioRXiv1.
5.3.1 Introduction
In the five years between 2009 and 2014, 51 new anti-cancer drugs have been approved
by the FDA [123] – among them, the first generation of immunotherapeutical drugs.
These novel drugs make use of the body’s inherent immune system to fight malignant
tissue. The approach brings potentially less side effects and is, for the appropriate patient
population, very effective. The selection of the right treatment strategy for individual
patients, however, is still challenging as information on the presence of immune cells in
the tumor environment can only be obtained by histology of tissue samples or based on
well-studied biomarkers that correlate with the infiltration of specific cell types in the
tumor environment.
In this section, I want to present a computational method for quantification of immune
and stromal cell content in bulk tumor tissue samples. First, the methodology of mixture
deconvolution is introduced and existing methods and their limitations are mentioned.
Next, single-cell RNA sequencing (scRNA-seq) data from three different human tissue
sources, i.e. melanoma, ovarian carcinoma ascites and peripheral mononuclear blood
cells (PBMCs) from healthy subjects, are analyzed to identify and assign the major cell
1http://biorxiv.org/content/early/2017/04/12/127001
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types contained in the samples. Using the combined data set, a benchmark setting is
established that allows for the systematic evaluation of patient heterogeneity and its
impact on the deconvolution result. Using this benchmark, we can asses the performance
of different deconvolution approaches and configurations systematically and select the
best performing methods for further analyses.
Besides the estimation of immune and stromal cell fractions, this revised deconvolution
method allows for the estimation of the fraction of tumor cells and can predict the gene
expression profile of the tumor cells in a patient-specific manner.
Tumor infiltrating immune cells
The human immune system consists of a complex network of highly specialized, inter-
acting cell types. While cytotoxic cells, such as CD8+ T cells, fight malignant tissue
by inducing programmed cell death, regulatory T cells suppress the immune response
to prevent, for instance, autoimmune disease. Therefore, the balance of effector and
suppressor cells is crucial for the correct functioning of the immune system. In cancer
patients, this balance is perturbed and suppressor cells protect the tumor from being
fought by the immune response [199]. The whole cycle of cancer-immunity, as proposed
by Chen & Mellman [28], is depicted in Figure 5.12 where each of the numbered boxes
shows a location within the body and denotes the respective stimulatory and inhibitory
factors.
Studies revealed that abundance and location of certain immune cells can predict patient
outcome with a high level of confidence [64]. The immune infiltration of tumors
therefore represents an important prognostic factor for disease progression and can
help to support treatment decisions. Recent developments in immunotherapy try to
restore the cancer immunity by blocking specific immune checkpoints such as CTLA4 and
PD-L1/PD1 [149]. However, a big challenge for immunotherapy in cancer treatment
remains the identification of patient populations that respond to the respective therapy.
Therefore, reliable approaches for computational mixture deconvolution represent a
promising way to gather information on immune cell infiltration in the tumor tissue
based on measurements that are often part of the clinical standard procedure.
Deconvolution of unknown cell mixtures
The deconvolution of unknown mixtures of cells can be tackled in several ways. Here, I
want to focus on deconvolution methods that are based on the linearity assumption of
the gene expression of all cells comprised in the mixture i.e. the gene expression of a bulk
98 Chapter 5 Computational approaches for optimized treatment of cancer-
associated health conditions
IFN-α
IFN-γ
TNF-α
TGF-β
Fig. 5.12.: The cancer-immunity cycle. The body can generate immunity against cancer at
multiple locations, indicated by numbers. For each step in the cycle, stimulatory and
inhibitory factors are indicated. Figure taken from Chen & Mellman [28].
sample can be represented as a linear combination of the gene expression of individual
cell types weighted by their proportions in the sample:
m⃗i = Bw⃗i (5.32)
where m⃗i is the gene expression of the mixture of the i-th patient, B is the signature
matrix and is composed of one column for each cell type and w⃗i is the initially unknown
fraction of each cell type within the mixture. Thus, if the gene expression of individual
cell types is known, the system can be solved computationally for w⃗i and the fraction of
each component can be determined.
Because the experimental data for m⃗i and B are obtained by measuring gene expression
of single cells or cell populations, biological variability and technical measurement errors
introduce noise. This noise can limit the accuracy of the deconvolution and makes the
selection of genes with high discriminative power a crucial part of the deconvolution
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process. Another source of uncertainty is the possible contamination of the sample with
other cell types that are not contained in B. In a realistic setting, this is very relevant as
most samples from patient tissue contain a variety of different cell types of which only a
part is known a priori.
Gene expression data as a basis for deconvolution
Since microarray data of cell populations and patient samples can be obtained at a
relatively low cost, the amount of available data, e.g. on NCBI‘s gene expression omnibus
(GEO)2, increases rapidly. Initiatives like the Cancer Cell Line Encyclopedia (CCLE) [10]
and The Cancer Genome Atlas (TCGA) [210] have been launched and aim for an extensive
collection and quantification of commonly used cancer cell lines and patient samples
using various measurement and analysis techniques. More recently, high-throughput
sequencing of RNA (RNA-seq) has been introduced to the community providing gene
expression quantification on an absolute scale with a higher accuracy especially for
low abundant RNAs (see also Section 2.1.6). These data form an ideal basis for the
development and application of computational deconvolution approaches.
Existing methods for mixture deconvolution
In 2009, Abbas et al. purified immune cells from whole blood and measured their
gene expression profiles using microarray. The authors could show that using these
data the relative fractions of immune cells in independent blood samples could be
accurately determined. Moreover, they applied their deconvolution approach to samples
from patients suffering from the autoimmune disease systemic lupus erythematosus
and compared the deconvolution results to healthy subjects showing that activation
states of lymphocytes differ significantly between both groups. Gong et al. [70] used a
quadratic programming approach to decipher immune cell fractions and evaluated the
performance of their approach on cell line data and data from human whole-blood data
from kidney transplant recipients. Qiao et al. [157] extended the method of Abbas et al.
[1] from an ordinary least-squares to non-negative least-squares strategy and successfully
utilized it to deconvolve whole blood samples under different micro-environmental and
developmental conditions. Recently, Newman et al. [139] developed a method called
CIBERSORT in which the authors applied support vector regression (SVR) to estimate cell
fractions from microarray data. They also compared CIBERSORT to previously published
2https://www.ncbi.nlm.nih.gov/geo/
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methods and showed that their approach outperforms existing methods when being
applied to well-known in vitro cell mixtures. Exhaustive reviews on the topic is given by
Mohammadi et al. [134] and Newman & Alizadeh [138].
Gentles et al. [67] applied the CIBERSORT method to a huge collection of publicly
available data such as TCGA. Based on the deconvolution result, the authors performed
a meta-analysis over 39 malignancies and identified complex associations between 22
distinct leukocyte subsets and overall survival of cancer patients.
The above-mentioned methods have been specifically developed for gene expression
profiles of cell mixtures or samples and purified cell types measured by microarray. Only
few attempts have been made to make use of data obtained by more recent methods
like RNA-seq. Gong & Szustakowski [69] presented an algorithm for using RNA-seq
data for deconvolution of immune cell fractions in patient samples. However, the proof-
of-principle experiments are kept artificially small (mixture of only three known cell
types and a small unknown cell fraction) and are thus only of limited value. Mehnert
et al. [130] applied the CIBERSORT method to RNA-seq data of POLE-mutant cancers
in TCGA. Based on the deconvolution result, the authors concluded that patients with
POLE-mutations are good candidates for immune checkpoint inhibitor therapy. However,
they did not show a proof-of-principle experiment to validate the correct operation and
accuracy of CIBERSORT being utilized for RNA-seq data.
Taken together, the potential of having absolute expression values from RNA-seq mea-
surements rather than relative data from microarray has not been fully exploited yet.
Therefore, a systematic evaluation and benchmarking on realistic data is required for
enabling the use of RNA-seq data for computational deconvolution.
5.3.2 Single-cell RNA-seq data from multiple tissues and patients
In the following, I want to present a proof-of-principle study for using single-cell RNA-seq
(scRNA-seq) data to deconvolve patient samples based on the CIBERSORT method. For
scRNA-seq measurements, the tissue samples are experimentally decomposed into single
cells (see also Section 2.1.6). These cells can be classified into cell types based on their
expression profiles. Thus, the ground truth of the mixture is known and can be used to
assess the accuracy of the deconvolution approach.
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Gathering single-cell data from multiple human tissue sources
In order to make our benchmark study robust against tissue- or patient-specific gene
expression patterns, we collected data from multiple human tissues sources obtained
from patient samples. We included a recently published data set of melanoma single-cell
sequencing data by Tirosh et al. [190] which provides the gene expression levels for 4645
single cells obtained from 19 melanoma patient samples. As a second indication, we
incorporated data from ascites samples of four ovarian carcinoma patients. This dataset
consists of a total of 3114 individual cells sequenced by scRNA-seq and the composition
of each sample was also quantified by qFACS (see also Section 2.1.2). As most of the
previous deconvolution studies have been performed on immune cell data from whole
blood, we also included single-cell data of PBMCs from four healthy subjects provided by
10x Genomics3 (“4k/8k PBMCs from a Healthy Donor”, “Frozen PBMCs (Donor A/B/C)”
[217]). As the merged PBMC dataset comprises a total of ∼33 k individual cells, we
randomly picked 1000 cells for each of the four donors to reduce the data to a comparable
extent.
Overall, the combined single-cell sequencing dataset contains gene expression data for
more than 17 k genes of ∼11 k individual cells spanning three human tissue sources.
Making the samples comparable
Gene expression values were used on the transcripts per million (TPM) scale as provided
by current quantification methods [116, 19, 150] and were transformed to the commonly
used non-negative log2-scale by
y = log2(TPM+ 1). (5.33)
To ensure cross-sample comparability, all three datasets were normalized to the average
expression of 3559 housekeeping genes [52] by
y˜i = yi · HKHKi , (5.34)
where yi represents the gene expression profile of the i-th sample, HKi denotes the
average gene expression over all housekeeping genes of the i-th sample and HK is
the average expression over all housekeeping genes and samples. Other normalization
3https://support.10xgenomics.com/single-cell/datasets
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methods like upper quartile or median normalization could not be applied to scRNA-
seq data as the single-cell measurements contain too many genes with zero expression
leading to a zero-upper quartile and median for several samples. Gene symbols of the
melanoma dataset needed to be corrected to account for automatic conversion into dates
by Microsoft Excel [220].
5.3.3 Classifying individual cells based on marker gene expression and
similarity
Traditional methods for classifying cells into cell types are based on cell sorting through
flow cytometry (see Section 2.1.2). Therefore, specific cell surface molecules, so-called
cluster of differentiation (CD) molecules, have been defined [221] and their expression,
whether positive (e.g. CD45+) or negative, defines the differentiation stage of each
cell.
For scRNA-seq data, however, the expression of the corresponding genes can be very
sparse and the classification solely based on a few CD genes seems to be unreliable.
Therefore, we suggest to use a combination of marker gene expression, dimensionality
reduction and machine learning-based classification in order to reliably assign a cell type
to each individual cell.
Dimensionality reduction and clustering
To reduce the very high-dimensional space provided by scRNA-seq data, the t-SNE
algorithm (see Section 2.2.2) was applied resulting in a two dimensional representation
of the data as shown in Figure 5.13a. The t-SNE mapping arranges the cells based on
their similarity in gene expression. We performed the analysis on a subset of 1015 genes,
that have been found to be differentially expressed in various immune cell types (see also
Section 5.3.5). On this two-dimensional map, a DBSCAN clustering (see Section 2.2.3)
was performed in order to assign a cluster index to each distinct group of similar cells, as
indicated by colors and numbers in Figure 5.13a. The parameters were set to MinPts=25
and Eps=1.5.
Initial cell type assignment based on marker gene expression
Next, we analyzed the gene expression of a total of 45 marker genes and merged the
expression to an overall cell type score according to three logical operators: (1) AND
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Fig. 5.13.: Clustering and marker gene expression of scRNA-seq data. (a) DBSCAN cluster-
ing was performed on the t-SNE map. Parameters of the algorithm were adjusted
in such a way that distinct cell groups are identified as separate clusters. Symbols
represent individual cells, shape of the symbol denotes indication. Colors and num-
bering denote the resulting clusters. (b) Heatmap of marker gene expression on the
t-SNE mapping. For each cell type, the expression of cell type-specific marker genes
was evaluated and merged to a score using three logical operators (AND, OR, NOT).
Resulting scores show mostly distinct populations of cell types.
genes that are all required, (2) OR genes where only the expression of one of them is
necessary, and (3) NOT genes where the expression is a negative selection criterion. The
marker genes for each operator and cell type are indicated in Table 5.4.
The combined cell type score was normalized to [0, 1] and plotted as a heatmap on top of
the t-SNE map as shown in Figure 5.13b. For each cluster, the predominant cell types
were determined by keeping only those cell populations that have a total score of at least
75% of the maximal score. This helps to prevent misclassification of closely related cell
types (e.g. Natural killer cells and T cells).
Cell type classification using decision trees
The resulting cell type assignment was used as a training set for a decision tree classifica-
tion approach (see also Section 2.2.5). The t-SNE representation of the training set is
depicted in Figure 5.14a.
The decision tree classifier, as shown in Figure 5.14b, performs several binary decisions
based on the expression value of individual features in the training set. The accuracy of
the classifier was evaluated using 5-fold cross-validation indicating a high classification
accuracy (98.06%). Subsequently, the trained classifier can be utilized to predict the cell
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Fig. 5.14.: Identification of cell types of scRNA-seq data using decision tree classification.
(a) t-SNE mapping of the training set. Predominant cell populations within each
cluster were identified with the corresponding cell type and were used as training
set for classification. 8864 of 11 759 cells were used for training. (b) Decision tree
classification of nine major cell types. Each node in the graph represents a binary
decision based on the value of one feature. Expression profiles were reduced to
the merged gene set and transformed using PCA before training the classifier. (c)
Predicted cell types upon decision tree classification. Cells with a posterior probability
of less than 0.99 were labeled as “Unknown”. After classification, 11 449 of 11 759 cells
were assigned to one of the nine major cell types. In all panels: Symbols represent
individual cells, shape of the symbol denotes indication, color indicates cell type
according to the legend.
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Tab. 5.4.: Marker genes used for cell type identification. For nine major cell types and three
T cell subtypes, marker genes were defined based on suggestions from literature. Each
gene was assigned to one of three logical operators (AND, OR, NOT) depending on its
known expression in the respective cell type.
Cell type AND marker OR marker NOT marker
T cells CD3D, CD3E, CD3G, CD27,
CD28
CD4+ T cells CD4 FOXP3,
IL2RA, CTLA4
CD8+ T cells CD8B CD8A CD4
Regulatory T cells CD4, FOXP3, IL2RA,
CTLA4
B cell CD19, MS4A1, CD79A,
CD79B, BLNK
Macrophages/
Monocyte
CD14, CD68, CD163,
CSF1R, FCGR3A
Dendritic cell IL3RA, CLEC4C, NRP1
Natural killer cells FCGR3A, FCGR3B, NCAM1,
KLRB1, KLRB1, KLRC1,
KLRD1, KLRF1, KLRK1
Endothelial cell VWF, CDH5, SELE
Cancer associated
fibroblasts
FAP, THY1, COL1A1,
COL3A1
Ovarian carcinoma
cells
WFDC2, EPCAM, MCAM
Melanoma cell PMEL, MLANA, TYR,
MITF
types of the whole data set, leading to the classification result shown in Figure 5.14c.
Cells with a posterior probability lower than 0.99 were marked as “Unknown”.
Separate identification of T cell subtypes
Because of the strong similarity among T cell subtypes, the first round of classification
was only performed on the nine major cell types indicated in Figure 5.13 and 5.14.
Identification of three selected T cell subtypes, i.e. CD4+, CD8+ and regulatory T cells,
was achieved by a second round of classification, taking only the previously determined
population of T cells into account. The parameters for DBSCAN clustering needed to be
adjusted to MinPts=25 and Eps=1.75 and the cross-validation showed an accuracy of
93.88%. The subtype classification is depicted in Figure 5.15.
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Fig. 5.15.: Classification of three T cell subtypes. (a) DBSCAN clustering on t-SNE map of the
T cell population. Colors and numbering denote the resulting clusters. (b) Heatmap
of marker gene expression on the t-SNE mapping. Expression of subtype-specific
marker genes was evaluated and merged to a score using three logical operators
(AND, OR, NOT). Resulting scores show mostly distinct populations of T cell subtypes.
(c) t-SNE mapping of the training set. Predominant subtype populations within
each cluster were identified with the corresponding T cell subtype and were used as
training set for classification. 1439 of 5067 cells were used for training. (d) Decision
tree classification of three T cell subtypes. Each node in the graph represents a binary
decision based on the value of one feature. Expression profiles were reduced to
the merged gene set and transformed using PCA before training the classifier. (e)
Predicted subtypes upon decision tree classification. Cells with a posterior probability
of less than 0.99 were labeled as “Unknown”. After classification, 5052 of 5067 cells
were assigned to one of the three T cell subtypes.
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5.3.4 Analyzing indication and patient-specific gene expression
Effects of the tumor micro-environment
The final classification result is shown in Figure 5.16a. Cell types and T cell subtypes
are indicated by different colors, source tissues are distinguished by the shape of the
marker symbol. In the t-SNE map, we find distinct clusters of cells according to the cell
type. Within each cell type cluster, sub populations corresponding to the source tissue
could be identified, indicating that immune cells potentially change their gene expression
depending on their micro-environment.
The similarity of corresponding cell types from different sources was further analyzed by
calculating the pair-wise Pearson‘s correlation of the averaged gene expression profiles
for each cell type. The resulting dendrogram of the correlations is shown in Figure 5.16b.
In accordance with the t-SNE mapping, we find a high similarity (ρ > 0.7) for T cell
subtypes originating from different sources. For natural killer cells, a correlation of
ρ > 0.8 was observed for all three indications. While B cells from melanoma and blood
samples are highly similar (ρ > 0.9), those from ascites samples are closer related to the
respective dendritic cells (ρ = 0.78) than to the other B cells (ρ = 0.7). Malignant cells
from ovarian carcinoma and melanoma are less correlated with each other (ρ = 0.54)
than with tumor-associated cells (ρ > 0.56). Interestingly, despite their different origin,
cancer associated fibroblasts from melanoma and ascites are highly similar in their gene
expression (ρ = 0.81).
The cellular composition of each patient sample is shown in Figure 5.16c. For the 19
melanoma samples, the composition covers the full range from no tumor at all in sample
58 up to a very high tumor content for sample 78. For all four ascites samples, a huge
fraction of macrophages/monocytes was identified while for PBMCs from blood samples
T cells represent the biggest fraction.
The classification result was also compared to the original classification of the published
melanoma data set by Tirosh et al. [190] and, for the ovarian ascites data set, to FACS
data of three of the samples. As depicted in Figure 5.17 the classification is in line with
previously published results and with the experimental measurements.
Malignant cells exhibit patient-specific gene expression
By mapping the sample/patient ID to the t-SNE map, as shown in Figure 5.18, we could
confirm previous observations by Tirosh et al. [190] that malignant cells cluster mostly
in a patient-specific manner. By contrast, for immune cells, heterogeneous clusters for
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Fig. 5.16.: t-SNE map of single-cell data from three sources. (a) Single cells (symbols) were
arranged in two dimensions based on similarity of their gene expression profiles by a
dimensionality reduction technique (t-SNE). The clusters that emerge spontaneously
can be associated with cell types (colors) and source location (symbol types: triangles
for melanoma, squares for PBMCs, and diamonds for ascites; legend as in panel b).
(b) Pair-wise correlation of averaged gene expression profiles of clusters encoding cell
type and source location as identified in a) visualized as dendrogram. (c) Composition
of individual tissue samples broken down by cell types.
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Fig. 5.17.: Comparison of the classification result with literature and experimental FACS
analysis. (a) The result of our cell type classification (left bars, dark colors) compared
to the cell types provided across all melanoma samples in the data set by Tirosh et al.
[190] (right bars, light colors). (b) Cell type classification (left bars, dark colors)
compared to FACS data (right bars, light colors) for three ovarian ascites patient
samples. For sample 7892M, macrophages/monocytes could not be detected by FACS.
each cell type rather than for each patient sample were observed. Within each cell type
cluster, sub-clusters are formed according to the tissue source.
5.3.5 Defining a benchmark based on single-cell gene expression data
After having identified patient- and indication-specific gene expression profiles, we want
to benchmark the deconvolution approach depending on the information provided to the
algorithm.
Generating bulk patient samples from single-cell data
By using single-cell gene expression data, we can construct “bulk” gene expression
profiles for each of the 27 patient samples by aggregating all single-cell gene expression
data. For these artificial samples, the actual composition is known a priori and serves as
the ground truth for benchmarking the deconvolution approach.
Defining reference gene expression profiles
To study how the results of deconvolution of bulk expression data are affected by micro-
environment-specific changes in gene expression and by patient-to-patient variation,
we consider three configurations of reference gene expression profiles (RGEPs). The
construction process is schematically depicted in Figure 5.19. Starting from several
patients for each indication (for the sake of convenience, in the example we consider
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Fig. 5.18.: Patient-specific t-SNE map of scRNA-seq data. Malignant cells (highlighted by red
dashed line) cluster according to patient sample while immune cells cluster primarily
according to the cell type. Symbols represent individual cells, shape of the symbol
denotes indication, color indicates patient of origin according to legend.
only two patients per indication), we define RGEP1 as the population average over
all single-cell gene expression profiles of a certain cell type originating from whole
blood samples. Because there are no tumor associated cell types contained in the
blood samples of healthy donors, the reference profiles for tumor cells, endothelial
cells and cancer associated fibroblast are unknown. For RGEP2 we use the population
average of the expression profiles from all indications. As stated previously, tumor cells
from melanoma and ascites can be very different in their gene expression and thus
require separate reference profiles. The third configuration, RGEP3, averages only over
expression profiles of cells belonging to the same indication. The indication-specificity
might be necessary as corresponding cell types from different sources can show altered
expression characteristics.
In addition to the three RGEPS, we set up two artificial control scenarios that are
extensions of RGEP3 and include patient-specific information. These scenarios are not
applicable in the real world, but serve to evaluate the relative importance of patient-
specific information. In control scenario 1 (CNTR1), patient-specific profiles are used
only for the malignant cells, whereas consensus profiles are used for each non-malignant
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Fig. 5.19.: Generating cell type-specific gene expression profiles from single-cell data. (a)
Individual single-cell expression profiles are obtained from scRNA-seq and illustrated
by cell type (colors) and patient (numbers). (b) Five different reference profile
configurations: (REGP1) Unknown tumor profile, profiles of normal cells obtained
by averaging over all cells of a certain cell type from PBMCs; (REGP2) reference
profiles are obtained from scRNA-seq data from three indications and averaged over
all patient samples. Tumor cells are indication-specific; (REGP3) All profiles are
indication-specific; (CNTR1) immune and stromal cell profiles are indication-specific
while tumor profiles are patient-specific; (CNTR2) All profiles are patient-specific.
cell type. In CNTR2, patient-specific profiles are used for all cell types. In principle,
CNTR2 serves as the upper limit on what is technically possible using deconvolution
approaches.
Signature gene sets for deconvolution
Besides the reference gene expression profiles, we need to define which genes we include
for the deconvolution. Based on published lists of characteristic genes from literature, we
define five signature gene sets and evaluate their impact on the deconvolution accuracy.
The smallest one is taken from Table S12 of the supplementary information of Tirosh
et al. [190]. It consists of 244 genes that were shown to be differentially expressed in
populations of T cell subtypes. Thereof, 239 are contained in the PBMC, melanoma and
ascites data sets. The second gene set is obtained from Table S3 of Tirosh et al. [190]) and
represents a list of 391 genes that have been identified as differentially expressed among
the cell types. Thereof, 374 genes are contained in all three scRNA-seq data sets. The
LM22 gene set by Newman et al. [139] consists of 547 genes of which 496 are contained
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in our data sets. The Merged gene set is generated by merging all genes from the LM22,
Table S3 and Table S12 gene sets and adding the 45 marker genes used for classification
training. It consists of 1076 unique genes, thereof 1015 genes are in common with the
scRNA-seq data. As a last gene set, All genes 17 936 genes that are contained in the all
three scRNA-seq data sets are used. Thereof, 17 933 have a non-zero expression for at
least one single-cell profile.
Deconvolution algorithms used for benchmarking
Next, we included a set of four algorithms to solve the deconvolution problem defined
in (5.32): As introduced in the CIBERSORT method, ν-Support vector regression (ν-
SVR) can be used. Here, we utilized the implementation of libSVM [24] for MATLAB
(version R2016a, The MathWorks Inc., Natick, MA, USA). The parameters were set
to -s 4 -t 0 -n 0.50 -h 0 -c 1 -q. The mldivide function from MATLAB uses the
pseudo-inverse of the matrix B for solving for w = pinv(B)*m. This is equivalent to
using w = mldivide(B, m). The fitlm function from MATLAB fits a linear model to the
data based on a least-squares fit. The main difference to the mldivide function is that
for fitlm an intercept is taken into account. For the CVX package [72] for MATLAB the
problem was defined as:
cvx_begin quiet
cvx_solver sdpt3;
variable w(size(B, 2)) nonnegative;
minimize( norm((B*w - m), 2) + lambda*norm(f, 2))
subject to
w <= 1;
sum(w) <= 1;
cvx_end
with lambda=1 and solved using the SDPT3 algorithm [191] for semidefinite-quadratic-
linear programming problems.
Processing of estimation results
The results for the proportions of known cell types w, as obtained by one of the above-
mentioned algorithms, are processed by replacing negative numbers by zeros [139]. The
proportion of unknown other cell types w˜, i.e. cell types for which no reference profile
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was available, is calculated by taking the difference between one and the sum of all n
known cell proportions:
w˜ = 1−
n∑
i=1
wi (5.35)
Assessing the estimation accuracy
To assess the accuracy of our deconvolution results, we compared the true cell fractions,
as calculated from the number of single-cell measurements for each cell type and patient,
with the estimation result by calculating Pearson’s correlation coefficient ρ for all patients.
We quantified the uncertainty of our quality measure by performing bootstrap re-sampling
(100 replications) of our deconvolution results and calculated the median and lower and
upper quartiles.
5.3.6 Impact of signature gene sets on deconvolution accuracy
We start evaluating the performance of different gene sets when deconvolving the
generate bulk samples using the ν-SVR algorithm. The reference gene expression profiles
were constructed using the RGEP3 configuration. As shown in Figure 5.20a, the overall
accuracy is relatively high for all gene sets (ρ > 0.94). However, the Merged and All
genes gene sets perform best with an overall correlation of ρ > 0.97. Looking at the
performance for individual cell types, we find only minor differences between the five
gene sets. Interestingly, despite the slightly lower overall correlation, the Merged gene
set outperforms All genes for several cell types such as natural killer cells, dendritic cells
and T and B cells. Furthermore, due to the much smaller size of this gene set (1015 vs.
17 933), the computation time using the Merged gene set is by a factor of 123 smaller
(13 s vs. 1600 s on an Intel Xeon X5680 3.33GHz CPU with 94GiB RAM). We therefore
pick the Merged gene set as the best performer for all further analyses.
5.3.7 Evaluating deconvolution algorithms
In the next step, we analyze the impact of the chosen algorithm on the deconvolution
performance. We use the Merged gene set and the RGEP3 configuration. The result is
depicted in Figure 5.20b. Again, the overall performance is very high (ρ > 0.97) for all
four algorithms but the highest for filtm and ν-SVR (ρ > 0.98). While filtm performs
slightly better for melanoma cells (ρ = 0.99 vs. ρ = 0.97), ν-SVR performs better for all
other cell types. Thus, we can confirm the accuracy achieved with the ν-SVR algorithm
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Fig. 5.20.: Comparison of different gene sets and algorithms. (a) The deconvolution accu-
racy of five different gene sets was assessed for the nine major cell types based on
the ν-SVR algorithm. (b) Four deconvolution algorithms are compared based on the
deconvolution result obtained with the merged gene set. Each dot represents the
correlation of the ground truth with the deconvolution result over all patient samples.
The shading shows the upper and lower quartile obtained by bootstrapping. Only the
results for RGEP3 are indicated. The detailed scatter plots for all configurations are
shown in Figure B.9–B.15 in the appendix.
as originally observed with the CIBERSORT method on microarray data and select this
algorithm for all subsequent analyses.
5.3.8 Impact of patient- and indication-specific reference profiles
Having selected the best performing signature gene set and deconvolution algorithm we
now want to go into greater detail of the deconvolution result and analyze the role of
patient- and indication-specific reference profiles. Therefore, for each of the five reference
profile configurations (RGEP1-3, CNTR1-2), we run the deconvolution and benchmark
the result against the ground truth. When plotting the estimated proportion against the
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Fig. 5.21.: Benchmark result for five RGEPs and nine major cell types. (a) Scatter plot of
true and estimated cell proportions for all 27 patient samples. Each dot represents
one patient sample. Values close to the diagonal correspond to high deconvolution
accuracy. Columns depict cell types; rows describe the five different configurations
(REGP1-3 and CNTR1-2). ρ denotes the Pearson’s correlation coefficient. In con-
figuration REGP1, estimates for tumor-associated cell types are not available. (b)
Pearson’s correlation coefficient between estimated and true cell fraction for all five
configurations. Dots denote the median of the correlation coefficient; the shading rep-
resents the uncertainty based on bootstrapping (upper and lower quartile). (Please
note the different scaling of the figure axes.)
true proportion, as shown in Figure 5.21a, we can determine the correlation over all
patient samples. Each row represents one configuration of reference gene expression
profiles while the columns represent cell types.
For RGEP1, the fractions of unknown cells are relatively high as no reference profiles were
available for tumor associated cell types. Nevertheless, a mediocre overall result (ρ =
0.82) can be achieved ranging from very weak results for dendritic cells (ρ = −0.04) up to
more or less exact deconvolution fractions for B cells and macrophages/monocytes (ρ =
0.99). In RGEP2, melanoma and ascites data are taken into account providing reference
profiles for endothelial cells, cancer associated fibroblasts and ovarian carcinoma as
well as melanoma cells. The overall performance increased significantly to ρ = 0.98
reflecting the very high accuracy for most cell types (ρ > 0.94). Only for dendritic cells
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and natural killer cells, despite the increase as compared to RGEP1, the accuracy is
still moderate (ρ = 0.82). As the proportion of unknown cells is very small (see also
Figure 5.16c), the correlation is no longer a good measure of accuracy. Adding indication-
specific reference profiles for all cell types in RGEP3 further improves the deconvolution
accuracy. Estimates for all cell types reach correlations of ρ > 0.95 indicating that natural
killer cells and dendritic cells require indication-specific information for an accurate
and reliable deconvolution. When adding patient-specific information for the tumor
cells in CNTR1 and for all cell types in CNTR2, the accuracy can be improved even
more until correlations of ρ = 1.00 are reached for CNTR2. These reference profiles,
however, are not available in real world scenarios and serve only as an upper limit of the
methodology.
In summary, our analysis revealed that reference gene expression profiles obtained
only from PBMC data are insufficient to reliably deconvolve patient samples from other
indications. Adding data from multiple indications could improve the accuracy for all
cell types. However, certain cell types such as dendritic cells and natural killer cells
seem to require indication-specific profiles for an accurate estimation of the sample
composition.
5.3.9 Estimating T cell subtypes and prognostic ratios
So far, we focused our analysis to nine major immune and tumor-associated cell types.
Our classification of scRNA-seq data also allows to distinguish between multiple T
cell subtypes, namely CD4+, CD8+ and regulatory T cells. Quantification of T cell
subtypes is especially interesting since it was shown that location and abundance can
be used to predict patient outcome [64, 90]. As in the previous section, we perform
the deconvolution on the Merged gene set using the ν-SVR algorithm and evaluate all
five configurations of reference gene expression profiles. The resulting scatter plots are
shown in Figure 5.22a.
While for CD8+ T cells, the estimation results are accurate (ρ > 0.94) for all five settings,
for CD4+ and regulatory T cells, the estimation results in RGEP1 are only mediocre
(ρ = 0.63 and ρ = 0.43) but improve significantly for RGEP3 (ρ = 0.87 and ρ = 0.94).
This is also reflected in the ratios of Treg/CD4+, CD8+/Treg and CD4+/CD8+ T cells
that reach accurate estimations for RGEP2 (ρ = 0.94, ρ = 0.96 and ρ = 0.93). The
estimation for all T cell subsets and ratios does not significantly improve for CNTR1
but does improve in CNTR2 (ρ = 1.00), indicating that gene expression of T cells is
influenced by patient-specific effects.
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Fig. 5.22.: Benchmark result for five RGEPs and three T cell subtypes and three T cell
ratios. Caption as for Figure 5.21, ratios are indicated on a log2-scale.
In summary, deconvolution using gene expression profiles based on data from the
respective micro-environment (RGEP3) were sufficient to obtain reliable estimates of the
cellular composition of the samples. Deconvolution using gene expression profiles based
on data from peripheral blood (RGEP1) were considerably less accurate.
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5.3.10 Predicting tumor expression profiles
As shown in Figure 5.18, the gene expression tumor cells clusters in a patient-specific
manner. In a real word scenario, however, it is unlikely that the tumor gene expression
can be quantified separately for each patient as only the bulk sample expression is
measured. Based on our deconvolution result obtained with the indication-specific
RGEP3, we can predict the tumor cell gene expression for each patient individually.
Therefore, we simply need to subtract the weighted expression of non-tumor cells from
the bulk sample expression and rescale the expression with the estimated percentage of
tumor cells, i.e.
t⃗i =
m⃗i −Bnon−tumor · w⃗i,non−tumor
wi,tumor
, (5.36)
where m⃗i represents the bulk sample expression of the i-th patient, Bnon−tumor is the
signature matrix for all non-tumor cell types and w⃗i,non−tumor and wi,tumor are the non-
tumor and tumor cell fractions of the patient sample.
In order to evaluate the accuracy of the predicted tumor profiles, we analyze the cor-
relation of the predicted profile with the true expression profile of the tumor cells.
Additionally, we want to know whether the estimated profile is reflecting the true tumor
gene expression better than the expression of the whole bulk sample. As a baseline,
we also plot the expression of the non-tumor cells in each sample against the tumor.
The scatter plots of the comparison are depicted in Figure 5.23a. The patient samples
are sorted by the estimated percentage of tumor cells and Pearson’s correlation ρ is
indicated in the respective color. Clearly, for samples with low tumor cell content, our
prediction is less accurate (0.39 ≤ ρ ≤ 0.69) than correlating the bulk sample with the
tumor (0.75 ≤ ρ ≤ 0.82). When exceeding an estimated percentage of tumor cells of
20%, however, the estimated tumor profile is improved and outperforms the correlation
with the bulk sample (0.93 ≤ ρ ≤ 0.99 vs. 0.86 ≤ ρ ≤ 0.98). For the upper end, i.e. when
the sample consists of more than 70% of tumor cells, the correlation of bulk sample
and our prediction with the true tumor cell profile converge to correlation values of
ρ ≥ 0.99.
The dependence of the prediction accuracy on the percentage of tumor cells in the sample
is shown in Figure 5.23b. For low tumor content, non-tumor and bulk sample gene
expression are very similar and result in the same basal correlation of 0.7 to 0.8. In
this range, our prediction for the tumor profile performs worse because the low signal-
to-noise ratio. For more than 20% tumor content in the sample, we can improve the
prediction of the gene expression significantly until the bulk sample correlation converges
for samples with more than 70% tumor content. The baseline correlation of non-tumor
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Fig. 5.23.: Estimation accuracy of patient-specific tumor cell gene expression profiles. (a)
Scatter plot of predicted vs. true transcriptome wide gene expression (17 933 genes)
of the tumor cells. Patient samples without any tumor cells have been excluded from
this analysis. ρ denotes the Pearson’s correlation coefficient including uncertainty
based on bootstrapping. (b) Correlation values from (a) plotted against the estimated
proportion of tumor cells for each patient sample. Symbols and numbering denote
individual patient samples.
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vs. tumor profile, by contrast, drops for samples with high tumor content as less and less
non-tumor cells are left in the sample.
In summary, for patient samples with a tumor cell content of 20% to 70% the tumor
cell gene expression profiles obtained using deconvolution are significantly improved as
compared to the bulk sample profiles.
5.3.11 Discussion
The recent advent of single-cell sequencing technologies enables, for the first time, the in
depth analysis of cellular heterogeneity of patient samples. However, to better understand
how the interaction of different immune cell types contributes to fight malignant cells,
it is essential to decipher the cellular composition of complex tissue samples. In the
clinical routine, bulk gene expression of samples from tumor biopsies is measured using
microarray or, more recently, using RNA-seq. While previous approaches to deconvolve
the cellular composition from expression data mainly made use of reference profiles
obtained by microarray of leukocytes and other PBMCs, the advantages of RNA-seq data
were not yet exploited for this purpose.
With the presented approach we are able to accurately determine the composition of
samples originating from 29 patients and three distinct tissue sources. As a proof-of-
principle, we used bulk gene expression data constructed from single-cell measurements
to benchmark the impact of several factors as the reference gene set, the deconvolution
algorithm and the source and quality of the reference gene expression profiles. We
showed that the choice of the genes used for deconvolution has only a minor impact on
the accuracy of the deconvolution result. When using the indication-specific reference
profiles (RGEP3), even with the T cell specific gene set Table S12, consisting only of
239 genes, the overall correlation of estimated vs. true cell fractions is still very high
(ρ = 0.95) and the deconvolution only fails for dendritic cells, endothelial cells and
cancer associated fibroblasts (0.34 ≤ ρ ≤ 0.71). A combination of multiple gene lists
to the Merged gene set, consisting of 1015 genes, performed best and led to accurate
predictions for all nine cell types (ρ ≤ 0.95). The population of T cells could be further
divided into three subtypes and prognostic ratios of the subtypes could be successfully
determined with mediocre to high accuracy (0.75 ≤ ρ ≤ 0.99).
We also investigated the effect of the algorithm used for deconvolution. Again, the
differences between the results obtained using different algorithms were relatively small
and all four variants had a high overall accuracy (ρ ≤ 0.97). The ν-SVR algorithm, as
used by the CIBERSORT method, performed best for all cell types but the melanoma cells
where the accuracy was still fairly high (ρ = 0.97).
5.3 Deciphering the cellular composition of unknown patient samples for
immunotherapy
121
The way how reference gene expression profiles are constructed, by contrast, strongly
affects the deconvolution result. We investigated five variants with different data bases
and increasing level of specificity in conjunction with the best performing gene set
(Merged) and deconvolution algorithm (ν-SVR). While RGEP1, which is solely taking
PBMC data into account, failed to estimate the fractions of dendritic cells (ρ = −0.04) and
performed only mediocre for natural killer cells (ρ = 0.78), RGEP2-3 could significantly
improve the accuracy. Thus, reference profiles obtained only from whole blood are
insufficient to deconvolve samples from other tissue contexts, possibly altered by the
tumor micro-environment. In RGEP3 source-specific reference profiles were generated
resulting in a highly accurate deconvolution of sample compositions. As an upper limit,
we also tested reference profiles using patient-specific information (CNTR1-2). These
could further improve the results but are unrealistic for real world application.
Although the patients under investigation were suffering from the same malignancy
(i.e. melanoma or ovarian carcinoma), the gene expression of malignant tumor cells
was found to cluster by patient suggesting great differences between patients. Based
on our estimation results we can “purify” the bulk expression profile and predict the
gene expression of tumor cells on a patient-specific level. By correlating the predicted
expression over all 17 933 genes contained in our data set with the true tumor cell
expression obtained from the single-cell data, we could show that for a range of 20% to
70% tumor cell content in the sample, our prediction performs significantly better than
correlating the bulk expression with the tumor.
A limitation of the presented approach can be found in the sequencing technology: While
our analysis is based on single-cell RNA-seq data obtained by the newest generation of
devices on the market, in clinical practice, biopsy samples from cancer patients are mostly
analyzed by bulk sequencing often on older devices. Therefore, the compatibility of data
obtained using bulk sequencing and single-cell technology needs to be systematically
evaluated and possible conversion factors for gene expression would need to be defined.
However, if sufficient data from both technologies are available for one and the same
sample, this issue should be straight-forward to be resolved.
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5.4 Conclusions
In this chapter, I demonstrated how computational methods from bioinformatics and
systems biology can bring the diagnosis and treatment of cancer and associated health-
conditions to the next level. On the way to a more personalized treatment of patients
suffering from anemia, computational modeling becomes more and more a focus of
publicly funded research, pharmaceutical industry and regulatory authorities. Severe
side effects caused by chemotherapy can be reduced by adapting dosing regimens
to patient-specific drug response and by supporting standard therapy with additional
immunotherapeutical agents.
In parallel, increasing availability and decreasing costs for high-throughput sequencing
technologies enable an integration into the clinical data acquisition pipeline. Together
with large databases, such as TCGA and CCLE, these data will allow for extensive retro-
spective analyses and can lead to novel prognostic markers for specialized therapeutic
approaches.
By adapting a published model of Epo-EpoR interaction and calibrating its parameters to
in vitro data of ESA depletion in the supernatant of several human cell lines, a predictive
tool for characterizing the properties of ligands and cells could be established. The
extension of the model by a pharmaco-kinetic and -dynamic part allows for model-
based risk prediction and for the development of an optimized dosing schedule on a
patient-specific basis.
In the second part, an existing computational method for deconvolution of bulk tumor
samples was adapted for the use with modern RNA sequencing data. Based on a
benchmark study performed with single-cell RNA-seq data, we could show that only
reference gene expression profiles from the tumor micro-environment allow for an
accurate deconvolution. Therefore, indication specific reference profiles for each type
of cancer need to be established in order to reliably predict the cellular composition of
tumor samples.
Both projects presented in this chapter address clinical problems with methods from
computational systems biology. Transferring results from basic research to the clinical
context is one of the biggest challenges on the way to precision medicine. While our
results could be validated in vitro and promising predictions for applications in patients
could be made, a validation in clinics has yet to be performed in order to ensure safety
and efficacy of the model predictions.
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Conclusions & Outlook 6
In this last chapter, I want to summarize the main findings of the previous chapters and
return to the questions raised in the introduction of this thesis. In addition, I will provide
an outlook on the presented research topics and highlight the role of computational
systems biology for the future development of treatment strategies.
6.1 Conclusions
In the first part of this thesis, I presented examples for community-driven software
development for systems biology. By providing established methods for parameter
estimation and identifiability analysis, these software tools enable researchers to construct
and calibrate computational models of the systems of interest. Further, these software
tools will help to use those models for generating valuable hypothesis and predictions.
In the subsequent chapters, I demonstrated how predictive computational models can
utilized to foster understanding of intracellular processes during virus infection, to
characterize ligand-receptor interactions and to optimize treatment in a patient-specific
manner. Furthermore, based on computational deconvolution of high-throughput gene
expression data, the infiltration of tumors by immune cells could be resolved which
potentially enables the selection of adequate immunotherapy agents to support anti-
cancer treatment.
Software development for systems biology
In systems biology, researchers from different disciplines such as molecular biology,
physics and mathematics collaborate on joint efforts often spanning multiple universities
or institutes. In order to make large data sets available to all partners within the project or
to provide software tools to the scientific community, decentralized, web-based platforms
show an increasing popularity.
In the scope of this thesis, I presented two projects: one for collaborative software
development and one dealing with data availability for joint projects. For the first project
we raised the following questions:
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Can community-driven software development accelerate and improve workflows in com-
putational biology research? What features do software solutions need to facilitate model
construction, calibration and analysis for systems biology modeling?
In 2003, the standardized modeling language SBML was introduced. Since then, many
software tools for model construction, simulation and parameter inference have been
developed aiming to provide implementations of established methods and algorithms
to the computational modeling community. The potential target audiences range from
experimental biologists with very little experience in mathematical modeling to experts
in the field of computational biology. As most of the applications have a non-commercial,
academic background, the development is mostly driven by one or two research groups
and the choice of the features is oriented towards the needs of their own research
projects.
The software tool presented in this thesis, namely the Data2Dynamics (D2D) software,
originated from a similar context but evolved differently: While the main focus still lies
on efficient parameter estimation based on data obtained under multiple experimental
conditions, the development is driven by a community of active researchers through the
collaborative platform GitHub. Instead of one person in charge for the development,
every user can suggest new features or implement a new version himself, which is then
curated by the community of other users and developers. Therefore, the reliability as well
as the extent of novel functionalities increased drastically within the last years. Thus we
can conclude that the community-driven development approach helps to accelerate and
improve workflows in computational biology research. The challenge of this concept lies
in the structure and organization of the source code and demands mutual code revisions
in order to keep the software running stably in the longer term.
In terms of the essential features of a software solution for systems biology modeling
there are different aspects to be considered. First of all, SBML import and export
capabilities are crucial to ensure compatibility of new software with existing tools and
models. Other features depend very much on the target user base. Other than for instance
COPASI, D2D has its main focus on data-based dynamic modeling which requires efficient
implementations of parameter estimation and identifiability routines. On the other
hand, rather than offering graphical user interfaces, D2D uses MATLAB scripts for the
modeling workflow. While this restricts the target group to researchers with at least
basic programming skills, it saves computational power for the actual tasks and renders
complex simulation setups more transparent and reproducible. Taken together, SBML
support and a lightweight and flexible architecture providing efficient algorithms for
ODE integration and parameter estimation are the key features of D2D that facilitate
model construction, calibration and analysis.
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In the second project, a different set of questions was asked:
Which functionality enables the initial assessment and analysis of big data sets? How can
data are made available to users from multiple institutions independently from their local
infrastructure and technical background?
Modern high-throughput experiments generate huge amounts of data providing ex-
pression levels of individual genes or proteins for the whole cell under investigation.
Data processing and analysis, as described in Section 2.2, can be challenging. High-
dimensional data need to be made tangible for scientist in order to identify features
of interest and to generate hypotheses. Within a collaborative research project, this is
especially challenging as each group or institution mainly manages their own data sets.
In the presented case, a simple web-based platform was developed to provide all project
partners with data acquired by contributing groups of the collaborative project. The aims
were to make it easy to combine, browse and filter all available data giving researchers
a first glimpse on the information contained therein. The backbone of the platform
was written in the open-source programming language R which provides a variety of
statistical analyses and tools for handling large data sets. The front-end, based on the
package R shiny, provides a well structured and easy access to the data through the
web-browser and is therefore independent of the operation system of the computer
in use and does not require any programming knowledge. Hence, basic features such
as merging, filtering and browsing multiple large data sets are very useful for a first
assessment. Through a web-based platform, all project partners could access the data
and run quick analyses directly on their local machines.
Identification of limiting factors during influenza virus infection
In this project, the influenza A virus infection was investigated. We focused on intracellu-
lar processes during the early infection and identified limiting factors during transport of
the viral genome towards the host cell’s nucleus. Our main questions were:
How can intracellular processes regulate host specificity and strain pathogenicity? Which
nodes in the reaction network are limiting for the infection? How do changes in pH-sensitivity
of the viral hemagglutinin affect the infectivity of IAV?
The infection of host cells with the influenza A virus requires a whole series of host-
pathogen interactions in order to be successful. Starting with the entry of the virus
into the host cell and the transport of the viral genome towards the nucleus, several
factors could be identified that potentially modulate the host specificity and pathogenicity
of a IAV strain. A critical step during this phase of the infection is the fusion of the
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viral envelope with the surrounding endosomal membrane. The conformational change
of the viral hemagglutinin protein is triggered by the acidification of the endosomal
lumen. The pH value, at which virus-endosome fusion and therefore release of the viral
genome takes place, is determined by the amino-acid sequence of HA. We showed that
modifications of HA can lead to an altered pH sensitivity. In nature, variations of the HA
segment occur due to antigenic shift or antigenic drift and were found to regulate the
pathogenicity of different H5N1 mutants in ducks and chicken [165, 48]. Also, these
mutations could be critical for adaptation of avian strains to mammals [216] and thus
contribute to host-specificity. Moreover, HA was found to have lower pH threshold values
for viruses from human isolates than for avian isolates of the same subtype [63]. By
using a combination of deterministic and stochastic modeling approaches, we could show
that a change in the pH-sensitivity of the HA protein results in an altered distance from
the nucleus which has to be bridged by passive diffusion. In addition, we predicted that
degradation of the viral genome during diffusion could limit infectivity which could be
validated experimentally.
Therefore, we could improve the understanding on how host specificity and pathogenicity
can be regulated by the characteristics of the HA protein. In the scope of this project, we
took only the first steps of infection into account, neglecting subsequent processes like
genome replication, synthesis of viral proteins as well as packaging, budding and release
of progeny virions. Each of these steps relies on multiple host-factors as summarized e.g.
in the FluMap [128] or in various extensive studies on the topic [101, 181, 208, 95].
Further computational studies on subsequent stages of infection require highly precise
measurement techniques such as single-molecule FISH and super-resolution microscopy
that allow observation of individual molecules within the infected cell over time.
Optimizing the treatment of cancer and associated health conditions
In the next chapter, I presented two projects on cancer-associated health conditions
and showed how approaches from computational biology can not only enhance the
understanding of involved intracellular processes, such as receptor-induced signaling,
but also improve the standard of care treatment strategies.
In the first part of the chapter, we asked the questions:
Is there a better way to treat anemic patients? How can an optimal dosing schedule for
individual patients be achieved?
Anemia can be treated either by blood transfusions or by stimulating the production of
red blood cells using erythropoiesis stimulating agents (ESAs). The binding characteristics
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of different ESAs determine the half-life in the body and therefore the dosing schedule
in clinics. The response to the ESA treatment depends on the amount of susceptible
progenitor cells within the patient’s bone marrow.
Here, an existing model of ligand-receptor interaction was used to characterize novel
therapeutic ligands based on the depletion in the supernatant of treated cells. The
calibrated model was then utilized to determine the number of binding sites of various
cell lines. The intracellular model was extended by a pharmacokinetic (PK) and -dynamic
(PD) part. By calibrating the combined ESA-EpoR-PKPD model to data from clinical trails,
patient-specific parameters could be estimated. In the final step, the combined model was
used to retrospectively predict an optimized dosing schedule for all individual patients
of the clinical trials. Therefore, the existing treatment of anemia could potentially be
optimized by choosing the most adequate ESA and by adapting the dosing schedule on a
patient-specific level based on our model predictions.
Many of the model predictions were validated experimentally in vitro. However, vali-
dation of the optimized treatment strategies would require a whole new clinical trial
which exceeded the budged and time frame of the project. Nevertheless, based on our
results, a patent [168] could be filed, facilitating the transfer of the obtained knowledge
to partners from industry.
For the second part of Chapter 5, we asked:
Does the micro-environment of immune cells affect gene expression? How reliably can the
immune cell content in tumor tissue be predicted from blood-derived reference profiles?
Mathematical deconvolution of cell mixtures or bulk tumor samples can be performed
based on gene expression data. However, the accurate deconvolution is challenging
due to biological and technical noise in the measurements and contamination of the
sample caused by cell types for which no reference gene expression profiles exist. To
date, existing approaches were mainly based on microarray data and were validated on
in vitro cell mixtures or whole blood samples [1, 157, 139]. As the gene expression of
immune and stromal cells is known to depend on the micro-environment, we performed a
benchmark study based on data from three different human tissue sources. Also, modern
high-throughput RNA sequencing is less noisy than microarray, especially for genes with
low expression numbers. Thus, we used data from single-cell RNA-seq to benchmark
the accuracy of existing deconvolution approaches and determined the best working
method.
In our data analysis, we found that malignant tumor cells cluster according to the patient
while most other cell types cluster by their cell type and tissue source. This indicates
that tumor cells might exhibit more patient-specific features as immune and stromal
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cells. In our deconvolution benchmark, we could show that reference gene expression
profiles (RGEPs) purely based on blood-derived cells are insufficient for deconvolution of
bulk tumor samples. Despite the variability of tumor cells from patient to patient, using
source tissue specific RGEPs we were able to obtain accurate deconvolution results for
most cell types. Furthermore, prognostic ratios of T cell subtypes could be determined
making the method valuable for identifying patient subpopulations for immunotherapy
treatment. Based on the deconvolution result, we could also predict improved gene
expression profiles of malignant tumor cells in a patient-specific manner. This could be
of further interest to identify biomarkers and genes that reliably correlate for instance
with the abundance of certain other cell types.
This proof of principle study revealed that micro-environment and patient-specific gene
expression have an impact on the deconvolution result that is not negligible. In clinical
practice, biopsies of malignant tissue and its surroundings are part of the standard
procedure. RNA sequencing of these samples is mostly performed as a bulk measurement
rather than on the single-cell level due to the reduced costs and effort. For a successful
application of the presented approach in a clinical setting, however, further validation on
bulk sequencing data would be needed proving the reliable and correct functioning on
data obtained from different experimental platforms.
6.2 Outlook
Cancer and infectious disease are among the leading causes of death worldwide. However,
several recent developments have the potential to drastically improve the existing pre-
vention measures and treatment strategies. In the following, I want to briefly introduce
these approaches and highlight their importance for the progress in fighting diseases.
Furthermore, the role of systems biology for the development of novel treatments and
for the progress towards precision medicine shall be discussed.
Towards universal influenza vaccines and cell culture-based vaccine production
As mentioned in Section 4.1, the current vaccines against seasonal influenza virus strains
rely on predictions for the most prominent strains in circulation. As the strains mutate
due to antigenic drift, vaccines require modifications each year [140]. Depending on how
well the prediction matches the actual strains in fluctuation, the vaccine effectiveness
strongly fluctuates [145]. Another challenge in the development and production of
influenza vaccines is the short time frame from strain prediction to large-scale production
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for a timely availability at the beginning of the season. Unlike current seasonal vaccines,
universal vaccines are not specific for an HA or NA antigen sequences but make use of the
conserved stalk domain of the HA, NA or M2 proteins [102]. Thereby, these vaccines do
not rely on strain predictions and can be used to prevent both, seasonal and pandemic
influenza virus infection.
A second factor for improving and accelerating the process of vaccine production relies
on cell-based assays rather than growing the viruses in embryonated chicken eggs.
For optimizing the virus yield, mathematical models have been developed describing
the population dynamics in bioreactors [61] and linking intracellular kinetics to the
population scale [75]. This approach could make the vaccine production independent
of the supply with embryonated eggs and therefore quickly scale the production to the
needs of the market [102].
While the first cell culture-based influenza vaccine was approved recently, for univer-
sal vaccines the first pre-clinical studies showed promising results but need further
investigation in a clinical setting, as summarized by Krammer & Palese [102].
Novel technologies and their impact cancer treatment – en route to precision
medicine
The cost for sequencing one human genome sequence dropped from more than $ 100M
in 2001 to less than $ 1000 dollars in 2014 [45]. Therefore, NGS technologies have found
their way into clinics and genome-wide sequencing such as RNA-seq is now often part
of the clinical routine for patients with cancer. This step enables clinicians to analyze
mutations that led to the specific type cancer on a patient-specific level. With this
information at hand, not only the therapy can be selected according to the mutation
status, for instance based on the HER2 status in breast cancer [94] and the KRAS
mutation status in colorectal cancer [155], but also the understanding of disease can be
improved in retrospective analyses. Furthermore, novel single-cell technologies, such as
scRNA-seq, reveal the heterogeneity of cells within tumor samples [190] and allow for
the characterization of immune cells based on their transcriptome-wide gene expression
[217].
The use of computational methods for predicting the micro-environment of the tumor
for immunotherapy and for optimizing the dosing schedule was extensively discussed in
this thesis. A new initiative on precision medicine, as announced by Barack Obama in his
State of the Union Address in 2015, supports this development by providing additional
funding but also by adapting the standards of regulatory authorities, such as the FDA, to
allow for the approval of novel treatment strategies [36].
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From systems biology to systems medicine
Diseases, such as cancer, involve a multitude of complex signaling pathways and regula-
tory networks. Therefore, a systems approach is essential to understand the interplay
of involved components and eventually to combat the disease. While systems biology
has its main focus on basic research, predictive computational models are also used to
establish diagnostic biomarkers, identify potential drug targets and to optimize existing
treatment strategies. With increasing availability of high-throughput data, models that
integrate heterogeneous data from in vitro experiments as well as from clinics have
become a valuable tool for medical research and diagnostics. Therefore, the transition
from systems biology to systems medicine is already under way [206].
The work presented in the scope of this thesis is exemplary for this transition. The
mechanistic ESA-EpoR multi-scale model presented in Section 5.2 showed that results
from “wet lab” can be transferred to predictions for the clinics. Furthermore, the dosing
of the drug can be adapted on a patient-specific basis thereby reducing the risk of
over- and underdosing and the associated side effects. Also the method presented
in Section 5.3 has a clear focus on the medical application. Knowing the cellular
composition of tumor samples is key for selecting the appropriate treatment strategy.
Using computational deconvolution, this precious information can be obtained from data
that is highly available in the clinical context. Furthermore, the prediction of improved
tumor gene expression profiles might be used for identifying novel diagnostic biomarkers
for immunotherapy. Taken together, predictive computational models promote and
accelerate the knowledge transfer from basic research to clinical application.
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Fig. A.1.: Spatial progression of intracellular influenza A virus-endosome fusion events
with respect to the nucleus. MDCK cells were incubated with R18-labeled influenza A
X-31 virus for 10min at 4 ◦C, washed and R18 was detected using confocal fluorescence
microscopy. (a) and (c) Overview images at 0 and 20min post-infection. (b) and (d)
Zoomed representation of the highlighted areas in (a) and (c). Nuclei are marked
by a dashed line. Scale bars are 20 µm (a, c) and 5 µm (b, d). (e) Fusion events can
be detected from R18 dequenching and their shortest distance to the nucleus was
measured using ImageJ. Figure adapted from Schelker et al. [176].
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Fig. A.2.: Trajectories of the dynamic IAV entry model. Most variables describe particle
numbers as indicated by the label amount. Endosomal pH levels are shown as H+
concentrations an as a pH curve. The grayed lines for the variable vRNPcyt,1−5 denote
the pseudo-variables of the linear chain introduced for the delay between vRNP release
and nuclear import.
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Tab. A.1.: Estimated parameter values. θˆ indicates the estimated value of the parameters. θlb
and θub indicate the lower and upper bounds imposed during optimization. The
non-log-column indicates the non-logarithmic value of the estimate. Parameters
highlighted in red color indicate parameter values close to their bounds.
index name θlb θˆ θub non-log θˆ
1 k_ATPase -5 -1.1001 +3 +7.94 · 10−02
2 h -5 +0.2796 +3 +1.90 · 10+00
3 h_WSN_H3_mut -5 +0.6285 +3 +4.25 · 10+00
4 h_WSN_H3_wt -5 +0.3599 +3 +2.29 · 10+00
5 init_Endosomes_FDQ -5 -4.8812 +3 +1.31 · 10−05
6 init_VirRec_end_140807 -5 -2.1374 +3 +7.29 · 10−03
7 init_VirRec_end_140822 -5 -1.1345 +3 +7.34 · 10−02
8 init_VirRec_end_150604 -5 -0.5521 +3 +2.80 · 10−01
9 init_VirRec_end_150612 -5 -3.6796 +3 +2.09 · 10−04
10 init_Virus_number_X31 -5 +0.5787 +3 +3.79 · 10+00
11 init_Virus_number_X31_nuclear_NP -5 +0.7553 +3 +5.69 · 10+00
12 init_Virus_number_X31_pH_end -5 -4.3996 +3 +3.98 · 10−05
13 k_Hplus -7 -5.3133 +3 +4.86 · 10−06
14 k_Hplus_WSN_H3_mut -7 -5.6787 +3 +2.10 · 10−06
15 k_Hplus_WSN_H3_wt -7 -5.3621 +3 +4.34 · 10−06
16 k_basal -5 -2.0345 +3 +9.24 · 10−03
17 k_deg -5 -0.7242 +3 +1.89 · 10−01
18 k_end -5 -1.0307 +3 +9.32 · 10−02
19 k_fus -5 -0.4449 +3 +3.59 · 10−01
20 k_imp -5 +4.0000 +4 +1.00 · 10+04
21 k_inhib_100uM -5 -3.7360 +3 +1.84 · 10−04
22 k_inhib_40uM -5 +3.9953 +4 +9.89 · 10+03
23 k_tau -5 +0.0821 +3 +1.21 · 10+00
24 offset_Fus_DiI_DiO -5 -0.4321 +3 +3.70 · 10−01
25 offset_Fus_R18 -5 -1.2652 +3 +5.43 · 10−02
26 offset_NP -5 -0.2488 +3 +5.64 · 10−01
27 offset_vRNP_140807 -5 -2.4147 +3 +3.85 · 10−03
28 offset_vRNP_140822 -5 -2.4716 +3 +3.38 · 10−03
29 offset_vRNP_150604 -5 -3.0353 +3 +9.22 · 10−04
30 offset_vRNP_150612 -5 -3.1259 +3 +7.48 · 10−04
31 pH_lb -5 +0.6498 +3 +4.46 · 10+00
32 pH_ub -5 +0.7926 +3 +6.20 · 10+00
33 scale_Fus_DiI_DiO -5 -0.4557 +3 +3.50 · 10−01
34 scale_Fus_R18 -5 -0.3111 +3 +4.89 · 10−01
35 scale_NP -5 -0.8445 +3 +1.43 · 10−01
36 scale_pH -5 -0.7445 +3 +1.80 · 10−01
37 scale_vRNP_140807 -5 +0.0996 +3 +1.26 · 10+00
38 scale_vRNP_140822 -5 -0.8552 +3 +1.40 · 10−01
39 scale_vRNP_150604 -5 -2.7923 +3 +1.61 · 10−03
40 scale_vRNP_150612 -5 +1.0336 +3 +1.08 · 10+01
41 sd_FDQ_H3_mut -5 -1.2285 +3 +5.91 · 10−02
42 sd_FDQ_H3_mut_rel -5 -1.0824 +3 +8.27 · 10−02
151
43 sd_FDQ_WSN_H3_wt -5 -1.1098 +3 +7.77 · 10−02
44 sd_FDQ_WSN_H3_wt_rel -5 -1.4075 +3 +3.91 · 10−02
45 sd_FDQ_X31 -5 -1.8986 +3 +1.26 · 10−02
46 sd_FDQ_X31_rel -5 -0.8759 +3 +1.33 · 10−01
47 sd_Fus_DiI_DiO -5 -1.5136 +3 +3.06 · 10−02
48 sd_Fus_R18 -5 -1.2216 +3 +6.00 · 10−02
49 sd_NP -5 -1.5560 +3 +2.78 · 10−02
50 sd_pH_MDCK -5 -1.5457 +3 +2.85 · 10−02
51 sd_vRNP_140807 -5 -1.1650 +3 +6.84 · 10−02
52 sd_vRNP_140822 -5 -1.1602 +3 +6.91 · 10−02
53 sd_vRNP_150604 -5 -0.6037 +3 +2.49 · 10−01
54 sd_vRNP_150612 -5 -1.0648 +3 +8.61 · 10−02
55 sd_vRNP_tot_140807 -5 -1.6770 +3 +2.10 · 10−02
56 sd_vRNP_tot_140822 -5 -0.3950 +3 +4.03 · 10−01
57 sd_vRNP_tot_150604 -5 -0.9325 +3 +1.17 · 10−01
58 sd_vRNP_tot_150612 -5 -0.9742 +3 +1.06 · 10−01
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Computational approaches for
optimized treatment of
cancer-associated health
conditions
B
B.1 Optimized treatment strategies for anemia patients
based on a mechanistic multi-scale model
B.1.1 Auxiliary ESA-EpoR model
d[SAv]
dt = −[SAv] · [EpoR] · kon_SAv + [SAv_EpoR] · koff_SAv + [SAv_EpoR_i] · kex (B.1)
d[EpoR]
dt = −[SAv] · [EpoR] · kon_SAv + [SAv_EpoR] · koff_SAv + SAvbind · kt − [EpoR] · kt
+ [SAv_EpoR_i] · kex_SAv (B.2)
d[SAv_EpoR]
dt = [SAv] · [EpoR] · kon_SAv − [SAv_EpoR] · koff_SAv − [SAv_EpoR] · ke (B.3)
d[SAv_EpoR_i]
dt = [SAv_EpoR] · ke − [SAv_EpoR_i] · kex_SAv − [SAv_EpoR_i] · kdi
− [SAv_EpoR_i] · kde (B.4)
d[dSAv_i]
dt = [SAv_EpoR_i] · kdi (B.5)
d[dSAv_e]
dt = [SAv_EpoR_i] · kde (B.6)
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Fig. B.1.: Model simulations and data for the revised model and data by Becker et al. [12].
Lines and symbols in light blue represent BaF3-HA-mEpoR cells stimulated with Epo
alfa, lines and symbols in purple depict BaF3-SBP-mEpoR cells stimulated with SAv.
Shading represents standard deviation of the data as estimated by a parametric error
model.
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Fig. B.2.: Depletion of ESA in the supernatant of BaF3-HA-mEpoR cells. Colors indicate ESA
(Epo alfa, light blue; Epo beta, dark blue). Measured data are depicted by symbols,
model curves of the core ESA-EpoR model are indicated by lines. Shading represents
standard deviation of the data as estimated by a parametric error model.
154 Appendix B Computational approaches for optimized treatment of cancer-
associated health conditions
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3 parental
-2*log(L) = -66.5
0 100 200
0
50
100
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3 parental
-2*log(L) = -49.8
0 100 200
0
50
100
150
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3 parental
-2*log(L) = -47.4
0 100 200
0
50
100
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3 parental
-2*log(L) = -75.0
0 100 200
0
50
100
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3 parental
-2*log(L) = -48.8
0 100 200
0
50
100
150
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3 parental
-2*log(L) = -68.8
0 100 200
0
50
100
NE
SP
 (p
M
)
Time (min)
BaF3 parental
-2*log(L) = -40.6
0 100 200
0
50
100
150
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3 parental
-2*log(L) = -61.5
0 100 200
0
50
100
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3 parental
-2*log(L) = -54.1
0 100 200
0
50
100
150
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -60.8
0 200 400
0
100
200
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -16.1
0 100 200
0
100
200
300
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -15.1
0 100 200
0
50
100
Ep
o 
alf
a 
(p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -78.7
0 100 200
0
50
100
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -53.5
0 200 400
0
100
200
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -7.1
0 100 200
0
100
200
300
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -16.7
0 50 100
0
200
400
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -32.3
0 100 200
0
100
200
Ep
o 
be
ta
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -78.1
0 100 200
0
50
100
NE
SP
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -65.9
0 100 200 300
0
100
200
NE
SP
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -62.3
0 100 200 300
0
200
400
600
NE
SP
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -23.4
0 100 200
0
50
100
150
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -91.6
0 200 400
0
200
400
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -48.4
0 200 400
0
100
200
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -63.2
0 50 100
100
200
300
400
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -69.0
0 100 200
0
50
100
150
C.
E.
R.
A.
 (p
M
)
Time (min)
BaF3-HA-hEpoR
-2*log(L) = -68.8
0 100 200
0
50
100
Fig. B.3.: Depletion of ESA in the supernatant of parental BaF3 and BaF3-HA-hEpoR cells.
Colors indicate ESA (Epo alfa, light blue; Epo beta, dark blue; NESP, orange; C.E.R.A.,
red). Measured data are depicted by symbols, model curves of the core ESA-EpoR
model are indicated by lines. Shading represents standard deviation of the data as
estimated by a parametric error model.
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Fig. B.4.: Depletion of ESA in the supernatant of NSCLC cell lines. Colors indicate ESA (Epo
alfa, light blue; Epo beta, dark blue; NESP, orange; C.E.R.A., red). Measured data are
depicted by symbols, model curves of the core ESA-EpoR model are indicated by lines.
Shading represents standard deviation of the data as estimated by a parametric error
model.
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Fig. B.5.: Depletion of ESA in the supernatant of the NSCLC cell line H1944 and of hCFU-E
and hCD34+ cells. Colors indicate ESA (Epo alfa, light blue; Epo beta, dark blue;
NESP, orange; C.E.R.A., red). Measured data are depicted by symbols, model curves
of the core ESA-EpoR model are indicated by lines. Shading represents standard
deviation of the data as estimated by a parametric error model.
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Tab. B.1.: Parameter values and likelihood-based 68%-confidence bounds. Asymmetric confi-
dence bounds were obtained from likelihood profiles (Figures B.6 and B.7).
Parameter log10(p) log10(conflb) log10(confub)
ESA_bind_A549 −0.112 −0.133 −0.095
ESA_bind_H1299 0.212 0.142 0.271
ESA_bind_H1944 −0.922 −1.180 −0.772
ESA_bind_H838 0.134 0.116 0.163
ESA_bind_H838_HA_hEpoR 2.022 2.012 2.031
ESA_bind_hCFU_E 0.857 0.837 0.880
ESA_bind_hCD34pos −0.460 −0.653 −0.224
ESA_bind_BaF3_HA_EpoR 2.114 2.092 2.134
ESA_bind_BaF3_parental −0.318 −0.489 −0.200
ESA_bind_SAv 1.535 1.463 1.623
hill_Epo_alfa 0.006 −0.010 0.023
hill_SAv 0.560 0.497 0.617
kD_CERA_hEpoR 3.035 2.974 3.088
kD_Epo_alfa_hEpoR 1.329 1.286 1.372
kD_Epo_alfa_mEpoR 2.303 2.267 2.339
kD_Epo_alfa_radio 1.913 −1.999 2.285
kD_Epo_alfa_radio_21C 2.153 2.096 2.203
kD_Epo_beta_hEpoR 1.334 1.298 1.370
kD_Epo_beta_mEpoR 2.362 2.339 2.417
kD_NESP_hEpoR 2.823 2.748 2.884
kD_SAv 3.529 3.386 3.665
kD_SAv_21C 2.811 2.718 2.940
kde −1.884 −1.913 −1.856
kdi −2.906 −3.096 −2.773
ke −1.300 −1.313 −1.287
kex −4.000 −4.000 −3.505
kex_SAv −6.000 −6.000 −2.814
kon_CERA_hEpoR −4.090 −4.173 −4.006
kon_Epo_alfa_hEpoR −3.075 −3.101 −3.048
kon_Epo_alfa_mEpoR −3.655 −3.687 −3.622
kon_Epo_alfa_radio −4.023 −4.059 −3.987
kon_Epo_beta_hEpoR −3.037 −3.061 −3.012
kon_Epo_beta_mEpoR −3.699 −3.752 −3.636
kon_NESP_hEpoR −3.901 −4.026 −3.770
kon_SAv −5.221 −5.334 −5.108
kt −1.771 −1.797 −1.743
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Fig. B.6.: Likelihood profiles for the kinetic parameters of the ESA-EpoR model. Model
calibration is based on data from BaF3 cells. The profile likelihood (PL) is calculated
as described in Section 2.3.3. The parabola shaped parameter profiles are identifiable.
The black solid line denotes the values of the likelihood profile, the gray asterisk
indicates the optimal parameter value and the red dashed line represents the 68%-
confidence threshold (point-wise).
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Fig. B.7.: Likelihood profiles for the kinetic parameters of the ESA-EpoRmodel. Parameters
obtained from BaF3 data are fixed to the optimal value given in Table B.1. The profile
likelihood (PL) is calculated as described in Section 2.3.3. The parabola shaped
parameter profiles are identifiable. The black solid line denotes the values of the
likelihood profile, the gray asterisk indicates the optimal parameter value and the red
dashed line represents the 68%-confidence threshold (point-wise).
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Fig. B.8.: Expression and functionality of EpoR in human lung cancer cell lines. (a) The
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Detection was performed by immunoblotting (IB) using an anti-phosphotyrosine
antibody (pEpoR) or an anti-EpoR antibody (EpoR). As indicated by the protein input
for BaF3 cells and NSCLC cell lines ,different amounts of cellular lysates were used
for the IP. For EpoR detection, both high and low exposure of the immunoblots are
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arrows. MW: molecular weight marker (Magic Marker, Invitrogen). Figure taken from
Rodriguez-Gonzalez et al. [170].
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B.2 Deciphering the cellular composition of unknown
patient samples for immunotherapy
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Fig. B.9.: Detailed deconvolution results based on the “mldivide” algorithm and the
“Merged” gene set. Caption as in Figure 5.21
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Fig. B.10.: Detailed deconvolution results based on the “SDPT3” algorithm and the
“Merged” gene set. Caption as in Figure 5.21
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Fig. B.11.: Detailed deconvolution results based on the “fitlm” algorithm and the
“Merged” gene set. Caption as in Figure 5.21
162 Appendix B Computational approaches for optimized treatment of cancer-
associated health conditions
Computational deconvolution of patient samples
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Fig. B.12.: Detailed deconvolution results based on the “Table S12” gene set and the “ν-
SVR” algorithm. Caption as in Figure 5.21
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Fig. B.13.: Detailed deconvolution results based on the “Table S3” gene set and the “ν-
SVR” algorithm. Caption as in Figure 5.21
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Fig. B.14.: Detailed deconvolution results based on the “LM22” gene set and the “ν-SVR”
algorithm. Caption as in Figure 5.21
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Fig. B.15.: Detailed deconvolution results based on the “All genes” gene set and the “ν-
SVR” algorithm. Caption as in Figure 5.21
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